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ABSTRACT 
 
Regardless of aetiology, the accumulation of scar tissue is the final common pathway of 
progressive kidney disease.  This so-called fibrosis or sclerosis manifests itself in three forms: 
glomerulosclerosis, vascular sclerosis and tubulointerstitial fibrosis, affecting the glomerulus, 
vessels and tubules/interstitium respectively.  Morphological studies have repeatedly shown 
that tubulointerstitial fibrosis is the key histological predictor of the progression of declining 
renal function.  However, despite its significance there are currently no treatments available to 
abrogate this process. Those that suffer from the progressive accumulation of scar tissue 
therefore eventually succumb to renal failure. 
Tubulointerstitial fibrosis is largely mediated by fibroblasts and myofibroblasts present in the 
interstitium.  Whilst quiescent and sparse in the normal interstitium of the kidney, in response 
to injury fibroblasts become activated by a complex array of inflammatory and pro-fibrotic 
mediators.  The subsequent differentiation of these cells into myofibroblasts is a histological 
hallmark of fibrosis.  Myofibroblasts share phenotypic properties with both smooth muscle 
cells and fibroblasts and express the phenotypic marker αSMA. These cells are characterised 
as the key synthesisers of extracellular matrix and their presence ultimately leads to the 
relentless accumulation of extracellular matrix proteins and loss of renal function.  
The pathological entities leading to fibrosis inextricably depend on complex signalling 
pathways that dictate the cell response by integrating a number of extracellular and 
intracellular cues.   Our current understanding of the mechanisms of tubulointerstitial fibrosis 
have largely focussed on the TGFβ signalling axis, primarily because this pathway is a central 
mediator in the regulation of an enormous number of pro-fibrotic events such as chemotaxis, 
regulation of the extracellular matrix, the autocrine activation of various growth factors and in 
the recently characterised phenomena of EMT.  This signalling axis therefore plays a major 
role in the regulation of interstitial fibroblast proliferation, differentiation and matrix 
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synthesis.  However, as we have come to understand that a large number of factors are 
capable of influencing fibroblasts (such as mechanical stress, proteases and various growth 
factors), it can be appreciated that the TGFβ axis is unlikely to mediate all of these responses. 
This is reflected in the current research, which increasingly highlights the involvement of 
other signalling pathways in fibrosis.  
Many of the well-known growth factors that exert effects on renal fibroblasts (such as 
FGF, EGF and PDGF) involve the activation of receptor tyrosine kinases. However, beyond 
activation of these receptors, the signalling events dictating the response of fibroblasts are 
relatively undefined.  It is well known that the serine/threonine kinase PI3K, most well known 
for its role in cell survival, is capable of mediating the responses of these growth factors. 
Moreover, mTOR, responsible for integrating stress and amino acids and controlling cell 
growth through downstream substrates, is increasingly known for its ability to integrate 
growth factor signals mediated through the upstream PI3K.  This is corroborated by a number 
of studies in VSMC and lung fibroblasts which have highlighted the potential role of PI3K 
and mTOR in the regulation of key events relevant to fibrosis.  This information has served as 
a basis for Chapter 3: The role of PI3K and mTOR in the regulation of fibroblast proliferation 
and collagen synthesis, and the first part of Chapter 5: The role of PI3K and mTOR in the 
regulation of myofibroblast differentiation.  These studies have identified a key role for PI3K 
and mTOR in the regulation of fibroblast proliferation, differentiation and collagen synthesis. 
The work described within has also attempted to more fully elucidate the derivation of 
myofibroblasts during fibrosis.  EMT is a process that is integral to embryogenesis and cancer 
and is becoming characterised as an important source of myofibroblast derivation. The 
proteome to engage EMT has been shown to involve a number of cellular cues, the 
surrounding microenvironment including the extracellular matrix as well as numerous 
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cytokines, vaso-active peptides and non-cytokine-mediated pathways.  In light of this and 
after encountering problems using an in vitro cell line to study EMT, work described within 
also includes Chapter 4: Development and validation of an ex vivo model of EMT.  This 
model aims to better represent the in vivo environment and allows for easy tracking of 
transitioning cells, and overcomes some of the difficulties with in vivo experiments.  Whilst 
previous studies have largely focused on the role of TGFβ and Smads in EMT, the signalling 
circuitry involved to fully engage the EMT proteome is not fully clear. This model has 
therefore been used to identify novel regulators involved in EMT and was utilised in the 
second part of Chapter 5: The role of PI3K and mTOR in EMT. 
Although cytokines and growth factor mediators are thought to be chiefly responsible 
for mechanisms of tubulointerstitial fibrosis, we now know that non-cytokine mediated 
pathways such as AGEs and PAI-1 can regulate mechanisms of fibrosis, some of which are 
independent of traditional cytokine agonists.  Serine proteases of the coagulation cascade may 
also play roles in renal disease in addition to their traditional role in haemostasis.  Members of 
the coagulation cascade primarily carry out cell-mediated effects by acting through specific 
cell-surface receptors called PARs.  A number of coagulation factors have been implicated in 
the formation of crescents in glomerular diseases however, the role of coagulation in 
tubulointerstitial fibrosis is less well-known.  The work described in Chapter 6: Constituents 
of the coagulation cascade are spatially and functionally related to experimental 
tubulointerstitial fibrosis has examined temporal and spatial relationships of coagulation 
factors, their specific cell-surface receptors and myofibroblasts in vivo to establish potential 
roles of non-cytokine-mediated pathways that aid our understanding of mechanisms of 
fibrosis.     
The renal fibroblast plays an indispensable role in tubulointerstitial fibrosis and the aim of this 
thesis was to examine those facets of renal fibroblast function that are most devastating to 
renal function and culminate in an expansion of the renal interstitium during fibrosis.  This 
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work hopes to provide useful information to aid the understanding of the multifaceted 
mechanisms involved in renal tubulointerstitial fibrosis.  
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1.1 INTRODUCTION 
Within Australia, as elsewhere, chronic kidney disease is a major public health 
problem with enormous social and economic cost to the community. Approximately 60,000 
Australians have some degree of renal impairment, with almost 5,000 of these receiving 
ongoing dialysis for end stage renal failure (ESRF) (Australian Kidney Foundation, 1999).  
On a global scale, it is estimated that the population with end stage renal disease (ESRD) will 
exceed 2 million patients by the year 2010 (Lysaght, 2002).  Even more worrying is the 
realisation that the population of patients with kidney failure is increasing at approximately 
5% per annum.  United States National Health Examination Surveys indicate that this is due 
in a large part to obesity and diabetes which are associated with an increased risk of 
developing chronic kidney disease (Fox et al., 2004).  Chronic kidney disease is therefore 
increasingly recognised as an epidemic and has been described as a critical health problem by 
those at the forefront of this area of research (Eddy and Neilson, 2006; Kiberd, 2006).   
For people who currently suffer with ESRF, the only options are dialysis and 
transplantation.  These therapies are forms of renal replacement and do not treat the cause of 
ESRF.  They present themselves with inherent difficulties such as undefined waiting periods, 
increased mortality and decreased quality of life.  Because accurate predictors of those at risk 
and those with established progressive renal disease are not available, there is an increasing 
emphasis on fundamental research that can identify new therapeutic targets to combat ESRD 
(Eddy and Neilson, 2006).   
Regardless of aetiology, chronic kidney disease culminates in the accumulation of 
excess extracellular matrix (ECM), characterised as glomerulosclerosis, tubulointerstitial 
fibrosis and vascular sclerosis.  Unfortunately, the best available therapies, primarily targeting 
the renin-angiotensin system (RAS), only delay progression by months and ultimately patients 
succumb to renal failure. It is therefore apparent that despite the underlying significance of 
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sclerosis and fibrosis, there is no current treatment available to abrogate the progression of 
renal fibrosis.   
In order to formulate viable treatment options, the current focus is on enhancing our 
understanding of the mechanisms of tubulointerstitial fibrosis at a molecular level.  Over 
recent years, research has identified key regulators that dictate the progression of renal 
disease. These factors may be extraneous variables, or the molecular and cellular pathways 
that lead to ESRF (Fig. 1.1).  Investigators in this field now strongly recognise the key roles 
of interstitial fibroblasts in mediating fibrosis.  These cells acquire features of smooth muscle 
cell differentiation in injury (Hewitson and Becker, 1995; Hewitson et al., 1998; Hewitson et 
al., 1995). Recognised from de novo expression of α-smooth muscle actin (αSMA), the so-
called myofibroblast is responsible for scarring through its proliferation, increased expression 
of ECM proteins and contraction of the surrounding matrix (Hewitson et al., 1998).   
Although seemingly a simple connective tissue cell, fibroblasts represent highly 
heterogenous cell populations with complex mechanisms of derivation and function.  
Although the presence of fibroblasts and their differentiated counterparts is a key indicator of 
the severity of tubulointerstitial fibrosis, our understanding of this cell during fibrosis lacks 
the type of detail that is needed to formulate viable therapeutic treatments to ameliorate 
fibrosis. Central to this, although the transforming growth factor β (TGFβ) signalling axis is a 
well-characterised mediator of fibroblast function, the complex array of fibroblast regulators 
in the interstitial milieu highlight the likely involvement of other signal transduction 
pathways.  
Indeed, given that the like of fibroblast growth factor (FGF), epidermal growth factor 
(EGF) and platelet derived growth factor (PDGF) act through receptor tyrosine kinases (RTK) 
and play roles in fibroblast regulation, this suggests that fibroblast signalling is not solely 
dependent on the TGFβ axis.  It is well known that the serine/threonine kinase 
phosphatidylinositol 3-kinase (PI3K) is a key integrator of these growth factors through RTK  
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and studies in lung fibroblasts and vascular smooth muscle cells (VSMC) highlight the role in 
this kinase in controlling proliferation, differentiation and ECM synthesis in these cells. 
Mammalian target of rapamycin (mTOR), most well-known for its role in 
immunosuppression, is increasingly recognised for its ability to integrate growth factor 
signals from PI3K by acting as a downstream mediator and is now tagged as a central 
regulator of cell cycle progression and differentiation. This suggests that these 
serine/threonine kinases may play roles in the regulation of fibroblast function. 
Studies have also highlighted roles of non-cytokine mediated pathways in 
tubulointerstitial fibrosis that can mediate effects through a GTP-binding (G-protein) protein 
coupled receptor (GPCR) family called protease activated receptors (PARs).  Whilst the roles 
of proteases of the coagulation cascade are well outlined in glomerular diseases, the role of 
this cascade in tubulointerstitial fibrosis is less well known. The most insightful information 
of their significance however can be ascertained from the serine protease thrombin which has 
been shown to mediate a number of fibrotic events in vitro. However, the roles of the 
coagulation cascade in the interstitium are relatively unknown. 
It has become increasingly recognised that myofibroblasts may be derived from a 
number of sources, including resident fibroblasts, migrating perivascular (adventitial cells), 
recruitment of circulating progenitor cells, and injured tubular cells through a process of 
epithelial-mesenchymal transition (EMT).  In vivo studies have underscored the importance of 
tubular EMT in renal fibrosis and this has changed the concept that fibroblasts are only locally 
derived.  EMT is a highly complex process and whilst TGFβ is a key regulator of this process 
and the likes of mitogen-activated protein kinase (MAPK) and Rho have also been implicated 
in renal EMT, the signalling circuitry involved in engaging the EMT proteome is not well 
established.     
This review therefore primarily focuses on facets of fibroblast function and regulation 
during fibrosis. Accordingly, it draws focus to the known cellular mechanisms of 
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tubulointerstitial fibrosis, the roles of the renal fibroblast in fibrosis, the role of the 
coagulation cascade in tubulointerstitial fibrosis, myofibroblast derivation including EMT, 
and mechanisms of fibroblast signalling in fibrosis. 
 
1.2 FIBROSIS 
Fibrosis can be defined as the deposition of excessive amounts of connective tissue in 
an organ.  Whilst repair and healing through fibrosis constitute an essential response to tissue 
injury in order to restore normal function, in some cases the inflammatory process becomes 
prolonged and fibrosis will ensue independently of the initial stimulus.  This type of response 
is maladaptive and can have devastating consequences on the parenchymal tissue of organs 
including the liver (Desmouliere et al., 2003), lung (Nagler et al., 1996), heart (Lim and Zhu, 
2006), and kidney (Strutz and Zeisberg, 2006) ultimately leading to organ failure.  
 
1.3 RENAL TUBULOINTERSTITIAL FIBROSIS 
The tubulointerstitium makes up more than 90% of the renal volume and comprises 
the tubules, renal parenchymal space between the tubules, glomeruli and vessels; the normal 
interstitium being made up of a loose hydrated matrix of collagens (especially types I and III), 
proteoglycans, and fluid, in which matrix-producing fibroblasts, macrophages, and dendritic 
cells are distributed.  The interstitial matrix is therefore important for both the structural and 
the functional integrity of the kidney.  Diffusion of oxygen from the peri-tubular capillaries to 
the tubules and the transfer of solute and water will largely be influenced by the width and the 
constituents within the interstitium. Any alteration to the interstitial matrix has profound 
effects on both fluid and electrolyte balance and renal function. 
Primarily for this reason, fibrosis of the interstitium is now the key correlate to the 
decline in renal function, often reflected by reductions in glomerular filtration rate (GFR) to 
less than 60ml/1.73M
2
 (Kiberd, 2006) (Rodriguez-Iturbe et al., 2005). Furthermore, 
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tubulointerstitial fibrosis occurs regardless of whether the initial pathology occurs in the 
glomeruli, tubules or vessels.  This was first noted by Spühler and Zollinger in 1953 (Spuhler 
and Zollinger, 1953) and it is now established that in most patients with chronic renal disease, 
a decline in renal function correlates with the severity of lesions of the tubular and interstitial 
compartments of the kidney more closely than with glomerular injury (Bohle et al., 1994; 
D'Amico, 1999; Nath, 1992; Risdon et al., 1968).  
Given the relative significance of the tubulointerstitium, renal tubulointerstitial 
fibrosis is the final common pathway leading to ESRF and may ultimately proceed 
independently of the initial stimulus (Kriz and LeHir, 2005).  Furthermore, it is a key feature 
of progressive renal disease regardless of the underlying aetiology. This may include 
hypertension, glomerulonephritis or vasculitis, diabetes, infection or kidney stones 
(Chatziantoniou and Dussaule, 2005).  
  Similar to fibrosis in other solid organs in the body, renal tubulointerstitial fibrosis is 
characterised by continuous tissue injury, inflammation and ECM deposition.  However, 
unlike fibrosis in the liver (Farci et al., 2004), heart (Diez et al., 2002) and skin (Delanian et 
al., 2003), the regression of kidney fibrosis is not as well-established.  Whilst the process of 
tubulointerstitial fibrosis involves a number of pathological entities including persistent 
proteinuria, hyperfiltration, cellular inflammation and the release of cytokines (Eddy and 
Neilson, 2006), the most significant feature of tubulointerstitial fibrosis and indeed the likely 
reason that this pathological process is linked to declining renal function is the unyielding 
expansion of the interstitial volume.  During progressive renal disease it is characterized by 
thickened tubular basement membranes and an expanded interstitial compartment with an 
increase in collagens I, III, V, VII, laminin (Eddy, 1996).  This relentless increase in 
interstitial volume is a complex process that is regulated by matrix degrading enzymes and 
their inhibitors, likely to be dictated by the interstitial milieu, and ultimately the expansion of 
interstitial components encroach the surrounding parenchymal tissue. Tubulointerstitial 
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fibrosis can therefore be characterised by glomerulosclerosis, tubular atrophy including 
obliteration of peri-tubular capillaries, and vascular sclerosis (el Nahas et al., 1997).  This 
facilitates the release of more cytokines, and inflammatory mediators, aggravating the 
repetitive cycle of tissue injury and ECM deposition, and this will often lead to ESRF (Fig. 
1.2).  
 
 1.3.1 Causes of tubulointerstitial fibrosis 
 Tubulointerstitial fibrosis can be induced as a result of damage to glomerular 
structures or can occur due to primary interstitial disease.  In humans and animal models, the 
majority of renal diseases which progress onto renal failure are a result of glomerular-based 
insults.  Consistent with the notion that renal tubulointerstitial fibrosis is the final common 
pathway of nearly all types of progressive renal disease, it is thought to be induced by a 
diverse range of pathogenetic stimuli.  These include toxins (eg. heavy metals) (Madrenas et 
al., 1991), drugs (eg. analgesics), crystals (eg. calcium phosphate, uric acid), infections, 
obstruction (Nagle et al., 1973), lipid deposition, immunologic mechanisms, acute elevations 
in capillary pressure and by ischemia.  Many of these factors activate tubular epithelial cells. 
Glomerular disease can also injure the tubulointerstitium through mechanisms that 
may involve glomerular cytokine release, complement activation (Camussi et al., 1983), 
effects of proteinuria (Eddy, 1989), ischaemia (Nagaoka et al., 2000), or cross-reactive 
immunity (Mendrick et al., 1980).  Although it is thought that many of these injurious 
mediators induce interstitial fibrosis through activation of the tubular segments of the 
nephron, the exact mechanisms are controversial.  As outlined by Kriz and LeHir (Kriz and 
LeHir, 2005), tubular damage may be brought about by mis-directed glomerular ultrafiltrate, 
present in sclerotic diseases, or by glomerular inflammation.  Whilst the former process is 
thought to lead to obstruction or atrophy, and degeneration of the tubule, in inflammatory 
diseases crescents form within the glomerulus leading to encroachment of the  
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glomerulotubular junction.   Tubular injury may also result from glomerular damage through 
leakage of protein. Tubular absorption of high concentrations of protein is sufficient to elicit 
an inflammatory response in a number of animal models (Abbate et al., 1998; Eddy and 
Giachelli, 1995; Eddy et al., 2000).  However, whilst proteinuria has been demonstrated in a 
number of studies to be a correlate of the degree of interstitial fibrosis (Burton and Harris, 
1996; Remuzzi, 1999; Zoja et al., 2003), there is little evidence to suggest the damage is 
irreversible  (Hoffmann et al., 2004; Kriz et al., 2003; Le Hir and Besse-Eschmann, 2003).  
For an outline of the various causes of tubulointerstitial fibrosis, see Fig. 1.3.  
 
1.3.2 Pathogenesis of tubulointerstitial fibrosis 
The evolution of fibrosis involves several discrete but overlapping events: 
inflammation, fibrogenesis, remodelling and resolution.  
 
 1.3.2.1 Inflammation  
1.3.2.1.1 Chemical signals in tubulointerstitial fibrosis 
Epithelial and endothelial cells can be damaged and consequently activated in a 
variety of ways as outlined above.  The response of these cells, particularly that of epithelial 
cells, includes degeneration and apoptosis (Yang et al., 2006c), proliferation (Bonventre, 
2003), the secretion of ECM components (Grande et al., 2002a; Shirato et al., 2003), or EMT 
(Iwano et al., 2002).  However, the primary cause of tubulointerstitial inflammation and 
indeed the key response of tubular epithelial cells is substantial release of inflammatory 
cytokines.  As outlined in Fig. 1.4, the activation of tubular epithelial cells and the subsequent  
induction of tubulointerstitial inflammation occurs in response to release of chemoattractants 
including monocyte chemoattractant protein-1 (MCP-1) and RANTES (regulated on 
activation, normal T-cell expressed and secreted), a process that is mediated by the up-
regulation of nuclear factor κB (NFκB) (Rodriguez-Iturbe et al., 2005). This leads to the  
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Fig. 1.4
Cellular mechanisms of tubulointerstitial fibrosis.
Tubulointerstitial fibrosis can be induced by diverse stimuli 
including toxic or drug insult, obstruction, proteinuria, 
misdirected glomerular ultra-filtrate and post-glomerular
ischaemia. This activates tubular epithelial cells which can 
respond by secreting various cytokines including MCP-1 and 
RANTES leading to the infiltration of mononuclear inflammatory 
cells including macrophages and lymphocytes. During this 
phase we also see the recruitment and activation of the 
interstitial fibroblast (regulated mainly by TGFβ1, PDGF and 
FGF) which responds in an autocrine or paracrine fashion by 
proliferating and differentiating into myofibroblasts. 
Myofibroblasts represent a key effector cell in fibrosis and may 
also be derived via EMT, a process which is mainly mediated by 
TGFβ amongst other cytokines. These molecular events 
culminate in renal fibrosis.
Adapted from Rodriguez-Iturbe et al, 2005.
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infiltration of mononuclear inflammatory cells including monocytes, macrophages and T 
lymphocytes into the tubulointerstitial space (Strutz and Neilson, 2003).  These cells secrete 
various cytokines, which leads to a further increment in the local cytokine pool.  
Consistent with the complexity of fibrosis, an array of mediators become up-regulated 
in the interstitium including TGFβ1, PDGF, connective tissue growth factor (CTGF), FGF, 
EGF, and vasoactive mediators such as angiotensin II and endothelin.  The increase in the 
concentration of this pro-fibrotic milieu acts to stimulate the chemokine-mediated recruitment 
of more interstitial mononuclear cells. 
   
1.3.2.1.2 Non-chemical mediators: Coagulation cascade in renal fibrosis 
Although cytokines and growth factors are recognized as key mediators of renal 
tubulointerstitial fibrosis, a number of non-cytokine mediated pathways are likely to be 
involved including tissue plasminogen activator (tPA) (Yang et al., 2002b), plasminogen 
activator inhibitor-1 (PAI-1) (Eddy, 2002; Matsuo et al., 2005), advanced glycation end 
products (AGEs) (Oldfield et al., 2001) and serine proteases of the coagulation cascade.   
Given that (a) the coagulation cascade can be directly activated during injury and 
inflammation (Grandaliano et al., 2001; Sekiya et al., 1994) and (b) that a number of studies 
have localized specific surface receptors of the family of coagulation factors to a number of 
renal cells including tubular epithelial cells (Sower et al., 1995; Vesey et al., 2005; Xiong et 
al., 2005; Xu, 1995), endothelial cells (Xu, 1995) fibroblasts (Hewitson et al., 2005; Sower et 
al., 1995; Xiong et al., 2005) and mesangial cells (Grandaliano et al., 2000a; Xu, 1995), a 
growing number of studies have demonstrated the presence of coagulation factors in renal 
diseases of varying etiology.  Although many experimental models have confirmed the 
involvement of the coagulation/fibrinolysis system during glomerular inflammation and repair 
in the kidney (Fig. 1.5a-b) (Grandaliano et al., 2000a; Hertig and Rondeau, 2004; Liu et al.,  
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2004; Liu et al., 2000; Ono et al., 2001), less is known about serine proteases, and the role 
they play in tubulointerstitial fibrosis.   
The traditional function of the coagulation cascade is to ensure that there is minimal 
blood loss through the formation of a mesh clot consisting of fibrin and platelets. Coagulation 
comprises a complex series of event that can be activated through either extrinsic or intrinsic 
pathways.  During the initial stages, tissue factor (thromboplastin; a membranous 
glycoprotein) acts in concert with factor VII to catalyse the formation of active factor Xa from 
factor X (Matsuyama et al., 2003). Stimulation of the intrinsic pathway on the other hand 
directly activates factor Xa.  Linking of factor Xa to factor Va then facilitates the generation 
of thrombin from prothrombin. This ultimately leads to the formation of fibrin, and the 
deposition of fibrin clots around injured vessels (Fig. 1.6).  This is the classical interpretation 
of the role that the coagulation cascade plays in physiological circumstances.   
  Growing evidence however, suggests that members of the coagulation cascade may 
facilitate inflammatory processes and fibrosis (Coughlin, 2000; Ossovskaya and Bunnett, 
2004; Rondeau, 2001).  These studies suggest that, although historically, cytokines have been 
shown to mediate key events in fibrosis, non-cytokine mediators can have pro-fibrotic effects 
independently, or working in cooperation with cytokine mediators.  In this theme, studies 
have demonstrated the concurrent activation of the coagulation cascade during disorders 
associated with inflammation and excessive deposition of ECM in the kidney (Bogatkevich et 
al., 2001).  
Fibrin, the end-product of coagulation, has become a persistent hallmark of the 
inflammatory response (Smiley et al., 2001) and correlates with the severity of renal 
tubulointerstitial damage in a number of studies (Cunningham et al., 1999; Liu et al., 2000; 
Ono et al., 2001). This has been documented in the tubulointerstitium of renal diseases 
including experimental unilateral ureteral obstruction (UUO), human allograft rejection and 
acute ischaemic renal failure (Enestrom et al., 1988; Faulk et al., 1989; Grandaliano et al.,  
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2000b; Wang et al., 1997; Wang et al., 1996; Wendt et al., 1995; Yamamoto and Loskutoff, 
1997).  Other studies have also identified the presence of factor Xa (Blanc-Brude et al., 2001), 
tissue factor (Grandaliano et al., 2000a), and factor V (Liu et al., 2000) during tissue damage 
and inflammation. Most work to date however has focused on the serine protease thrombin 
which can be found in the interstitium as a consequence of increased capillary permeability 
(Plante et al., 1996) and misdirected filtration from the glomerulus to the interstitium (Kriz et 
al., 2001), both features of interstitial pathology. 
The serine protease thrombin plays regulatory roles in vascular tone, wound healing 
and inflammatory reactions through the stimulation of platelets, leukocytes, endothelial cells, 
smooth muscle cells and fibroblasts (Grand et al., 1996; Ludwicka-Bradley et al., 2000; 
Sekiya et al., 1994), consistent with its ability to be generated independently of the 
coagulation cascade (Cole et al., 1985; Sekiya et al., 1994).  The potential pro-fibrotic cell-
mediated effects of thrombin have existed for over 30 years. Thrombin’s ability to induce cell 
mitogenesis was initially noted in chick embryo fibroblasts in 1975 (Chen and Buchanan, 
1975).  Since then thrombin has been found to have a plethora of pro-fibrotic effects including 
acting as a chemo-attractant for fibroblast populations (Bogatkevich et al., 2001; Hewitson et 
al., 2005), up-regulating CTGF (Chambers and Laurent, 2002; Chambers et al., 2000; Howell 
et al., 2001), interleukin-6 (IL-6) (Sower et al., 1995), MCP-1 (Vesey et al., 2005), 
TGFβ1 (Bachhuber et al., 1997; Grandaliano et al., 2001; Vesey et al., 2005), PDGF (Ohba et 
al., 1994), tissue inhibitor of metalloproteinase-1 (TIMP-1) (Shirato et al., 2003), and up-
regulating ECM components including fibronectin (Shirato et al., 2003; Vesey et al., 2005) 
and procollagen mRNA (Chambers et al., 1998; Hewitson et al., 2005; Howell et al., 2001).  
Furthermore, it has been documented that thrombin and αSMA can co-exist in the 
inflammatory and early fibrotic stages in a number of pathological situations (Coughlin, 
2000), and accordingly, thrombin has also been shown to be an activator of fibroblasts in vitro 
in the lung (Bogatkevich et al., 2001; Tani et al., 1991), skin (Dawes et al., 1993) and kidney 
 18
(Hewitson et al., 2005) and can also mediate TGFβ1-independent differentiation of fibroblasts 
into myofibroblasts (Bogatkevich et al., 2001).   
 
1.3.2.2 Fibrogenesis  
Whilst a process like wound healing leads to relatively normal functioning with 
minimal scar tissue, the process of tubulointerstitial fibrosis is generally a relentless process 
that occurs when the inflammatory response is prolonged, leading to the continued 
inflammatory cell release of pro-fibrotic moieties and mesenchymal cell stimulation 
(Bitterman and Henke, 1991).   During this phase we see the activation and recruitment of 
interstitial fibroblasts, which hyperproliferate in response to cytokines such as FGF, PDGF 
and EGF, migrate to areas of damage in response to chemotactic substances, and differentiate 
into αSMA-positive myofibroblasts.  As mentioned, this phenotype facilitates the deposition 
of abundant ECM proteins and indeed, these cells are the principal generators of ECM 
proteins in fibrosis (Fig. 1.4).  Other cells may also become activated during interstitial 
inflammation and it has been shown that both mesangial cells and epithelial cells can 
contribute to the accumulation of ECM proteins (Liu, 2006).   
Although the reasons of why tubulointerstitial fibrosis does not resolve are somewhat 
elusive, there are a number of likely mechanisms to explain the prolonged nature of the 
response in the kidney.  It is believed that the fibrotic response is enhanced because of the 
presence of continuous fibrogenic signals which may become increasingly amplified (Liu, 
2006).  Integral to the amplification of fibrogenic signals is the perpetuation of the activated 
fibroblast (Zeisberg et al., 2000) independent of the initial stimulus and the subsequent 
generation of exuberant amounts of ECM proteins (Fig. 1.7a-c). 
Furthermore, in fibrosis the accumulation of ECM proteins is believed to develop as a 
result of disruption to the turn-over and production and of its constituents, potentially due to 
respective down regulation of metalloproteinase (MMP) activity, and increases in TIMPs   
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(Jones et al., 1992) and PAI-1 (Johnson et al., 2002).  This may also result from prolonged 
autocrine and paracrine stimulation from local cells.  Lastly, the termination of fibroblast 
activity by apoptosis, unlike wound healing (Darby et al., 1990; Desmouliere et al., 1995), has 
not been convincingly shown in renal fibrosis (Hewitson et al., 2000a; Strutz and Muller, 
1999).  
In cases where inflammation subsides, matrix synthesis may also continue due to 
prolonged autocrine stimulation from activated resident fibroblasts (Lonnemann et al., 1995). 
Furthermore, it has been noted that whilst myofibroblast differentiation from resident 
fibroblasts may be an early event in fibrosis, EMT may be a delayed event (Yang and Liu, 
2001).  This provides a mechanism whereby the fibroblast pool may be replenished with 
ongoing fibrosis and provides a driving force for the sustenance and aggravation of tissue 
injury and inflammation during progressive renal disease.   
 
1.3.2.3 Remodelling 
The composition of interstitial scars primarily consist of collagen types I, III and IV, 
fibronectin and tenascin as well as other glycoproteins such as proteoglycan, thrombospondin 
and osteopontin (Harris and Neilson, 2006).  Newly synthesised matrix is progressively 
remodelled by various proteases (secreted by fibroblasts and macrophages), while contraction 
of matrix increases its density leading to the loss of blood supply rendering the tissue acellular  
and fibrotic. This distorts the parenchymal architecture of the kidney leading to its collapse 
and loss of kidney function.  
 
1.3.2.4 Resolution  
The resolution of tubulointerstitial nephritis represents an important step in limiting 
the extent of renal scarring (Kuncio et al., 1991).  How fibroblasts are removed at the 
completion of scarring remains unclear, with phenotypic regression, cell death and ex-
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migration all possible mechanisms however they have not been convincingly proven.  Studies 
in skin wound healing (Darby et al., 1990; Desmouliere et al., 1995) suggest that fibroblastic 
cells are removed by apoptosis at the completion of wound healing.  Importantly apoptosis 
leads to the safe removal of cells by phagocytosis, whereas in contrast, necrosis provokes 
tissue injury and inflammation (Savill, 1994).  To date evidence that renal fibroblasts are 
removed efficiently by apoptosis is inconclusive (Lane et al., 2002; Tang et al., 1996).  
 
1.4 ROLE OF THE FIBROBLAST IN TUBULOINTERSTITIAL FIBROSIS 
 In the normal kidney, fibroblasts are typically found surrounding arterioles but their 
distribution is relatively sparse and they have a low turn over rate.  However, in fibrosis these 
cells become activated, and are responsible for the generation of scar tissue through 
hyperproliferation, increased synthesis of ECM proteins, and contracture of the surrounding 
tissue.  These cells are influenced by a variety of cytokines, growth factors, and non-cytokine 
agonists, however many studies indicate that fibrosis is dictated by a hierarchy of mediators, 
the most important arguably being TGFβ1, PDGF and FGF.  
 
1.4.1 Fibroblast structure and function 
Fibroblasts are the prototypical mesenchymal cell (Qi et al., 2006). Renal fibroblasts 
were originally classified into ‘fibroblast-like’ cells in the cortex and ‘lipid-laden’ cells in the 
medulla (Bohman and Jensen, 1976; Bohman and Jensen, 1978). Since then, a number of 
fibroblasts have been classified into different groups based on mitotic and matrix synthesising 
activities (Grupp and Muller, 1999; Muller et al., 1992; Zeisberg et al., 2000). The fibroblast 
displays a typical elongated spindle phenotype with cortical actins (γ and β) in their 
cytoplasm.  Intracellularly, they have a large nucleus, dense endoplasmic reticulum and an 
extensive golgi apparatus however mitochondria are sparse (Qi et al., 2006) (Fig. 1.8a).  
Fibroblasts have abundant microtubules allowing them to contact tubules of adjacent  
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As demonstrated by EM, fibroblasts have a spindle shape morphology with slender polar 
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(c) αSMA microfilaments in myofibroblasts demonstrated by Immunofluorescence (Hinz 
et al., 2001) and EM (d); a fully differentiated myofibroblast displays characteristic 
features including a prominent rER, a large golgi apparatus, myofilaments (arrow heads) 
and a substantial fibronexus (arrows).
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fibroblasts, capillaries, parietal cells, other interstitial cells and nerve terminals through focal 
adhesions within their cytoplasm (Qi et al., 2006). Functionally, these cells are therefore an 
integral part of the interstitium providing structural support and integrity to the ECM.  
Fibroblasts are also a major regulator of the ECM. ECM is normally maintained by 
controlling the amount of matrix synthesis in balance with that which is degraded and this is 
chiefly regulated by MMPs and TIMPs.  Fibroblasts are a major source of these proteases and 
their inhibitors (Valle and Bauer, 1979) as well as PAI-1 and interstitial collagens (Fig. 1.8b). 
These cells are therefore a key regulator of ECM balance.  Moreover, fibroblasts express 
many growth factor receptors, integrins such as α1, α4, α5 and β1 (Norman and Fine, 1999), 
cell adhesion molecules and non-integrin matrix receptors such as discoidin domain receptors 
(Qi et al., 2006). This allows them to respond to a variety of stimuli and efficiently regulate 
the ECM through communication inter-cellularly and with the surrounding matrix. Although 
active fibroblasts are heterogeneous in their biochemical synthesis and are capable of 
secreting many types of proteins, increased synthesis of fibronectin is a universal event and 
acts as an important mediator of collagen deposition by acting as a scaffold on which 
subsequent interstitial collagen is fixed (Goyal and Wiggins, 1991) (Clark, 1989).  Once 
fibronectin has been deposited in the ECM, this facilitates the deposition of a variety of 
interstitial collagens including collagen types I, III and V (Rodemann and Muller, 1991).   In 
vitro studies with non-renal fibroblasts suggest that they are also capable of synthesising 
several other ECM components including chrondroitin sulphate (David et al., 1989) and 
hyaluronan (Heldin et al., 1989).  
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1.4.2 Myofibroblast structure and function 
The term myofibroblast is given to differentiated fibroblasts that express the VSMC 
associated protein αSMA (Hewitson and Becker, 1995; Hewitson et al., 1998; Hewitson et al., 
1995). Accordingly, these cells share phenotypic similarities between VSCM and fibroblasts. 
These cells were originally identified as the cells responsible for wound healing by Gabbiani 
et al (Gabbiani et al., 1971), and are characterised in the kidney as the major ECM generating 
cells in tubulointerstitial fibrosis (Neilson, 2006; Qi et al., 2006).  They have been 
demonstrated in a wide variety of renal diseases associated with renal interstitial fibrosis in 
humans (Goumenos et al., 1994; Yang et al., 1998)(Hewitson and Becker, 1995) and 
experimental models (Diamond et al., 1995; Hewitson and Becker, 1995).  It is the acquisition 
of these cells that is therefore a key indicator of the severity of tubulointerstitial fibrosis (Qi et 
al., 2006).  
In contrast to the reduced and spindle shaped cytoplasm of an inactive fibroblast, 
myofibroblasts have a much larger cytoplasm to facilitate the synthesis and secretion of 
collagen, elastin and reticulin precursors as well as the glycosaminoglycans found in ground 
substance. Their cytoplasm also contains an extensive rough endoplasmic reticulum (rER) and 
golgi apparatus, and hemidesmosomes (Fig. 1.8d). Myofibroblasts also have structural 
features similar to the smooth muscle cell including longitudinal cytoplasmic bundles of 
microfilaments and nuclear membrane folds (Sappino et al., 1990).   These differentiated cells 
also express vimentin, desmin (Eyden, 2001) and αSMA bundles (Fig. 1.8c).   These actin 
bundles terminate at the myofibroblast surface in the fibronexus. The fibronexus is an 
adhesion complex that uses transmembrane integrins to connect with extracellular fibronectin 
and therefore provides a mechano-transduction system where myofibroblasts can transmit 
force generated by stress fibres into the surrounding matrix (Tomasek et al., 2002). 
Myofibroblasts are also connected to each other through Gap junctions potentially allowing 
them to form multi-cellular contractile apparatuses during healing.  
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1.4.3 Phenotypic markers of the fibroblast and myofibroblast 
Because fibroblasts are a heterogenous cell population with poor immunogenicity, 
reliable markers have been difficult to identify. In vitro studies of cultured renal fibroblasts 
suggest that they undergo a one-way terminal differentiation through 3 mitotically active 
progenitor fibroblasts, then after mitosis differentiate to 3 post-mitotic cell types (PM; PMF 
IV, PMF V, PMF VI), with increasing biosynthetic activity for various fibroblast proteins, 
including collagen (Muller et al., 1992).  The characterisation of fibroblasts can therefore be 
ambiguous when differentiating these cells from other mesenchymal cells like VSCM or 
pericytes. Recently fibroblast specific protein (FSP1) has become a widely used marker of 
fibroblasts (Iwano et al., 2001; Strutz et al., 1995), however this marker has come into 
question as it has been shown in vivo that the human homologue s100A4 is expressed by 
mononuclear inflammatory cells (Le Hir et al., 2005). Myofibroblast-specific markers are also 
lacking and to complicate matters, it is thought that only a subset of activated myofibroblasts 
express the most widely used marker of these cells, αSMA (Okada et al., 2000a). 
Furthermore, αSMA is also found in numerous other cells including smooth muscle cells, 
pericytes, myoepithelial and interstitial cells of Cajal (Eyden, 2004).  Table 1.1 outlines the 
various putative markers of fibroblasts and myofibroblasts. 
 
Cell Marker Reference 
 
Interstitial fibroblast 
5’ ectonucleotidase, CD44, 
PDGF α and β receptors, FSP1, 
ICAM, DDR2, HSP47, NGF 
(Iwano et al., 2002; 
Ohba et al., 2005; Qi et 
al., 2006; Strutz et al., 
1995) 
Myofibroblast αSMA (Darby et al., 1990) 
 
Table 1.1: Putative markers of fibroblasts and myofibroblasts.  
Intracellular adhesion molecule (ICAM), discoidin domain receptor (DDR), heat shock protein (HSP), nerve growth factor  
(NGF).  
Adapted from Strutz and Zeisberg (Strutz and Zeisberg, 2006). 
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1.4.4 Activation of the fibroblast in tubulointerstitial fibrosis 
Fibroblasts from fibrotic kidneys display a higher mitogenic potential and a 3-5 fold 
increase in the rate of collagen synthesis as compared to their quiescent counterparts 
(Rodemann and Muller, 1991), consistent with the concept that fibroblasts from normal 
kidneys differ from fibroblasts found in fibrotic kidneys.  The activation of fibroblasts can 
occur through four distinct mechanisms: (a) paracrine or autocrine stimulation by growth 
factors (TGFβ, PDGF, FGF and CTGF); (b) direct cell-cell contacts (leukocytes and 
macrophages); (c) through the ECM though integrin signalling (α and β), and (d) by changed 
environmental conditions in renal disease (hypoxia, AGEs, ROS and high glucose) (Qi et al., 
2006; Zeisberg et al., 2000).  Once activated, fibroblasts can maintain their activated 
phenotype after the initial stimulus has been long removed (Strutz and Muller, 1995), 
presumably through autocrine stimulation (Strutz et al., 2000). It is these activated fibroblasts 
that are good predictors of the development of tubulointerstitial fibrosis (el Nahas et al., 1997) 
and animal studies that have incorporated a suicide transgene have been shown to 
conditionally minimise fibrosis through the depletion of fibroblasts (Iwano et al., 2001).   
  Activated fibroblasts become motile and migrate through the surrounding interstitial 
matrix to sites of damage, aided by the secretion of stromelysins and collagenases (Kuncio et 
al., 1991) and chemotactic substances (Wiggins et al., 1993).   They are also capable of 
secreting collagens type I, II and V (Rodemann and Muller, 1991) and fibroblasts in anchored 
lattices also increase expression of genes coding for collagens I, III, VI, XII and tenascin-C, 
(Chiquet, 1999; Chiquet-Ehrismann et al., 1994; Lambert et al., 1992).   It is likely that the 
migration to the site of injury precedes the phenotypic change to αSMA expressing 
myofibroblasts, since it has been shown in vitro that the fully differentiated myofibroblast is 
not motile (Ehrlich and Rajaratnam, 1990).  The increase in fibroblast number doesn’t only 
occur through migration but also local proliferation.  Early during chronic renal disease, 
fibroblasts rapidly proliferate to occupy the interstitium.  Anchored collagen lattice studies 
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show that fibroblasts become elongated, align in a plane of force offering least resistance and 
hyperproliferate (Lambert et al., 1992; Nakagawa et al., 1989). This proliferation is mainly 
mediated through the direct or indirect actions of local cytokines and other factors (Kovacs 
and DiPietro, 1994).  For a complete list of such factors that regulate fibroblast proliferation, 
differentiation (outlined below) and ECM synthesis (outlined below), see Table 1.2.   
 
1.4.5 Fibroblast differentiation in tubulointerstitial fibrosis 
As previously mentioned myofibroblasts, are usually recognized by their de novo 
expression of αSMA.  The differentiation of these cells is a fundamental event in fibrosis and 
is thought to be chiefly regulated by TGFβ1 (Desmouliere et al., 1993).  Given that it has 
been noted that only a subset of these cells express αSMA (Desmouliere et al., 1992a), the 
term ‘proto-myofibroblast’ has been given to an intermediate form of a differentiated 
fibroblast that does not express this contractile protein (Tomasek et al., 2002) (Fig. 1.9). It is 
believed that mechanical tension and PDGF (Desmouliere et al., 1992b) are the main inducers 
of the proto-myofibroblast phenotype. These cells express cytoplasmic actins (but not αSMA) 
and the ED-A splice variant of fibronectin which is not expressed by fibroblasts, and they are 
capable of generating contractile force. 
Myofibroblasts are distinguished from proto-myofibroblasts by the presence of αSMA 
microfilaments and also by increased expression of ED-A fibronectin, focal adhesions and 
more stress fibres.  For a proto-myofibroblast to differentiate into an αSMA-positive cell, it is 
believed that TGFβ1 is an essential mediator of this process, which can be released by 
platelets, macrophages and parenchymal cells (Desmouliere et al., 1993; Tomasek et al., 
2002). TGFβ1 can facilitate differentiation by enhancing the assembly of stress fibres and the 
formation of fibronexus adhesion complexes (Tomasek et al., 2002). Differentiation is also 
facilitated by the expression of fibronectin when it is expressed in the ED-A splice variant 
form (Serini et al., 1998) and by sustained mechanical stress (Fig. 1.9).   
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Effector 
 
Fibroblast specific effects 
 
Signalling 
mechanism 
 
References 
TGFβ1 +/-Proliferation, ECM 
synthesis, differentiation, 
CTGF expression, 
decreases MMP 
expression, increases TIMP 
expression 
 
TGFβ-TβR-Smad 
2/3 axis, abl 
 
(Ignotz and 
Massague, 1986), 
(Igarashi et al., 1993), 
(Edwards et al., 1987; 
Frazier et al., 1996), 
(Reisdorf et al., 2001), 
(Strutz et al., 2001), 
(Desmouliere et al., 
2003), (Wang et al., 
2005) 
PDGF-BB Proliferation, 
differentiation and ECM 
deposition 
PDGFR, PI3K, Ras  (Bonner, 2004), (Tang 
et al., 1996), (Tang et 
al., 1997). 
 
*CTGF +/-Proliferation, 
differentiation, ECM 
deposition  
 
Smad axis 
 
(Duncan et al., 1999) 
(Yokoi et al., 2001), 
(Frazier et al., 1996). 
bFGF Proliferation and 
differentiation, inhibition 
of ECM synthesis 
FGFR1  
 
(Ichiki et al., 1997), 
(Strutz et al., 2000), 
(Strutz et al., 2001). 
 
EGF Proliferation 
 
EGFR  
 
(Alvarez et al., 1992), 
(Kikuchi et al., 1995), 
(Heldin et al., 1989). 
AGEs Proliferation, CTGF 
expression, ECM 
synthesis, apoptosis 
 
RAGE, JAK/Stat5 
 
(Peterszegi et al., 2006), 
(Huang et al., 2005), 
(Alikhani et al., 2005), 
(Lee et al., 2004), 
(Twigg et al., 2002), 
(Guh et al., 2001). 
 
Thrombin Proliferation, 
differentiation, ECM 
synthesis, CTGF synthesis 
PAR-1, MAPK, 
JNK 
 
(Hewitson et al, 2005), 
(Bogatkevich et al., 
2001), (Chambers et al., 
2000), (Chambers et al., 
1998), (Remillard and 
Yuan, 2005). 
 
Angiotensin II TGFβ synthesis, 
proliferation, ECM 
synthesis, differentiation 
Smad axis, RhoA, 
p38, ERK, JNK, 
PI3K 
 
(Kellner et al., 2006), 
(Huang et al., 2006), 
(Lijnen et al., 2006), 
(Liu et al., 2006b), 
(Pokharel et al., 2002). 
 
Endothelin Differentiation, 
contraction, migration 
ETA, PI3K, 
#
MAPK 
(Shi-Wen et al., 2004), 
(Wang et al., 1994)  
 
Table 1.2 Major regulators of fibroblast function.  
abl = abelson non-receptor tyrosine kinase, FGFR = fibroblast growth factor receptor, EGFR = epidermal growth factor 
receptor, ETA = endothelin A (receptor).  
*CTGF primarily acts as a downstream mediator of TGFβ.  
 #  In cells similar to myofibroblasts (mesangial cells). 
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The process of myofibroblast differentiation. Fibroblasts are thought to be able to 
transdifferentiate into proto-myofibroblasts in response to mechanical stress. Proto-
myofibroblasts contain cytoplasmic stress fibers that terminate in fibronectin adhesion complexes 
and express ED-A fibronectin at their cell surface. For the full differentiation of these cells into 
myofibroblasts, TGFβ in the presence of ED-A fibronectin and mechanical tension is required.
Myofibroblasts secrete large amounts of the ED-A splice variant of fibronectin and express 
αSMA. These cells contain large fibronexus adhesion complexes and are capable of generating 
more contractile force than proto-myofibroblasts. (Dashed line indicates not strongly supported).
Adapted from Tomasek et al, 2002.
Focal adhesion site
Cortical cytoplasmic actins
Cytoplasmic actins
aSMA
Fibronectin
ED-A fibronectin
Fibroblast
Proto-myofibroblast
Differentiated 
myofibroblast
Mechanical  
tension
TGFβ1 
ED-A fibronectin
Mechanical 
tension
Fig. 1.9
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  The sequence of events of fibroblast activation, proliferation, migration, 
differentiation and ECM synthesis is not entirely clear. It is generally thought that fibroblasts 
are activated and proliferate locally or migrate to the site of damage to then proliferate in 
response to chemotactic mediators. These cells can then differentiate into their contractile 
counterparts. The myofibroblast is thought to be a less motile cell whose primary role is the 
secretion of matrix proteins and contracture.  It is unclear whether myofibroblasts undergo 
significant proliferation, however animal studies have demonstrated exponential increases in 
myofibroblast mitosis and incorporation of bromo-deoxyuridine, a marker of cells that have 
entered the S phase of mitosis (Hewitson et al., 1995).   
 
1.4.6 Myofibroblast contraction and ECM synthesis in tubulointerstitial fibrosis 
Once significant numbers of myofibroblasts have formed in the area of tissue damage, 
they begin to actively secrete various collagens into the interstitium and are stimulated to 
contract. It is believed that matrix accumulation results from a combination of excessive 
production of ECM, and an inhibition of matrix breakdown, however these mechanisms are 
not clear.  TGFβ1 is a key mediator of the synthesis of ECM proteins such as fibronectin and 
collagen type I (Strutz and Neilson, 2003), however a number of factors in the fibrotic milieu 
are capable of also inducing ECM synthesis.  The myofibroblast is likely to play a major role 
in the dis-regulation of ECM homeostasis during fibrosis, and when taken with the ability of 
myofibroblasts to contract the surrounding matrix, activation of these cells can result in the 
compression of the surrounding parenchyma.  
  The contraction of myofibroblasts has been shown to be largely mediated by integrins 
through collagen lattice studies (which mimic the in vivo condition) (Kelynack et al., 2000; 
Klein et al., 1991). The intracellular stress filaments in myofibroblasts are bound to collagen 
fibrils through focal adhesions and fibronexus junctions which signal through integrin 
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transmembrane receptors.  Stress-fibre contraction leads to force generation and local matrix 
contraction causing a shortening and bundling of the surrounding collagen network. 
Myofibroblasts then secrete new matrix components to stabilise the new collagen organization 
increasing the density of collagen in the ECM (Tomasek et al., 2002). This type of response is 
magnified when the myofibroblast is continuously stimulated to contract, which may lead to 
an increase in interstitial volume and contracture of the matrix.   
 
1.5 MYOFIBROBLAST DERIVATION IN TUBULOINTERSTITIAL 
FIBROSIS 
1.5.1 Resident fibroblasts 
Local proliferation and migration from adjacent tissues, in particular the perivascular 
region, have been generally accepted as the mechanisms by which tissue myofibroblast 
numbers increase (Ross et al., 1970; Wiggins et al., 1993). The close association with 
fibroblasts in wound healing systems (Clark, 1989) supports the view that the myofibroblast 
phenotype is derived from fibroblasts.  Much of this rationale is based upon in vitro studies 
where after stimulation, previously quiescent fibroblasts express αSMA (Ronnov-Jessen and 
Petersen, 1993). Sequential ultrastructural studies in renal biopsies also imply that 
myofibroblasts are derived from resting fibroblasts (Yang et al., 1998).  It has also been 
suggested that renal interstitial myofibroblasts are mitotically active, suggesting that they may 
also be derived from local proliferation of other myofibroblasts (Hewitson et al., 1995).  Other 
possibilities including a pericyte origin (Nehls and Drenckhahn, 1993) and even a 
macrophage derivation have been proposed (Bhawan and Majno, 1989). In some fibrogenic 
tissues, the myofibroblast may be derived from a specialised cell type, as in hepatic fibrosis 
where myofibroblasts represent activated perisinusoidal or hepatic stellate cells (Hines et al., 
1993).  To complicate matters further, the pathogenesis of atheroma involves invasion of 
migrating smooth muscle cells, phenotypically similar to the myofibroblast, into the intima of 
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vessels (Desmouliere and Gabbiani, 1992; Hosenpud, 1993) which probably represents a 
partial loss of smooth muscle cell phenotype to resemble myofibroblasts.   
Moreover, mesangial cells can also differentiate into myofibroblasts. Mesangial cells 
create the ECM supporting network of the glomerular apparatus, secrete growth factors 
controlling normal cell turnover, and modulate filtration via contraction / relaxation.  Upon 
stimulation by glomerular injury, mesangial cells acquire phenotypic characteristics of 
myofibroblasts.  These activated myofibroblasts have the ability to proliferate at the site of 
injury, acquire smooth muscle cell properties, express αSMA and secrete collagens I and III 
as well as coagulation factors (Hertig and Rondeau, 2004).   
These and other studies have confirmed that the derivation of the myofibroblast is 
diverse and heterogenous pools of myofibroblasts are likely play a role in fibrosis. Whilst the 
derivation of myofibroblasts from the sources listed above are likely to contribute to the 
population of myofibroblasts, it is now suggested that the majority of interstitial 
myofibroblasts are derived from interstitial fibroblasts, bone-marrow derived pluripotential 
cells and through renal EMT (Iwano et al., 2002). 
 
1.5.2 Bone-marrow-derived pluripotential cells  
There is evidence that bone-marrow derived fibrocytes exist within the interstitium 
during fibrosis (Grimm et al., 2001; Iwano et al., 2002) and that these cells are recruited to 
sites of injury by undergoing mesenchymal-epithelial transition (MET).  In an experimental 
model of sex mismatched bone marrow transplants, they demonstrated mismatched 
deoxyribonucleic acid (DNA) in these cells, showing they were of donor origin, and that these 
donor cells were detectable in host skin wound chambers suggesting a fibroblast-like role in 
tissue repair. These cells have been shown to express ECM proteins such as procollagen I and 
procollagen III (Phillips et al., 2004) suggesting a role for these cells in the formation of 
connective tissue.  Moreover, studies using bone marrow chimeras, have established that 12% 
 33
of resident interstitial FSP1
+
, CD34
-
 fibroblasts may be derived from bone marrow (Iwano et 
al., 2002).   
 
1.5.3 Renal epithelial mesenchmyal transition 
EMT is a phenomenon that occurs in various biologic processes such as embryonic 
and post-natal development, carcinogenesis and chronic diseases (Kalluri and Neilson, 2003).  
EMT can be defined as the acquisition of phenotypic as well as functional properties of 
mesenchymal cells by epithelial cells (Zeisberg et al., 2001).  In this process epithelial cells 
lose their markers and phenotypic characteristics, acquire a mesenchymal phenotype, degrade 
the basement membrane and migrate into the surrounding matrix.  During embryogenesis, 
EMT and MET give rise to an array of fully differentiated adult cell types derived from 
pluripotential cells present in the developing embryo (Khew-Goodall and Wadham, 2005).  In 
the adult such transitions have been thought to generally be confined to those seen in wound 
healing and angiogenesis (Khew-Goodall and Wadham, 2005).  Of late it has however been 
noted that embryonic EMT can be recapitulated during certain adult disease states such as 
cancer (Grunert et al., 2003; Lee et al., 2006) and fibrosis (Iwano et al., 2002; Thiery and 
Sleeman, 2006) whereby dramatic morphological and functional changes take place to allow 
cells to develop a migratory and invasive capacity.  In fact, the potential for EMT in adult cell 
types has been documented for nearly twenty years and it is possible that this phenomena may 
be a relatively ubiquitous phenomenon in labile cell types (Boyer et al., 1989; Gilles et al., 
1994; Miettinen et al., 1994; Pagan et al., 1997).  Accordingly, accumulating evidence 
suggests that cellular plasticity in the adult may have been underestimated (Grunert et al., 
2003; Lee et al., 2006; Thiery and Sleeman, 2006).  
Furthermore, given that renal tubular epithelial cells (apart from the collecting duct) 
develop from metanephric mesenchyme during embryogenesis through MET (Liu, 2004a; 
Okada et al., 2000b), the existence of correct genetic cues and biological stimuli such as organ 
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remodelling (Hay, 1995) may underlie the potential for tubular epithelia to undergo a reversal 
of their embryonic development pattern (Okada et al., 2000b).  Indeed, the frequent 
observation of EMT in human Immuoglobulin A (IgA) nephropathy, rapidly progressive 
glomerulonephritis (RPGN)(Jinde et al., 2001), marked tubulointerstitial fibrosis 
(Vongwiwatana et al., 2005), diabetic glomerulosclerosis, lupus nephritis (Rastaldi et al., 
2002), and in animal  models of renal disease (Burns et al., 2006; Ng et al., 1998; Strutz et al., 
1995; Yang and Liu, 2001) implicates tubular epithelial cells as a source of interstitial 
myofibroblasts.  Amongst the animal models used to demonstrate EMT, the most convincing 
and widely acknowledged study was that by Iwano et al (Iwano et al., 2002).  In a model of 
UUO, genetically tagged Lac Z tubular epithelial cells were shown to express both Lac Z and 
FSP-1. This group came to the conclusion that during fibrosis induced by UUO, 
approximately 36% of renal fibroblasts were derived from EMT.  This suggests that a process 
that was once thought to be confined to embryogenesis may in hindsight be a fundamentally 
important process in the pathogenesis of renal scarring.   
 
1.5.3.1 Sequential events involved in EMT 
Although it has been established that EMT does occur in a wide variety of renal 
diseases, we are only beginning to learn about the mechanisms involved in EMT from in vitro 
studies.  EMT has been shown to be a highly complex process which relies on an interplay of 
different cytokine and non-cytokine mediators that in turn influence the integrity of the 
tubular epithelial cell, its basement membrane, expression of cell adhesion proteins, and the 
nearby interstitium (Iwano et al., 2002; Okada et al., 2000b).  Renal EMT is therefore 
inherently dependent on the surrounding microenvironment, the interstitium and a cocktail of 
mediators, which can fully induce this process or various events involved in EMT. 
As outlined in Fig. 1.10, EMT can be induced by the release of inflammatory 
mediators in the surrounding environment, including those released by the disrupted epithelia  
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and fibroblasts (Iwano et al., 2002; Kalluri and Neilson, 2003).  The majority of research to 
date has focused on elucidating agonists of EMT and these include TGFβ1 (the principle 
inducer of EMT) (Fan et al., 1999; Strutz and Neilson, 2003; Yang and Liu, 2001), FGF 
(Strutz et al., 2002), EGF (Okada et al., 1997; Strutz et al., 2002; Zeisberg et al., 2002), 
interleukin 1 (IL-1) (Fan et al., 2001), IGF (Morali et al., 2001) and CTGF (Burns et al., 
2006).  Many of these factors do not appear to be able to induce EMT independently but 
rather act in concert with TGFβ1 or other mediators.  Given the complexity of EMT, it can 
also be induced by a number of other factors including components of the ECM (collagen 
type I (Fan et al., 1999), non-cytokine mediated pathways such as AGEs (Li et al., 2004b; 
Oldfield et al., 2001) and tPA (Yang et al., 2002b), and vasoactive peptides such as 
angiotensin II (Chen et al., 2006; Liu, 2004a).  Furthermore, endogenous negative regulators 
of EMT have been identified in HGF and bone morphogenic protein (BMP-7). These two 
mediators are the most notable inhibitors of EMT both in vitro and in vivo (Liu, 2004a; 
Mizuno et al., 1998; Zeisberg et al., 2003) and they normally act by counteracting the actions 
of TGFβ1 and restoring E-cadherin (Yang and Liu, 2002; Zeisberg et al., 2003).   
In response to the local up-regulation of one or more of these cytokines, the initial 
event is thought to be the loss of epithelial cell adhesive proteins such as E-cadherin and tight 
junction proteins such as zona occludens-1 (ZO-1) (Okada et al., 1997; Yang and Liu, 2001). 
This leads to the de-stabilisation and a compromised epithelial cell integrity including loss of 
apical-basal cell polarity (Yang and Liu, 2001).  This type of dissociation from neighbour 
counterparts promotes cytoskeletal reorganisation involving loss of cytokeratin and gain of 
vimentin (Strutz et al., 2002; Yang and Liu, 2001), de novo αSMA expression and F-actin 
reorganization (Alpers et al., 1994; Boukhalfa et al., 1996; Hewitson et al., 1995; Muchaneta-
Kubara and el Nahas, 1997; Ng et al., 1998; Yang and Liu, 2001).  Even though αSMA 
expression has been shown previously to negatively correlate with migration in 
myofibroblasts (Hinz et al., 2001), this seems to precede and promote migration and invasion 
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of these transitioning cells into the interstitium (Liu, 2004a; Yang and Liu, 2001).  This is 
primarily initiated by degradation of the type IV collagen and fibronectin basement membrane 
(Ng et al., 1998; Zeisberg et al., 2001), facilitated by gelatinase enzymes MMP-2 (Yang and 
Liu, 2001) and MMP-9 (Zeisberg et al., 2002).  These cells then acquire synthetic capability 
which culminates in an increased deposition of ECM which can lead to destruction of normal 
renal architecture and organ failure (Khew-Goodall and Wadham, 2005).   
 
1.5.3.2 Signal transduction pathways involved in renal EMT 
Epithelial cells and mesenchymal cells represent two extreme cell types in the 
spectrum of cell classes and contain a number of distinguishable features. Epithelial cells can 
be characterised by: (a) forming continuous cell layers; (b) apical, lateral and basal membrane 
domains; (c) tight junctions; (d) intracellular organelle polarization; and (e) lack of mobility.  
This is in contrast to mesenchymal cells which (a) do not form continuous cell layers; (b) 
have no clearly demarcated membranes; (c) lack polarisation and (d); are motile (Larue and 
Bellacosa, 2005).  For an epithelial cell to change its phenotype into that of a mesenchymal 
cell, as seen in the phenomenon of EMT, drastic molecular alterations are therefore required.  
This involves the binding of growth factors to epithelial ligand receptors which stimulate 
intrinsic kinase activity (Boyer et al., 2000; Fan et al., 1999; Morali et al., 2001; Okada et al., 
1997; Strutz et al., 2002) and the subsequent recruitment of various signal transduction 
pathways.     
TGFβ1 has been shown to be the key inducer of renal EMT, and has been shown to be 
involved in the sequential events of EMT including expression of mesenchymal markers, the 
down regulation of epithelial markers, induction of F-actin reorganization, up-regulation of 
basement membrane proteases and enhancement of cell migration and invasion (Fan et al., 
1999; Strutz and Neilson, 2003; Strutz et al., 2002; Yang and Liu, 2001; Zeisberg et al., 
2002). It is therefore clear that the majority of research to date has focused on elucidating the 
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role of the TGFβ-Smad signalling axis. However, given (a) the complexity of EMT, (b) the 
involvement of a plethora of cytokine and non-cytokine mediators and (c) that EMT has been 
shown to be induced independently of TGFβ1 (Burns et al., 2006; Li et al., 2004a; Li et al., 
2004b), a number of signalling transduction pathways are likely to be involved in this process.  
To date, it is believed that in addition to Smads, members of the MAPK cascade and the Rho 
kinases play key roles in renal EMT. 
 The TGFβ signalling axis involves the Smad family which act by transducing signals 
of TGFβ from the cell surface to the nucleus. Of the Smads, a number of studies strongly 
suggest that Smad2/3 play key roles in TGFβ-induced EMT.  The roles of these Smads are 
demonstrated in studies that have over-expressed Smad7, which is an endogenous inhibitor of 
Smad2/Smad3 phosphorylation.  Over expression of Smad7 in tubular epithelial cells, inhibits 
EMT induced by TGFβ1 (Li et al., 2002) and αSMA induction (Valcourt et al., 2005). 
Conversely, over expression of Smad2/3 also leads to EMT, whereas, as expected, the BMP-
specific Smads1/5 do not (Valcourt et al., 2005).  
  A number of studies have demonstrated the cross-talk between TGFβ signalling and 
members of the MAP kinase family in EMT including Ras, RhoA, MAPK-ERK kinase 
(MEK1/2) and extracellular signal related kinase (Erk1/2) (Bhowmick et al., 2001; Healy et 
al., 1999; Li et al., 2004a; Schramek et al., 1997; Xie et al., 2003). It is believed that these 
signalling pathways are involved mainly in cytoskeletal remodelling and the dissociation of 
epithelial cell adhesion during EMT.  
  GTPases of the Rho family have been implicated in the induction of stress fibre 
formation (Bhowmick et al., 2001), focal adhesions (Ridley and Hall, 1992), actin 
polymerisation associated with filopodia (Ridley and Hall, 1992) and E-cadherin clustering  
(Fukata and Kaibuchi, 2001; Ozdamar et al., 2005). Furthermore, loss of cell adhesion may 
also be facilitated by a change in GTPase activity (Zondag et al., 2000) and also by activation 
of Ras and Src pathways (Boyer et al., 2000) leading to the downstream recruitment of the 
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Raf/MAP kinases and the engagement of the EMT transcriptome.   Furthermore, ERK has 
also been implicated in a number of studies and is thought to be involved in migration, 
conversion to an invasive phenotype and repression of E-cadherin (Grande et al., 2002b; Irie 
et al., 2005; Janda et al., 2002; Xie et al., 2004; Zavadil et al., 2001).  The MAPK cascade 
may also induce EMT independently of TGFβ et al (Li et al., 2004b). In this study, AGEs 
induced receptor for AGEs (RAGE)-mediated EMT with expression of αSMA and loss of E-
cadherin directly through the MEK1-ERK1/2 pathway. Furthermore, inhibition of ERK 
inhibits TGFβ induced Smad2 phosphorylation and the inhibition of p38MAP kinase and 
ERK abolishes TGFβ-induced EMT (Rhyu et al., 2005). 
 
1.5.3.3 Transcription factors involved in EMT 
The culminating effect of signalling pathways is to regulate the transcriptional activity 
of specific genes within the nucleus (Boyer et al., 2000). To date a number of factors have 
been identified including the integrin-linked kinase (ILK)-associated transcription factors 
lymphoid enhancer-binding factor (LEF) and β-catenin, and members of the Snail/Slug family 
of transcription factors. It is believed that these factors play roles in the suppression of E-
cadherin expression (Arias, 2001; Zeisberg et al., 2003). 
The importance of ILK in TGFβ-induced EMT has been shown by Li et al (Li et al., 
2003) where over-expression of kinase-dead ILK abolished epithelial transition in a Smad 
dependent manner.  ILK has also been shown to regulate the transcription factors, β-catenin 
and LEF. β-catenin normally mediates the contact of E-cadherin with the cytoskeleton 
(Zavadil and Bottinger, 2005) and stabilisation or degradation of this cytoplasmic protein can 
lead to repression of E-cadherin expression as demonstrated in TGFβ/Smad –mediated or 
integrin-mediated ILK activation inhibition of β-catenin/LEF translocation to the nucleus 
(Kim et al., 2002b; Labbe et al., 2000; Li et al., 2003; Tan et al., 2001).  
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This process is thought to involve the transcription factor Snail (Batlle et al., 2000; 
Grille et al., 2003), whose expression is ablated in Smad3 knock-out mice and in cells 
neutralised with antibodies to TGFβ (Sato et al., 2003). This transcription factor has also been 
shown to increase the expression of mesenchymal genes (Comijn et al., 2001). Furthermore, 
other transcription factors have been identified in EMT including Hey1, Jag1 and Notch. 
TGFβ-induced EMT has been shown to be blocked by ribonucleic acid (RNA) silencing of 
Hey1 or Jag1, and by chemical inactivation of Notch (Zavadil et al., 2004). Moreover, the 
transcription factor Slug induces the first phase of growth factor-induced EMT, including 
desmosome dissociation, and the initiation of cell separation (Savagner et al., 1997). 
 
1.6 SIGNALLING IN FIBROSIS 
  Because the signalling pathways that regulate fibroblast function are indispensable to 
renal fibrosis and the culminating effects of proliferation, differentiation and ECM synthesis 
can result in loss of kidney architecture and function, it is important to characterise the 
signalling pathways involved in the regulation of this key pro-fibrotic cell.  Cell signalling 
entails those events at the membrane level where growth factors/cytokines bind membrane 
receptors, and the subsequent recruitment of intracellular signalling cascades which allow 
membrane bound receptors to dictate changes to nuclear gene expression patterns. 
  
1.6.1 Membrane-bound receptors  
  Apart from those molecules that are lipid soluble, most regulatory molecules exert 
their effects on cells by binding to specific membrane receptors and stimulating intracellular 
signal transduction cascades.  TGFβ, the most well-known agonist of renal fibrosis exerts its 
effects through pairs of type I and type II receptors (known respectively as TβR I and TβR II) 
and can be classified as serine/threonine kinase receptors. These receptors have been the 
target of small molecule inhibitors including activin receptor like kinase-5 (ALK-5) used to 
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down-regulate fibroblast function (Callahan et al., 2002)(Fig. 1.11). A number of other 
membrane-bound receptors may also dictate responses in fibrosis including (a) growth 
hormone receptors (eg. Jak/Stat pathway) (b) GPCR which can activate or inactivate plasma-
bound membrane proteins or ion channels and can ultimately activate downstream cascades 
such as the MAPK cascade, and (c) RTK which act by phosphorylating tyrosine residues 
within the receptor domain and mediate a number of effects in fibrosis by responding to 
signals from agonists such as FGF, PDGF and EGF, and linking key downstream pathways 
such as Ras and PI3K.  The latter two mechanisms are particularly interesting because (a) 
although GPCR are not well characterised in fibrosis, thrombin has been shown to activate 
members of GPCRs known as PARs on a number of renal cells and (b) although it is well-
known that RTK can be activated in response to extracellular ligands, the intracellular 
signalling cascades are less well understood.  Those receptors most well characterised in renal 
fibroblasts are outlined in Fig 1.11. 
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Cell signalling mechanisms in renal fibroblasts and current intervention strategies. TGFβ signalling
has been most well characterised in fibroblasts and is stimulated when the catalytically inactive 
TβRI is assembled with the TβRII upon ligand binding. This leads to activation of Smads 2/3, PAK-2 
or abl, and subsequent differentiation, proliferation and ECM synthesis as well as the synthesis of 
CTGF.  The other key membrane receptor family, RTK’s, integrate a number of growth factor 
signals that are involved in fibroblast function including FGF, HGF, PDGF, EGF and IGF. 
PAK-2 = p21 activated kinase-2. 
Adapted from Hirschberg and Wang, 2005.
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1.6.1.1 Protease activated receptors 
Thrombin and other serine proteases activate GPCRs belonging to the PAR family 
through a unique mechanism of proteolytic cleavage (Chambers and Laurent, 2002).  To date, 
four PARs have been identified, PAR-1 to PAR-4, which can be distinguished by a unique N-
terminal cleavage site.  Thrombin can activate PAR-1, -3 and -4 (Chambers and Laurent, 
2002) but not PAR-2 (specific for trypsin and other proteases) (Bradshaw, 2004b).  PAR-1 
and PAR-2 have been identified in the kidney (Grandaliano et al., 2003; Xu et al., 1995) with 
PAR-1 being found on endothelial cells, mesangial cells, epithelial cells and fibroblasts 
(Grandaliano et al., 2000b; Hewitson et al., 2005; Xu et al., 1995), and PAR-2 found in 
tubular epithelial regions (Grandaliano et al., 2003), specifically on the basolateral membrane 
of  collecting ducts (Bertog et al., 1999).  Although less is known about the respective roles 
and distribution of PAR-3 and PAR-4 (Vesey et al., 2005), it is thought that PAR-3 acts as a 
thrombin binding site rather than a fully activated receptor whilst higher concentrations of 
thrombin are required to stimulate PAR-4.  The current literature has heavily focused on the 
role of thrombin acting through PAR-1 and therefore suggests that thrombin carries out most 
of its cell-mediated effects through this receptor. 
PARs have evolved to respond through a common mechanism which has been most 
thoroughly elucidated by examining the action of thrombin through PAR-1.  Once the 
protease binds to PAR-1, it cleaves the amino terminal exo-domain exposing the amino acid 
sequence SFLLRN (Fig. 1.12a). This newly exposed N-terminus then acts as the tethered 
peptide ligand and binds to the heptahelical portion of the receptor to activate transmembrane  
signalling (Coughlin, 2000) (Fig. 1.12b).  When thrombin proteolytically activates PAR-1, 
downstream signalling is mediated through GPCRs. PAR-1 is capable of coupling a number 
of G proteins including members of the G12/13, Gq and Gi families (Coughlin, 2000; Dery et 
al., 1998).  
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Mechanism of action of PAR-1. Chiefly through Gα, PAR-1 can activate PLC-β
leading to the formation of DAG with subsequent Ca
2+
 mobilisation and 
activation of PKC. This can activate members of the MAPK cascade and lead to 
mitogenesis, growth and transcription (Ossovskaya and Bunnett, 2004, Dery et al, 1998).  
PLC = phospholipase C; DAG = diacylglycerol; PKC =protein kinase C; Ca
2+
 = calcium.  
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Studies have examined PAR-1 in renal disease. It has been demonstrated in crescentic 
glomerulonephritis that PAR-1 knock-out mice show greatly reduced glomerular lesions as 
compared to mice treated with thrombin receptor agonist peptide (TRAP) (Cunningham et al., 
2000).  Grandaliano has shown in vivo in human allograft nephropathy and in vitro that 
proximal tubular epithelial cells express PAR-1 in response to exogenous thrombin 
(Grandaliano et al., 2000b). Furthermore, the up-regulation of PAR-1 correlates with 
interstitial fibrin deposition, the severity of tubulointerstitial fibrosis and urinary excretion of 
TGFβ 1 (Grandaliano et al., 2001), suggesting a possible role for PAR-1 in mediating fibrosis. 
However, when examined in vitro by utilising synthetic agonist peptides of PAR 1 and 2, it 
was shown that key fibrotic responses of tubular epithelial cell including the secretion of 
fibronectin, TGFβ1 and MCP-1 in response to thrombin was only reproduced by the PAR-2 
synthetic peptide and not by PAR-1 (Vesey et al., 2005).  This makes the role of up-regulated 
PAR-1 during fibrosis unclear, however recently it has been demonstrated that elevated 
expression of PAR-1 in the presence of thrombin, mediated the spread and migration of 
endothelial cells in association with the acquisition of mesenchymal characteristics 
(Archiniegas et al., 2004).  This provides a possible unidentified role for PAR-1 in the 
regulation of thrombin-induced EMT. 
 
  1.6.1.2 Receptor tyrosine kinases 
RTK’s integrate a number of growth factor signals that are involved in fibrosis 
including FGF, HGF, PDGF, EGF and IGF.  The commonality shared by each of these 
subgroups is the presence a protein tyrosine kinase domain in their intracellular portion.  RTK 
also have a glycosylated extracellular domain, to which the appropriate growth factor binds, 
and a short transmembrane domain. Activation of RTKs leads to diverse biological responses 
including proliferation, differentiation, cell motility, changes in cell morphology, ECM 
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production and gene transcription, and many of these responses are central to fibrosis.  When 
a growth factor binds to its receptor, this promotes dimerisation (formation of two stable 
receptor molecules) and auto-phosphorylation.  The receptor then undergoes a conformational 
change or there may be the creation of binding sites for signalling molecules that interact 
specifically with phosphotyrosine residues. These new protein domains are often tyrosine 
kinase substrates and include Src homology 2 (SH2), phosphotyrosine, SH3 and pleckstrin-
homology (PH) domains. Once the creation of signalling complexes has occurred, they often 
serve to recruit cytoplasmic enzymes to the plasma membrane and into close proximity to 
their membrane-related substrates.   
A number of studies have highlighted the involvement of RTK and their ligands in 
fibrosis (Bonner, 2004; Chevalier et al., 2000; Rossini et al., 2005; Strutz et al., 2001; Terzi et 
al., 2000; Wang et al., 2005). Studies utilising imatinib, an inhibitor of the PDGF receptor 
(PDGFR) and the abelson non-receptor tyrosine kinase (abl), significantly reduce renal 
fibrosis in vivo (Wang et al., 2005). PDGF has also been shown to stimulate fibroblast 
proliferation independently of Smad2/3 (Wang et al., 2005).   
 
1.6.2 Intracellular signalling cascades 
  Cell surface receptors do not directly regulate gene expression but rather they relay 
signals through intracellular signalling cascades.  These cascades provide the link between 
extracellular signals and transcription/translation activation.  The most studied intracellular 
signal transduction pathways in renal fibrosis are the TGFβ-Smad signalling axis, the 
ERK1/2MAPK cascade, and the Ras and Rho kinases.   
  In addition to membrane-bound serine/threonine kinase receptors, the TGFβ axis also 
includes the Smads, a family of conserved transcription factors that are intimately involved 
with mediating TGFβ1 responses.  Formation of the heterodimer receptor complex leads to 
activation of receptor Smads (R-smads; Smads 2/3) and their subsequent translocation to the 
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nucleus with the cofactor of R-Smad (co-Smad; Smad 4). Smad2/3 have been shown to play 
key roles in fibrosis in a number of fibrotic models (Fujimoto et al., 2003; Ma et al., 2003; 
Sato et al., 2003) and in fibroblasts (Piek et al., 2001; Verrecchia et al., 2001; Yang et al., 
2003). This axis is the central mediator of a number of key processes in fibrosis including 
fibroblast regulation and ECM synthesis, EMT, tubular apoptosis and chemotaxis (Border and 
Noble, 1997; Ma et al., 2003; Roberts, 1998; Roberts, 2002; Sato et al., 2003). Because TGFβ 
plays a key immuno-modulatory role, the Smad family have been a much more viable 
therapeutic target and a number of endogenous and exogenous inhibitors have been used to 
target this axis including HGF/BMP-7 (Liu, 2004b; Morrissey et al., 2002), CTGF inhibitors 
(Yokoi et al., 2004) and statins (Watts and Spiteri, 2004) (Fig.1.11).  There are also many 
other known regulators of key events in fibrosis which can mediate these effects 
independently of TGFβ (Burns et al., 2006; Hocevar et al., 1999; Li et al., 2004a; Ma et al., 
2003; Piek et al., 2001), independently of Smads (Wilkes et al., 2005; Wilkes et al., 2003) or 
in concert with TGFβ signalling (Massague, 2000; Massague and Chen, 2000).  Indeed, the 
induction of TGFβ signalling has been noted as a point of convergence through which the 
integration of many other pathways is likely to occur (Liu, 2006), and this has been 
demonstrated in a number of studies (Bakin et al., 2000; Bhowmick et al., 2001; Chen et al., 
2002; Daniels et al., 2004; Fukami et al., 2004).  
The ERK1/2MAP kinase family consists of the ERK pathway (Tian et al., 2000), and 
the stress activated pathways; the c-jun N-terminal kinase and the p38 pathways. This 
pathway is not only a likely point of cross-talk with the TGFβ axis (Engel et al., 1999; Funaba 
et al., 2002; Furukawa et al., 2003; Kretzschmar et al., 1999), but is also involved in 
fibronectin synthesis (Furukawa et al., 2003; Suzuki et al., 2004),  proliferation and survival 
(Pat et al., 2003).  
  Ras/Rho are kinases that are involved in proliferation, growth and inflammation. 
Recent work suggests an extensive role for the small monomeric GTPases of the Ras 
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superfamily in fibroblast proliferation (Sharpe and Hendry, 2003) and also myofibroblast 
contraction (Hendry and Sharpe, 2003).  In human fibroblasts, various Ras isoforms, 
including Ki-Ras, are involved in serum- and EGF-stimulated proliferation in vitro (Sharpe et 
al., 2000) and are therefore likely to be involved during the early stages of fibrosis as 
fibroblasts occupying the interstitium rapidly increase in number.  Ras is also involved in 
inducing growth arrest and differentiation (Bar-Sagi and Feramisco, 1985).   
  Rho-associated coiled-coil forming protein kinase (ROCK) has been implicated in the 
progression of renal interstitial fibrosis.  Inhibition of ROCK has been shown to reduce renal 
fibrosis in vitro and in vivo by suppressing αSMA expression, macrophage infiltration, 
TGFβ1 and α1(I) collagen mRNA expression in UUO (Nagatoya et al., 2002).  Moreover, 
Rho has been shown to be necessary for TGFβ−mediated up-regulation of CTGF (Heusinger-
Ribeiro et al., 2001), a key downstream mediator of TGFβ signalling, and is also involved in 
the regulation of αSMA microfilament contraction (Han et al., 2002).  
The Janus family of tyrosine kinases (JAK) / Signal transducer and activator of 
transcription (Stat) pathway, a ubiquitous signalling cascade that is activated by growth 
factors and cytokines involved in proliferation and growth, has also been implicated in the 
regulation of fibroblast function. Huang et al (Huang et al., 1999) found that JAK and Stat1/3 
mediate AGE-induced mitogenesis in kidney fibroblasts and collagen production (Huang et 
al., 2001). JAK2/Stat5 signalling has also been implicated in similar experiments involving 
AGE-induced fibroblast proliferation (Guh et al., 2001). Finally, Stat6-/- mice subjected to 
UUO exhibit decreased collagen synthesis (Yukawa et al., 2005). 
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1.6.2.1 Phosphatidylinositol 3-kinase 
RTK provide the link between a number of key effectors in fibrosis and the 
intracellular signalling cascades that ultimately regulate gene expression.  This receptor 
family can recruit the involvement of a number of downstream kinases including Ras and 
PI3K.  Interestingly, there are a growing number of studies to suggest that PI3K and its 
downstream liaison mTOR act as central controllers of cell growth and proliferation.  This 
suggests that these pathways may play roles in the regulation of fibroblasts during fibrosis, by 
either acting independently or in concert with TGFβ signalling. 
PI3Ks are a family of serine/threonine kinases that play key roles in the regulation of 
growth factor signals involved in proliferation, cell survival, glucose metabolism and insulin 
signalling.  These kinases phosphorylate the D3 position of the inositol ring of 
phosphoinositides.  There are three classes of PI3K which are organised according to 
substrate preference and sequence homology (Engelman et al., 2006).   The first class of 
PI3K’s have been the most extensively studied. This class is divided into class IA and class 
IB, and whilst class IB is thought to be exclusively activated by GPCRs, class 1A is 
predominantly activated by RTKs.  Class II PI3K can be activated by RTK, cytokine 
receptors and integrins however their specific functions are not well understood.  The role of 
class III is also relatively unknown however the yeast homologue vacuolar protein-sorting 
defective 34 (Vps34) has been shown to regulate mTOR suggesting a role in the control of 
cell growth.  Given the sparse availability on the latter two classes of PI3K, this review will 
focus on class I PI3Ks. 
 
1.6.2.1.1 Structure of Class I PI3K 
 Class I PI3K is composed of families of homologous proteins containing regulatory 
(p85) and catalytic (p110) subunits, of which there are various isoforms of each subunit.  The 
p85 regulatory subunit consists of a core p110 binding domain which is flanked by two SH2 
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domains. The longer isoforms also have an extended N-terminal region (Engelman et al., 
2006) (dashed line, Fig. 1.13a).   The p110 catalytic subunit contains an N-terminal p85-
binding domain, a Ras-binding domain (RBD), a C2 domain, a phosphatidylinositol kinase 
homology domain (PIK) and a C-terminal catalytic domain (Fig. 1.13a) (Engelman et al., 
2006).  In mammals, this class of PI3K controls glucose homeostasis, cell migration, growth 
and proliferation (Cantley, 2002). 
 
 1.6.2.1.2 Mechanism of action of PI3K 
Class I PI3K primarily play the role of converting phosphatidylinositol-(4,5)-
biphosphate (PIP2) to phosphatidylinositol-(3,4,5)-triphosphate (PIP3).  As outlined in Fig. 
1.13b, extracellular ligands such as PDGF, EGF, FGF or IGF, RTK bind to the glycosylated 
extracellular domain of RTKs which then become activated and dimerise (formation of two 
stable receptor molecules).  Activation of RTK leads to the creation of signalling complexes 
with domains which often serve to recruit cytoplasmic enzymes to the plasma membrane into 
close proximity to their membrane-related substrates [231].  In particular, it allows for the 
recruitment of the regulatory p85 subunit, or adapter proteins such as insulin receptor 
substrate (IRS) to bind to phosphotyrosine residues of the SH2 domain of RTK.  Binding in 
this manner relieves the basal inhibition that p85 normally exerts over the catalytic subunit, 
allowing the p110 catalytic subunit to become activated.  This leads to the recruitment of PIP2 
to the plasma membrane and the generation of PIP3 (negatively regulated by the phosphatase 
and tensin homologue tumour suppressor; PTEN).  The generation of PIP3 leads to the 
recruitment of molecules with a PH to the cell membrane including the serine/threonine acute 
transforming retrovirus thymoma (Akt) and phosphoinositide-dependent kinase 1 (PDK1).   
Akt is a protein serine/threonine kinase that exists in mammalian cells as three 
different isoform proteins (Akt1, Akt2, Akt3) encoded by different genes (Hay and 
Sonenberg, 2004), and is composed of three functional domains: an N-terminal PH domain, a  
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Structure and mechanism of action of class I PI3K. (a) Class 1A is 
predominantly activated by RTK highlighting its ability to be activated by 
extracellular growth factors. (b) Mechanism of action of class I PI3K. 
Adapted from Engelman et al, 2006.
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kinase domain and a C-terminal hydrophobic motif (Scheid and Woodgett, 2003).  When 
recruited to the plasma membrane, Akt is phosphorylated at serine-473 (S-473) within its  
hydrophobic motif by phosphoinositide-dependent kinase 2 (PDK2), recently identified as 
mTOR complex 2 (mTORC2) (Sarbassov et al., 2005). This preceded and facilitates the 
phosphorylation of threonine-308 (T-308) within its activation loop by PDK1. Once Akt is 
activated, it plays a role in the inhibition of apoptosis through the phosphorylation (and 
inhibition) of pro-apoptotic proteins such as Bad and the forkhead transcription factors, 
regulation of metabolism by phosphorylating glycogen synthase kinase 3 (GSK-3) 
(Downward, 2004), glucose metabolism, cell cycle progression and growth through a number 
of downstream effectors (Shaw and Cantley, 2006). 
 
1.6.2.1.3 Roles of PI3K 
LY294002 and wortmannin are the most widely used inhibitors to examine the role of 
PI3K in growth factor mediated signalling.  Using these inhibitors, genetic deletion or through 
the knock out of various isoforms, PI3K has known to regulate several biological functions in 
addition to survival including proliferation, differentiation and ECM synthesis (Brennan et al., 
1999; Gerasimovskaya et al., 2005a; Kanayasu-Toyoda et al., 2002; Krymskaya et al., 1999; 
Runyan et al., 2004; Shao et al., 2004).  Studies have implicated PI3K in the regulation of T 
cell (Breslin et al., 2005), muscle cell (Derossi et al., 1998) and endothelial cell (Kanda et al., 
1997) proliferation. More importantly, PI3K regulates fibroblast proliferation in in vitro 
studies on cultured human cardiac fibroblasts (Hafizi et al., 1999) and pulmonary artery 
adventitial fibroblasts (Gerasimovskaya et al., 2005b).  Furthermore, PI3K can be activated 
by the pro-fibrotic molecules EGF, FGF and PDGF via RTKs to induce ECM deposition 
(Burgering and Coffer, 1995; Floege et al., 1999; Strutz et al., 2001; Tang et al., 1996) and 
has been shown to be involved in mesangial cell collagen synthesis (Runyan et al., 2004).  
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This suggests that this kinase may play a previously unrecognised role in fibroblast 
regulation.   
 
 1.6.2.2 Mammalian target of rapamycin 
Signalling through the phosphorylation of Akt, PI3K is able to activate multiple 
effectors including mTOR (Raught et al., 2001; Scott et al., 1998). TOR is the founding 
member of the PI3K related protein (Ser/Thr) kinase family and was discovered fortuitously 
when the mechanism of action of rapamycin, a natural product of a strain of the soil 
bacterium, Streptomyces Hygroscopicas, was being investigated (Bradshaw, 2004b). mTOR 
regulates ribosome biosynthesis and cap-dependent translation through the downstream 
ribosomal protein S6 kinases (S6Ks) and the eukaryotic initiation factor 4E (eIF4E) binding 
proteins (4EBP1) respectively (Fingar and Blenis, 2004; Ponticelli, 2004), and is heavily 
involved in the regulation of cell proliferation, growth, glucose homeostasis and cell survival. 
This pathway contains a number of kinases that when mutated give rise to various cancers 
including lymphangioleiomyomatosis (LAM), tuberous sclerosis complex (TSC) (Ma et al., 
2005), and Peutz-Jeghers syndrome (Inoki et al., 2005a). However, in the kidney this kinase is 
currently most-well known for as the key controller of T cell proliferation and hence is the 
target of the immunosuppressive drug rapamycin after transplantation. 
  
1.6.2.2.1 Structure of mTOR 
 mTOR exhibits a 42% amino acid sequence identity to the yeast TOR protein and 
contains 2549 amino acids comprised of several conserved structural domains. The N-
terminus contains 20 tandem HEAT (Huntingtin, EF3, A subunit of PP2A, TOR1) repeats at 
its NH2 end, which are implicated in protein-protein interactions. Its C- terminal consists of a 
FAT domain and an FKBP12 receptor binding (FRB) domain (site of rapamycin-FKBP12 
complex binding), a PI3K-like kinase domain (Hay and Sonenberg, 2004), a repressor domain 
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(S-2448) and a FATC domain (FAT and FATC may be involved in the regulation of kinase 
activity (Peterson et al., 2000) (Fig. 1.14).  The kinase domain of mTOR constitutes only 
approximately
 
10% of the total protein, and the in vivo function of the remainder
 
is essentially
 
unknown (Oldham et al., 2000).   
 
1.6.2.2.2 mTOR forms two active complexes 
Over the past five years, studies on mTOR signalling have distinguished two active 
mTOR complexes; mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). 
mTORC1 is the complex originally identified as the target of rapamycin and has been more 
extensively studied. Relatively less in known about the functions of mTORC2 and its 
upstream inputs, however the regulatory proteins that form both complexes are becoming 
increasingly characterised.  mTORC1 is formed by mTOR, regulatory associated protein of 
TOR (raptor) and GβL/mLST8 and is responsible for mediating mTOR’s downstream effects 
(Fig. 1.15a). The mTOR interacting protein raptor is required for mTOR mediated 
phosphorylation of 4EBP1 and S6K (Hara et al., 2002) and has been shown to be 
indispensable to mTOR function (Hara et al., 2002; Oshiro et al., 2004).    
mTORC2 is formed by mTOR, rapamycin insensitive companion of mTOR (rictor) 
and GβL/mLST8 (Sarbassov dos et al., 2006) and a very recently characterised protein; mSin 
(mammalian stress activated protein kinase interacting protein) (Frias et al., 2006; Jacinto et 
al., 2006; Yang et al., 2006b) (Fig. 1.15b).  mTORC2 has been identified to date to play two 
key roles: (a) directly phosphorylating Akt S-473 (Sarbassov et al., 2005) and (b) in the 
regulation of cytoskeletal organization (Inoki et al., 2005b). This complex, in contrast to 
mTORC1, is insensitive to rapamycin (Sarbassov et al., 2004). 
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Structure of mTOR. The repressor domain (S-2448) may be involved in a negative feedback 
loop with S6K (Chiang et al, 2005) and has also been characterised as an Akt substrate (Sekulic
et al, 2000). 
Adapted from Fingar and Blenis, 2004.
Fig. 1.14
Composition of mTORC1 and mTORC2.
Adapted from Sarbassov et al, 2005.
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1.6.2.2.3 mTOR signalling and key upstream regulators 
mTORC1 signalling, and the activity of its downstream targets is dependent on the 
integration of intracellular stress (eg. osmotic stress; (Inoki et al., 2005b) or hypoxia (Arsham 
et al., 2003)), nutrients (eg. nitrogen and carbon sources; (Beretta et al., 1996)), energy (Hahn-
Windgassen et al., 2005) and amino acid levels (eg. glutamine; (Crespo et al., 2002)).  The 
loss of dTOR in Drosophilia results in phenotypes characteristic of amino-acid deprivation, 
including reduced nucleolar size, lipid vesicle aggregation, and cell cycle arrest (Zhang et al., 
2000), and the withdrawal of amino acids within the media of mammalian cells leads to 
deactivation of S6K and de-phosphorylation of 4EBP1 (Hara et al., 1998).  Similarly, 
glucose-deprived cells demonstrate severe inhibition of phosphorylation of T-36/45 of 4EBP1 
(Patel et al., 2001).  Whilst it has been established for many years that mTOR integrates these 
factors to control cell growth and proliferation, the underlying signalling mechanism is only 
beginning to be elucidated. It is now believed that the two tumour suppressor proteins, TSC1 
(hamartin) and TSC2 (tuberin) (TSC1/2) are key integrators of converging mTOR signals 
(Inoki et al., 2002) (Fig. 1.16a).   
Originally identified as negative regulators of TOR signalling in Drosophila, (Gao et 
al., 2002), TSC1/2 is now thought to serve as a point of integration between growth-
stimulatory and growth-suppressive signalling by modulating the activity of a small GTPase, 
Rheb (rapamycin homologue enriched in brain) (Saucedo et al., 2003; Stocker et al., 2003).   
Rheb acts as a means for integration of a variety of intracellular signals as well as growth 
factors (Inoki et al., 2005b), and cycles between a GTP-bound active state and a GDP-bound 
inactive state. When activated, Rheb phosphorylates mTOR and consequently activates 
downstream signalling.  The state of Rheb is dependent on signalling upstream of TSC1/2 
which receives a number of positive and negative input signals and in turn this regulates the 
GTPase activating protein (GAP) activity that is exerted over Rheb. 
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Mechanism of mTOR signalling and downstream effectors 
(a) mTOR integrates stress, nutrients and amino acids with growth factors directly or through the tuberous sclerosis complex (TSC1/2) which plays a role in 
integrating converging mTOR signals. TSC1/2 controls mTOR activity by exerting GAP activity over Rheb which cycles between an active GTP-bound 
state and an inactive GDP-bound state. In cases of increased cellular stress (hypoxia) or decreased energy (?AMP:ATP ratio) these signals can be 
integrated via Redd1 and AMPK respectively ultimately activating the GAP activity of TSC2 leading to an accumulation of GDP-bound Rheb and 
inactivation of mTOR.  mTOR also integrates growth factors through PI3K and Akt leading to inactivation of TSC2’s GAP activity and ultimately to 
mTOR activation. mTOR carries out its effects through a number of downstream effectors including (b) 4EBP1 and (c) S6K (see text for details). 
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For instance, in cases of decreased availability of nutrients, amino acids, energy 
(↑AMP:ATP), or intracellular stress, these signals can converge onto the TSC2 complex and 
act to phosphorylate and activate TSC2.  Recent studies have identified upstream signalling 
pathways involved in the transference of these signals to TSC2 including REDD1 (regulated 
in development and DNA damage 1; responsive to stress via hypoxia inducible factor; HIF) 
(Corradetti et al., 2005), and AMPK (adenosine monophosphate-activated kinase; responsive 
to decreased ATP) (Hahn-Windgassen et al., 2005).  This allows TSC2 to exert its GAP 
activity over Rheb, leading to an accumulation of GDP-bound Rheb and inhibition of the 
downstream effectors of mTOR.  In these cases, the net effect is the negative regulation of 
protein synthesis by mTOR and the up-regulation of autophagy (Dennis et al., 1999).  In 
contrast, in response to growth factor signalling, mediated predominantly through PI3K and 
Akt, although this similarly phosphorylates TSC2, the phosphorylation inactivates its GAP 
activity leading to an accumulation of GTP-bound Rheb and activation of its downstream 
effectors (Fig. 1.16a).   
Whilst TSC1/2 is likely to be a key integrator of converging mTOR signals, it should 
be noted that because TSC1 and TSC2 do not exist in budding yeast, these complexes 
including Rheb are unlikely to mediate all signals converging on mTOR (Sarbassov dos et al., 
2005) and it is postulated that a number of direct inputs also control mTOR activity (Fig. 
1.16a). 
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1.6.2.2.4 The relationship between PI3K and mTOR  
In addition to the integration of stress, growth factors, amino acids and energy by 
mTOR, mTOR is also increasingly known for its ability to regulate growth factors through 
PI3K and Akt (Bradshaw, 2004b; Fingar and Blenis, 2004).  These responses are similarly 
mediated through mTOR downstream effectors S6K and 4EBP1 (Bradshaw, 2004b).  This is 
supported by the following findings: (a) Akt has been shown to directly phosphorylate mTOR  
at T-2446 and S-2448 (Sekulic et al., 2000); (b) Chung et al (Chung et al., 1994) has shown 
that mutated PDGF receptors that inhibit the activation of PI3K also inhibit the downstream 
phosphorylation of S6K1 and the use of PI3K pharmacological inhibitors also inhibit S6K and 
4E-BP1 (Brunn et al., 1996; Cheatham et al., 1994); (c) if Akt is over-expressed, it promotes 
rapamcyin sensitive 4EBP1 phosphorylation (Gingras et al., 1998) and (d) over-expression of 
a dominant-negative form of Akt or deletion of Akt1 inhibits 4EBP1 and S6K1 
phosphorylation respectively (Peng et al., 2003).  Lastly, PTEN deficient cells (the negative 
regulator of PI3K signalling) have a high level of 4EBP1 and S6K1 phosphorylation (Neshat 
et al., 2001). This suggests that dTOR is at least
 
is epistatic to dPTEN (Oldham et al., 2000). 
These and other studies strongly implicate PI3K as a growth factor-mediated regulator of 
mTOR and its downstream kinases. 
 
1.6.2.2.5 Downstream targets 
mTOR regulates ribosome biosynthesis and translation through the downstream 
ribosomal protein S6Ks and the eIF 4EBPs (Fingar and Blenis, 2004; Ponticelli, 2004).  It is 
thought that raptor facilitates this process by acting as a scaffold protein and physically 
linking S6K and 4EBP1 to mTOR allowing these substrates to be phosphorylated within their 
TOR signalling (TOS) motif (Inoki et al., 2005b). 
  Mammalian cells express two forms of S6K called S6K1 and S6K2. These kinases 
are thought to be major regulators of the S6 ribosomal protein (S6RP) substrate. These 
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isoforms share a high degree of homology and the second form of this kinase was originally 
identified in mice which displayed a sustained S6RP phosphorylation in response to deletion 
of the S6K gene (Shima et al., 1998). Full phosphorylation of S6RP is thought to be carried 
out by this more recently identified kinase (Ruvinsky and Meyuhas, 2006).   
Kim and colleagues have shown that through the knockdown of mTOR, the activation 
of S6K is repressed (Kim et al., 2002a), and over-expression of mTOR increases the 
phosphorylation of S6K (Brown et al., 1995). Studies such as these have therefore 
characterised S6K as a key downstream effector of mTOR (Harrington et al., 2004) and have 
implicated it as a key regulator of cell size.  Drosophila deficient in the dS6K gene exhibit
 
a 
large delay in development and a severe reduction in body
 
size without affecting cell number 
(Montagne et al., 1999), whilst the growth of mice with homozygous disruption of S6K is also 
largely retarded (Ruvinsky et al., 2005) (Fig. 1.17). 
This kinase is also involved in the regulation of a number of downstream effectors of 
mTOR including BAD (Harada et al., 2001), SKAR (S6K1 Aly/Ref-like target) (Richardson 
et al., 2004), eukaryotic elongation factor 2 kinase (eEF2K) (Wang et al., 2001b), eIF4B 
(Raught et al., 2004), IRS (Harrington et al., 2004) and mTOR itself (Chiang and Abraham, 
2005). These substrates are involved in regulating cell survival (BAD), cell size (SCAR) and 
protein synthesis (eEF2K and eIF4B), whilst IRS and mTOR are thought to be part of 
reciprocal negative feedback loops, allowing S6K to regulate upstream signalling (Sekulic et 
al., 2000) (Manning, 2004)(refer to Fig. 1.16c). The main substrate of S6K however is S6RP 
which is often used as a read-out of mTOR activity and is thought to contribute up to 30% of 
total cellular protein (Toker, 2000).   
S6K and S6RP have traditionally thought to be involved in the control over mRNA 
transcripts with a 5’ tract of pyrimidine (TOP) motif which encode various proteins associated 
with the function or the assembly of the translational apparatus (Jefferies et al., 1997; 
Krymskaya et al., 1999; Lane et al., 1993). This has been largely based on the temporal  
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activation between these effectors and the translational activation of TOP mRNAs, leading to 
the formation of a model that related translational efficiency of TOP mRNAs to S6RP 
phosphorylation (Jefferies et al., 1994).   
Recently it has been shown that both S6K and S6RP are disposable for these roles 
(Ruvinsky and Meyuhas, 2006; Ruvinsky et al., 2005). By knocking in alanine substitutions at 
all five phosphorylatable serine residues of S6RP (Ruvinsky et al., 2005), and knocking out 
S6K1 and S6K2 in mice (Pende et al., 2004), it provides compelling evidence that the primary 
role of these downstream effectors is not in the control over mRNA transcripts. It is now 
believed that the key roles of S6RP include the negative regulation of protein synthesis 
(because the global rate of protein synthesis is higher in S6RP-/- knockout mice than in wild 
type mice (Ruvinsky et al., 2005), in the modulation of glucose metabolism and in the 
regulation of cell size (Ruvinsky et al., 2005) (Fig. 1.17).  
  4EBP1 is the other main downstream effector of mTOR.  The initiation of translation 
of nuclear transcribed eukaryotic mRNAs is dependent on the cap binding protein, eIF4E, and 
the eIF4 initiation factors.  When mTOR is activated directly or through Rheb, it primarily 
controls these initiation factors by regulating 4EBP1 (Brunn et al., 1997).  The 
phosphorylation of this downstream effector is inhibited by rapamycin, preventing cap-
dependent translation by the eIF4E family of translation factors (Beretta et al., 1996; Gingras 
et al., 1998; Graves et al., 1995), whilst over-expression of FK506 (a molecule that competes 
for binding with rapamycin to FKBP12) reverses the rapamycin-mediated inhibition of 4E-
BP1 phosphorylation (Beretta et al., 1996).  
The regulation of the eIF family of translation factors depends on 4EBP1’s 
phosphorylation state.  Phosphorylation of 4E-BP1 prohibits its association with eIF4E, 
allowing eIF4G to bind to eIF4E and form the active eIF4F complex (during translation 
eIF4G functions as a complex with eIF4A and eIF4E; called eIF4F) (refer to Fig. 1.16b) 
(Bradshaw, 2004a).  Hypophosphorylation of 4EBP1 however promotes the binding of 4E-
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BP1 with eIF4E, preventing the initiation factor from forming the translational complex and 
in these cases 4EBP1 acts as a translational repressor (Inoki et al., 2005b).  The role of 4E-
BPs during translation is therefore to regulate this cap-dependent translation by competing 
with eIF4G for binding with eIF4E.  
 
1.6.2.2.6 Functional roles of mTOR - Rapamycin 
Studies of mTOR have heavily relied on rapamycin and its derivatives (CCl779, 
RAD001, AP23573), as TOR mutations have not yet been reported in
 
multicellular organisms 
(Zhang et al., 2000).  These pharmacological inhibitors have been shown to be highly specific 
and bind mTOR by forming a complex with intracellular FKBP12. This complex then binds 
to the region upstream of the C terminus called the FRB region and acts to inhibit the activity 
of mTOR. However, the exact mechanism of inhibition is unclear.  
mTOR plays a chief role in cell cycle progression from the G1-to-S phase (Abraham, 
2005) predominantly by regulating levels of cyclin D and p27
kip
 polypeptides.  mTOR has 
therefore been implicated in the control of IL-2 stimulated T-cell proliferation as shown by 
p27 knockout mice (Cohen, 2002; Nourse et al., 1994), VSMC, endothelial cell (Mohacsi et 
al., 1997), hepatic stellate cell (Zhu et al., 1999) and human renal epithelial cell proliferation 
(Pallet et al., 2005), as well as bile duct hyperplasia (Biecker et al., 2005).  Accordingly 
rapamycin induces cell-cycle arrest and is prescribed as an effective immunosuppressant after 
kidney transplantation (Breslin et al., 2005). The potential roles for rapamycin have however 
grown over the past decade. Rapamycin is now also used to inhibit vascular stent occlusion 
(Marx and Marks, 2001), and mTOR inhibitors are also being widely tested in clinical trials 
for the treatment of cancer (Cully et al., 2006; Hidalgo and Rowinsky, 2000; Panwalkar et al., 
2004; Sawyers, 2003).  Moreover, very recent studies have established the potential benefit of 
rapamycin in insulin resistance (Shah and Hunter, 2006; Um et al., 2004), and renal (Chen et 
al., 2005; Sakaguchi et al., 2006) and heart (Boluyt et al., 2004) hypertrophy. 
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  Emerging studies have also highlighted its potential use as a therapeutic agent in 
fibrosis. mTOR is involved in the regulation of mesangial cell proliferation (Daniel et al., 
2000),  PDGF-induced cardiac fibroblast proliferation (Simm et al., 1997) and lung fibroblast 
proliferation after transplantation (Azzola et al., 2004).  In addition, it has been established 
that differentiation and ECM synthesis is regulated by mTOR and S6K in VSMC (Martin et 
al., 2004).  In vivo studies have shown that rapamycin inhibits liver fibrosis (in bile-duct 
ligation (Biecker et al., 2005) and carbon tetrachloride models (Zhu et al., 1999) by 
decreasing key mediators of fibrosis including TGFβ1.  The potential for rapamycin to inhibit 
renal fibrosis has been demonstrated in a model of renal ischaemia reperfusion injury where a 
reduction in the expression of fibrosis-associated genes was demonstrated (Jain et al., 2001).  
Together, these studies underscore the importance of fully elucidating all dimensions of 
mTOR and PI3K function in key fibrogenic mediators.   
  Given that rapamycin and its derivatives have been shown to inhibit a variety of 
functions potentially relevant to fibrosis including proliferation and differentiation, ECM 
synthesis, and TGFβ1 expression in a number of studies, an investigation into the role of 
mTOR and PI3K in the regulation of renal fibroblast function, a key mediator of fibrosis is 
now warranted.  
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1.7 AIMS AND RATIONALE 
 Tubulointerstitial fibrosis is the final common pathway all of types of progressive 
renal disease. As evident from the previous passages, the interstitial fibroblast is a key 
effector cell in fibrosis responsible for the secretion of exuberant amounts of ECM proteins 
that can eventually lead to the demise of renal structure and function.  This thesis therefore 
contends to further elucidate the molecular mechanisms encompassing the derivation and 
regulation of the renal fibroblast.   
In summary, specific aims of this study include: 
   
1.7.1 Are PI3K and mTOR involved in the regulation of renal fibroblasts?  
Whilst it has been established that the TGFβ signalling axis is a key regulator of 
fibroblast activation and ECM synthesis, it is likely that other signalling pathways are 
involved consistent with the complexity of fibrosis.  Given that the involvement of other 
signalling pathways are not well characterised, the aim of this study is to examine the 
potential of PI3K and mTOR to regulate renal fibroblast function. 
 
1.7.2 Do PI3K and mTOR regulate myofibroblast differentiation and EMT? 
The differentiation of fibroblasts into myofibroblasts is a key indicator of the severity 
of tubulointerstitial fibrosis.  It is therefore important to identify the regulatory mechanisms 
involved in differentiation, in addition to the TGFβ signalling axis.  Given that PI3K and 
mTOR are implicated in the differentiation of VSMC (which share inherent similarities to 
fibroblasts), this study aimed to investigate the role of PI3K and mTOR in myofibroblast 
differentiation.  
The importance of EMT in renal tubulointerstitial fibrosis is becoming universally 
accepted underscoring the need to delineate the regulatory and signalling mechanisms 
involved in this process. The aim of this study is also to use a model of EMT to study 
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regulatory mechanisms of EMT including the elucidating the role of PI3K and mTOR in 
renal EMT.  
 
1.7.3 Is there a relationship between the coagulation cascade and tubulointerstitial 
fibrosis? 
In addition to their role in clotting, the coagulation cascade has been implicated in 
renal disease.  Whilst more heavily elucidated in glomerular-based lesions, less is known 
about their roles in tubulointerstitial fibrosis.  The aim of this work is to understand the role 
that members of the coagulation cascade may play in tubulointerstitial fibrosis.   
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General Methods 
 
 
Chapter 2 
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2.1 INTRODUCTION 
 
This chapter describes those general methods which have been used across 
experimental chapters
*
.  Outlined in this chapter are (a) a description of the procedure of 
UUO, (b) the generic procedure of explanting to obtain cells for experimental purposes, (c) 
cell culture protocols, (d) immunohistochemistry protocols and (e) protocols for biochemistry 
studies (Northern blotting, Western blotting and Real time PCR). 
Details of the specific experimental design are included after the introduction of each 
experimental chapter whilst those methods which were specific to the chapter are included in 
a section labelled Specific Method Protocols, located at the back of each experimental 
chapter.  A detailed description of material derivation, reagents and stock solution protocols, 
as well as antibody specifications used throughout this thesis can be found in the relevant 
Appendices: Appendix 1: Materials and Suppliers; Appendix 2: Reagents, Buffers and Stock 
Solutions and Appendix 3: Primary and Secondary Antisera. 
 
2.2 EXPERIMENTAL MODELS 
Experiments in this thesis utilised cells and tissue from UUO (2.2.1) and explant tissue 
from the rat normal renal cortex (2.2.2) of Sprague-Dawley rats.   
 
2.2.1 Experimental tubulointerstitial fibrosis 
All experimental chapters apart from Chapter 4 have utilised cells or tissue derived 
from UUO at 3 days post-ligation.  UUO was performed in rats in order to mimic the 
pathological changes that occur in progressive kidney disease in humans. UUO is amongst the 
most common experimental models of interstitial fibrosis (Bascands and Schanstra, 2005) 
(Klahr and Morrissey, 2002). This model was chosen because as a result of stress-induced 
injury, it encompasses the various stages of renal injury leading to an accelerated form of 
                                                
*
 To avoid long descriptions in experimental chapters, Northern blotting is an exception and has been included 
within this chapter. 
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tubulointerstitial fibrosis without the complications of glomerular disease.  This includes 
cellular infiltration, tubular proliferation and apoptosis, EMT, myofibroblast accumulation, 
increased ECM deposition, and tubular atrophy (Fig. 2.1) (Bascands and Schanstra, 2005).  
Accordingly, fibroblasts derived from this model are activated in a similar manner of the in 
vivo equivalent (Muller and Rodemann, 1991).   
Under general anaesthesia, the left ureter of male Sprague-Dawley rats (250-300g) 
was ligated in two places using 5/0 gauge surgical silk and cut in-between.  The contralateral 
ureter was left intact.  Animals were sacrificed after 3 days for the retrieval of tissue for cells, 
and at various intervals between 3-21 days for histological studies (Chapter 6).  The 
procedure was approved by The Royal Melbourne Hospital Animal Ethics Committee and was 
conducted in accordance with the NHMRC Code of Practice for the Care and Use of Animals 
in Research. 
 
2.2.2 Explants from Sprague-Dawley rats 
 Kidney cortical tissue for explants was derived from normal kidneys of Sprague-Dawley 
rats killed by asphyxiation with an 80%:20% mixture of CO2:O2.  Tissue was collected in 
ice-cold Hanks' salt solution containing gentamycin.  Tissue and cells obtained from these 
kidneys were the basis for studies on EMT (used in Chapter 4-6). The procedure was 
approved by The Royal Melbourne Hospital Animal Ethics Committee and was conducted in 
accordance with the NHMRC Code of Practice for the Care and Use of Animals in Research.  
 
2.3 EXPLANTING OF THE RENAL CORTEX 
Explanting served a dual purpose in this thesis: (a) to obtain cells and tissue from 
fibrotic kidneys and (b) to examine cells grown from normal rat renal kidneys in studies of 
EMT.  In each case the same methodology was used, albeit using different tissue. The 
following passages outline the general technique of tissue explanting and any subsequent 
adaptations. 
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UUO as an experimental model of tubulointerstitial fibrosis. UUO represents a form of obstructive 
nephropathy and although rarely seen in adults, it is one of the rare experimental models of 
primary tubulointerstitial disease.
Adapted from Bascands et al, 2005.
Sequence of events following UUO
Epithelial cell Macrophage Apoptotic cell
Fibroblast
Myofibroblast
Fig. 2.1
 71
 
2.3.1 Explanting procedure 
 Petri dishes were prepared by coating each dish with warm 1% gelatin matrix 
(diluted at a ratio of 1:1 in phosphate buffered saline; PBS).  1ml of gelatin solution was 
delivered into each petri covering the entire surface evenly, and washed with 2-3ml of PBS.  
Petris were then incubated at 37°C for at least 30min.  After the preparation of Hanks buffer 
solution with gentamycin, a sterile dressing pack containing sterile gauze pieces, forceps and 
tray was used to explant the tissue.  
 Using sterile gauze, the kidney was orientated to expose the cortex and a midline 
incision using a scalpel blade was made.  The capsule was then pinched back.  The cortex was 
removed and placed into the gelatinised petri dishes where it was then minced and embedded 
into the gelatin in a criss-cross fashion.  Approximately 2ml of Dulbecco’s modified eagle’s 
medium (DMEM) plus fetal calf serum (FCS) was then added to the explanted tissue and the 
petris were placed into a 37°C 5%CO2/95%O2 incubator overnight (O/N).  The next day, an 
additional 2ml of medium was added to the tissue preparations and petris were left at 37°C.  
Explant outgrowths to be used for the ex vivo model of EMT were fixed in cold methanol at 
3-17 days post-explanting (section 2.3.2) by flooding petris with cold methanol for 10min and 
then air-drying.  Cells obtained from UUO to be used for in vitro studies were propagated for 
17-21 days in DMEM + 10%FCS before being passaged and transferred to 25cm
2
 flasks cells, 
to be used for subsequent experiments (section 2.4).  The explanting methodology is 
summarised schematically in Fig. 2.2. 
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Subculture cells (UUO)
Primary cell 
outgrowth
Remove cortex
Mince and embed 
tissue
Explanting 
procedure 
of the
renal 
cortex
Fix in cold methanol 
(ex-vivo)
Explanting procedure of the renal cortex. Those cells obtained for in vitro studies from 
UUO were sub-cultured (left) whilst cells grown out of explants in the ex-vivo model of 
EMT were fixed at various time points post-explanting (right).
Fig. 2.2
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2.4 CELL CHARACTERISATION 
2.4.1 Characterisation of cells obtained from UUO 
Sub-cultured cells grown from fibrotic kidneys subjected to UUO were routinely 
characterised by immuno-cytochemistry to confirm the propagation of fibroblasts. Standard 
staining techniques (section 2.6.1) were used to identify positive and negative staining for 
phenotypic markers (Table 2.1), as described previously (Hewitson et al., 2000b). 
 
Antisera Specificity 
Vimentin Mesenchymal cells (smooth muscle, 
fibroblasts, de-differentiated epithelium)  
αSMA Smooth muscle cells, myofibroblasts 
Desmin Mesangial cells 
Collagen III Mesenchymal 
Pan-keratin Epithelial cells 
RECA Endothelial cells 
 
Table 2.1: Specificity of antisera used. RECA = Rat endothelial cell antigen 
 
Cells consistently stained for vimentin and collagen III, 40-50% for αSMA, 
approximately 10% for desmin. Only very occasional cells stained for pan-cytokeratin or rat-
endothelial cell antigen (RECA) (<1%).  On this basis, cells were classified as fibroblasts, a 
proportion of which showed myofibroblast differentiation.   
 
2.4.2 Characterisation of cells derived from normal Sprague-Dawley rats 
 Cells from normal kidney explants were phenotyped by immunocytochemistry for 
αSMA, FSP1, desmin, RECA, E-cadherin and cytokeratin (Table Appendix; Apx. 3.1) to 
determine the composition of cells that grow out of explants. Standard staining techniques 
(2.6.1) were used to identify positive and negative staining for phenotypic markers.  
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2.5 PASSAGING, FREEZING, THAWING and COUNTING of FIBROBLASTS 
DERIVED from UUO 
2.5.1 Passaging  
For cells undergoing the first passage, media was discarded and the explant layer 
washed with 2ml sterile PBS.  1ml of trypsin was added and left for 15min at 37
o
C. After 
15min, 2ml of medium was added to each explant and the remaining cells that did not 
dislodge were gently removed with a sterile cell scraper. The cell suspension was then 
transferred to a 25cm
2
 flask and approximately 7ml of fresh medium was added.  For all other 
passages, 2ml of trypsin was added to confluent flasks and left for 15min at 37
 o
C.  Five ml of 
medium was then added and cells were centrifuged at 5000rpm for 10min. Cell supernatant 
was then removed and cells were resuspended in 10ml DMEM.  Cells were then either seeded 
for experiments or placed into new flasks and left at 37
 o
C.   
 
2.5.2  Freezing and thawing 
 
Nine ml of medium was aliquoted into a sterile 10ml tube with 1ml of dimethyl 
sulphoxide (DMSO).  This was placed in a freezer or on ice until ready to use. Cells were 
passaged as per normal and slowly resuspended in the prepared DMSO/medium mixture.  The 
cells were then transferred to sterile nunc tubes, wrapped in tissue paper and placed at -80°C, 
to be later transferred to liquid nitrogen.  When cells required thawing, 9 ml of medium was 
aliquoted into a falcon tube and warmed in the water bath.  The frozen cells were then thawed 
at 37°C and the contents were then placed into the sterile tube.  The pre-heated medium was 
then slowly added with gentle agitation to resuspend the cell solution.  The cells were then 
transferred to a flask and left for at least 4-6hr for cell attachment. The next day, fresh 
medium was added to remove any remaining traces of DMSO. 
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2.5.3 Cell counting  
Cells were quantified with a 1/400mm haemocytometer in order to seed cells at a 
specific density.  100µl of cell solution was placed into a test tube and diluted 1:1 with 100µl 
trypan blue (to exclude dead cells). 
Cell number was found by:  
Cell no. = x / Sq × 104 × D × V 
where 
x = number of cells  
Sq = number of large squares counted  
D = dilution factor 
V = Volume remaining (ml) 
The total number of cells to seed per well was found by: 
 
x = Density × volume remaining  
Total cell number 
 
The appropriate number of cells were seeded into petri dishes / six well plates and the 
desired medium added to each well.  Cells were then left in the incubator O/N at 37°C to 
adhere. 
 
 
2.6 IMMUNOHISTOCHEMISTRY and CYTOCHEMISTRY 
 
2.6.1 Cytochemistry (Immunoperoxidase) 
Cells were grown on coverslips and fixed in methanol. Standard Avdin-biotin-
complex (ABC) techniques were used to stain cells using the antisera in Table Apx. 3.1 
(Hewitson et al., 2001).  In each case, cells were washed in PBS, blocked with normal species 
relevant serum, and incubated with primary antisera for 1hr.  Following incubation, coverslips 
were washed in PBS, incubated with the appropriate biotinylated secondary antibody (Table 
Apx. 3.2), washed in PBS, incubated with ABC and exposed to diaminobenzidine (DAB) 
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chromagen for 2-5min.  Finally, cells were washed in water, counterstained with Harris’ 
haematoxylin and mounted with Gurr Aquamount. 
  
2.6.1.1 Enumeration of cells 
In cases where cells were enumerated based on staining patterns, the cells within a 
number of random fields were counted. A real representation of the staining pattern was 
gained by counting between 800-1000 cells per slide throughout a number of randomly 
chosen fields. Slides were counted blindly. In the majority of cases, results are expressed as a 
percentage of control of total cells counted.  
 
2.6.2 Immunohistochemistry 
 
2.6.2.1 Paraffin-embedded rat tissue sections  
Embedded sections were placed at -20°C prior to cutting and were then cut using a 
microtome.  Tissue was then placed into water, alcohol and immersed in water at 40°C.  
Sections were then removed, placed on silane-coated glass slides and air-dried.  Slides were 
then placed in an incubator O/N at 42°C, baked at 60°C for a further 45min, and then stored 
for future use. 
 
2.6.2.2 Immunohistochemistry of tissue sections 
Immunohistochemistry was carried out on paraffin embedded sections by using 
antibodies against fibrinogen/fibrin, factor V and αSMA (Table Apx. 3.1-3.2) as described 
previously (Hewitson et al., 1998). 
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2.7 BIOCHEMISTRY STUDIES: NORTHERN BLOTTING, WESTERN BLOTTING, 
REAL TIME PCR 
 
2.7.1 Extraction of cellular protein, DNA and RNA 
To obtain cellular RNA, DNA and protein from fibroblasts for Northern blotting, real 
time PCR and Western blotting, TRIZOL reagent was utilised according to the manufactuer’s 
instructions.  An RNA clean-up kit was also used to remove proteinaceous material or DNA 
for the preparation of samples for real time PCR as per the guidelines. 
 
2.7.2 NORTHERN BLOTTING  
Samples were centrifuged at 12000 rpm for 20min at 4°C and the pellets washed in 
1ml cold 75% ethanol. Pellets were then vortexed, centrifuged at 7500 rpm for 5min and air 
dried for 15min.   
The gel apparatus was washed with 0.1%SDS and two changes of dH2O and the tray 
was then set up.  An appropriate agarose gel was prepared by heating the agarose, MOPS and 
water until the agarose had dissolved. The formaldehyde was then added.  The agarose gel 
buffer was then made up and each test sample was prepared with 20ul RNA, 10ul sample 
buffer, and 5µl ethidium bromide.  The samples were loaded and the gel was run at 115V for 
about 1hr.  If mRNA bands were even northern blotting was carried out.  In this case the gel 
was placed in 10% SSC into a pyrex dish and placed O/N at 4°C.   
The next day, two large gel tanks and four glass plates were washed with 0.1%SDS 
and rinsed with sterile dH2O. Two paper wicks were then cut using 3M chromatography 
paper.  Whilst resting glass plates on a gel tank, the wick was set across it and wet and 500ml 
10×SSC was poured into the tank.  The gel was placed upside down onto the middle of the 
wick and the nylon membrane placed on top.  This was covered with two small pieces of 3M 
chromatography paper, a stack of blotting paper and secured with second glass plate and a 
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weight. The apparatus was left O/N at room temperature.  The following day the membrane 
was removed and soaked in two changes of 2xSSC for 15min (10ml 20xSSC: 90ml dH2O).  
The membrane was then wrapped in glad wrap and the RNA fixed to the membrane by UV by 
placing wrapped membrane onto the transilluminator for 10min.  The UV fixed membrane 
was stored at -70°C. 
To carry out the pre-hybridisation reaction, the membranes were placed into sterile 
roller bottles.  The pre-hybridisation solution was then prepared and added to each roller 
bottle.  After denaturing 10mg/ml ssDNA by heating above 95°C for 2min, 50µl per filter was 
added to each bottle and left rotating in the hybridisation oven for 4hr at 42°C. 
In sterile tubes the hybridisation reaction mixture was made up consisting of 5µl 
DNA, 10µl labelling buffer, 5µl primers and 17µl dH2O. This was then denatured at 95°C for 
2min, followed by the addition of 10µl labelling buffer, 5µl 32P and 3µl Klenow enzyme and 
subsequent incubation for 2hr at 42°C.  Unincorporated 
32
P was removed by spinning the 
labelling mixture through a sephadex-G50 column.  The syringe was filled with sephadex G-
50 saturated tris-EDTA-NaCl (TEN) buffer and centrifuged at 1600rpm for 4min.  A sterile 
tube was placed into the bottom of 10ml tube to collect the purified radiolabelled insert.  This 
was centrifuged at 1600rpm for 4 min and the purified probe was transferred to a sterile tube. 
The probe was then denatured by heating to 95°C for 2min and added the to filters in the 
prehybridisation solution.  This was left rotating O/N at 42°C.   
 The following washes of increasing stringency were prepared in sterile 100ml 
bottles: 10×SSPE, 0.1% sodium dodecyl sulphate (SDS), 5×SSPE, 0.1% SDS and 2×SSPE, 
0.1% SDS.  The pre-hybridisation solution containing the probe was removed and 10-20ml of 
wash solution added to each roller bottle.  Each wash was performed for about 1hr at 42°C 
with rotation.  Filters were then removed from filter bottles and placed between two pieces of 
gladwrap.  Membranes were then exposed to x-ray film for 2hr or O/N, developed and     
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photographed.  Lastly, procollagen mRNA was quantified using densitometry software 
(Kodak 1D image analysis). 
 
2.7.3 WESTERN BLOTTING: SDS-PAGE 
The Western blotting apparatus was initially washed with de-ionised distilled water 
and 100% alcohol and dried. Plates were assembled together with stackers in a pouring 
chamber.  An appropriate polyacrylamide gel according to the molecular weight of the desired 
protein was then prepared (Apx. 2.5). Contents were mixed in a small conical flask, pipetted 
between glass plates and overlayed with distilled water. Gels were left to set for 
approximately 45min.  The stacking gel was then prepared and once water was poured off 
from the base gel, the stacking gel was pipetted on top, well combs arranged in the stacker, 
and left to set for 20min.  Combs were removed and wells washed with de-ionised distilled 
water.  Protein samples that were extracted with Trizol were prepared according to the 
following protocol: 
1. Protein samples were thawed and heated at 60ºC for 10min and samples with equal 
amounts of 2×SDS buffer with or without 2-Mercaptoethanol (bME) were prepared. 
2. A Rainbow Standard and Biotinylated protein ladder/HRP-conjugated anti-biotin 
antibody were also prepared according to the manufacturer’s instructions. Both the 
standards and the samples were heated at 90ºC for 10min and pulse centrifuged.   
3. Glass plates were then transferred to the electrode apparatus, snapped into place and 
inserted into the miniprotein gel tank.  500ml of tank buffer (1%SDS) was prepared and 
poured into the apparatus to cover the wells in the upper gel tank. 
4. Standards and samples were then loaded using a Hamilton pipette and the lower gel tank 
was filled with the rest of the 1%SDS buffer.  Gels were run at 80V for 10min and once 
samples had passed through stacking gel, the voltage was increased  to 200V for 40min.  
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5. Gels were stained with Coomassie blue or prepared for transfer to nitrocellulose 
membrane. If staining for Coomassie blue, gels were immersed in the dye for 30-60min 
and destained in 50% MeOH and 10% acetic acid.  The destainer was changed until 
protein bands were evident.  The gel was then stored in acetic acid or photographed. 
 
Alternatively, gels were pre-treated according to the following: 
1. Gels that were transferred were initially soaked in prepared cold transfer buffer for at 
least 30min. 
2. To pre-treat the PVDF membrane, membranes were cut to size and immersed in 
methanol for 15sec, dH2O for 5min, and transfer buffer for at least 15min.   
3. The gel sandwich apparatus was then set up consisting of fibrous pads soaked in transfer 
buffer, 3M paper (cut to pad size) also soaked in buffer and placed on top of pad, 
followed by the addition of the gel.  
4. The apparatus was completed by adding another piece of 3M paper and finally another 
fibrous pad.  The apparatus was clipped together and placed in the transfer holder.  The 
holder was placed in the tank and an ice-pack was added.  
5. Cold transfer buffer was added and transfers were run at 100V for 1hr. Upon 
completion, the sandwich was disassembled and membranes were soaked in cold 5% 
skim milk/PBS-Tween O/N at 4ºC.   
 
Antibody labelling was then carried out according to the following: 
1. The next day, skim milk solution was removed and membranes were rinsed in PBS-
Tween for 45min while shaking.  The primary antibody, diluted in PBS-Tween, was 
then added for 1-2hr at room temperature with shaking, or O/N at 4ºC.   
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2. Membranes were then washed in PBS-Tween for 45min and the secondary horse-radish 
peroxidase (HRP)-conjugated secondary antibody, diluted in PBS-Tween, was added for 
1hr with shaking (Appendix 4; Table 3.3).   
3. Membranes were then washed in PBS-Tween for 1hr with shaking.   
4. Using a chemiluminescence (ECL) detection kit, the reagent was prepared according to 
the manufacturer’s instructions and membranes were incubated for the specified amount 
of time.  
5. Excess liquid was rinsed off and membranes placed between two sheets of acetate paper. 
Membranes were placed inside an x-ray cassette and exposed to x-ray film.   
6. X-ray film was then developed for 2min, washed in water and fixed for 2min in fixative.   
7. If the membranes were to be stripped and re-probed, western blotter stripper was added 
for 15min with shaking. They were then exposed to a new film to ensure removal of the 
previous probe. Membranes could then be re-probed, as described above.   
8. Results were quantified (in the case of αSMA) using densitometry software. 
 
2.7.4 REAL TIME  PCR 
The concentration of RNA in the samples was analysed by (a) spectrophotometry or 
(b) SYBR Green RNA quantitative analysis. 
(a) Using sterile tubes, 119µl of water and 1µl of test RNA were placed into each. 
120µl of water was used in the control sample.  Using a crystal quartz, the spectrophotometry 
machine was zeroed with the control, and samples were then analysed at a wavelength of 
260nm.  This was repeated three times for each sample and the results averaged.       
(b) The SYBR Green assay was carried out according to the manufacturer’s 
instructions.  Fluorescence values were plotted against a standard curve to find the RNA 
concentration of each sample. 
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Once the concentration of values were attained, DNA was removed from samples: 
1ug/µl of RNA was made up to a total of 10µl with appropriate volumes of DNase, 
DNase buffer and dH2O.  Samples were then vortexed, centrifuged and left at room 
temperature for 30min.  1µl of stop buffer was then added and samples were left for 15min at 
65°C and then placed on ice. 
 
Samples were then reverse transcribed according to the following: 
1. The RNA concentration was adjusted to 100ng by taking placing 1µl into thin walled PCR 
tubes and adding dH2O, random hexamers and RNAse out to a total volume of 7µl. After 
briefly centrifuging, samples were heated to 65°C for 5min and cooled on ice.   
2. A master mix was then prepared using the superscript III reverse transcription kit 
consisting of sample buffer, MgCl2, Dithiothreitol (DTT), deoxyribonucleotide 
triphosphate (dNTP), dH2O and superscript III enzyme.   
3. 13µl was added per tube and briefly centrifuged.  Samples were then heated at 25°C for 
10min, 50°C for 50min, 85°C for 5min and cooled at 4°C before placing on ice.   
4. Finally, 15µl of dH2O was added, and samples were pulse centrifuged and stored at -20°C.  
5. Stock primers were thawed and heated to 75°C for 5min and primers and housekeeper 
gene were prepared according to the optimal running temperature. At a concentration of 
0.5µM, 20µl of each of the forward and reverse primers were added to dH2O.   
6. A master mix of each primer set was prepared which consisted of Jump Start, forward 
primer, reverse primer and dH2O.  A total of 25µl was loaded as either duplicates or 
triplicates into 96 well PCR plates with 23µl of the primer master mix and 2µl of the DNA 
of interest.   
7. Negative controls containing primer only and water only were included and samples were 
run according to the set up below.  The melt curve of each sample was analysed to verify a 
single product according to the peak melting temperature time. 
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Cycle 
Repeats Step Dwell time 
(min) 
Hold Set point 
(°C) 
Melt 
curve 
Temp 
(°C) 
1 3 1 5  95.0   
2 60 1 1  94.0   
  2 30sec  60.0   
  3 1  72.0   
3 1 1 1  55.0   
4 85 1 10sec  55.0 # 0.5 
5 1 1 - # 4.0   
 
Table 2.2: Biorad real time PCR program  
 
2.8 STATISTICAL ANALYSIS 
All data is represented as mean ± standard deviation (SD), unless indicated. Treatment 
groups were compared using one-way analysis of variance (ANOVA) with the TUKEY test 
correction for multiple comparisons. p<0.05 was considered statistically significant in all 
studies. 
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3.1 INTRODUCTION 
The interstitial fibroblast is a key mediator of tubulointerstitial fibrosis and in response 
to a cocktail of circulating cytokine and non-cytokine mediators, these cells can (a) proliferate 
autonomously, (b) secrete chemotactic substances which may recruit more fibroblasts, 
inflammatory cells or activate other interstitial/glomerular cells and (c) differentiate into more 
potent counterparts that are capable of secreting ECM proteins and mediating the contracture 
of parenchmyal and matrix tissue.  Whilst the cytokine agonists that mediate these processes 
have been well characterised, the intracellular signalling axes that mediate fibroblast 
proliferation and synthetic activity are less well-known.   
Of those pathways that regulate fibroblast activity, the TGFβ signalling axis is most 
well characterised. This signalling axis integrates a variety of signals including those from 
angiotensin II (Fukami et al., 2004), CTGF (Grotendorst, 1997), AGEs (Li et al., 2004a), 
PDGF (Daniels et al., 2004), FGF (Strutz et al., 2001) and TGFβ1 itself (Runyan et al., 2004). 
However, given the complexity of cell-signalling pathways, the control of fibroblast function 
is likely to involve other signalling pathways.  This study therefore aimed to identify other 
signalling pathways involved in regulating two important responses of the fibroblast; 
proliferation and ECM synthesis. 
Proliferation and ECM synthesis can be regulated through integrin signalling 
(Chiquet, 1999) or local environmental stressors (Zeisberg et al., 2000) however, key 
mediators of these processes are growth factors.  Although typically associated with cancer, 
cell survival and glucose metabolism (Inoki et al., 2005b), phosphatidylinositol 3-kinase 
(PI3K) also regulates proliferation, differentiation and ECM synthesis (Asano et al., 2004; 
Brennan et al., 1999; Breslin et al., 2005; Gerasimovskaya et al., 2005a; Krymskaya et al., 
1999) and is increasingly known for its ability to integrate growth factor signals through 
receptor tyrosine kinases (RTKs).  In response to extracellular ligands such as PDGF, FGF, 
EGF or IGF, RTK’s dimerise and autophosphorylate leading to the generation of 
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phosphatidylinositol-(3,4,5)-triphosphate (PIP3) from phosphatidylinositol-(4,5)-biphosphate 
(PIP2) and the recruitment of molecules to the plasma membrane with a pleckstrin homology 
(PH) (Engelman et al., 2006). One such PH containing kinase is acute transforming retrovirus 
thymoma (Akt), which once translocated, can be phosphorylated by mammalian target of 
rapamycin complex 2 (mTORC2) at S-473 (Sarbassov et al., 2005). This precedes and 
facilitates the phosphorylation of Akt T-308 by phosphoinositide dependent kinase 1 (PDK1) 
(Alessi et al., 1997; Balendran et al., 1999a). Once activated, Akt is capable of activating the 
downstream serine/threonine kinase mTOR.  This founding member of the PI3K related 
protein kinase family is involved in cell cycle progression and cell proliferation (Inoki et al., 
2005b), primarily by regulating the G1-S phase of the cell cycle.  
mTOR is a key integrator of stress, nutrient and growth factor signals and many of 
these converging signals are integrated through the tuberous sclerosis complex (TSC1/2) 
(Inoki et al., 2002). TSC1/2 exerts GTPase activating protein (GAP) activity over the positive 
regulator of mTOR Rheb.  This latter protein cycles between an active GTP-bound state and 
an inactive GDP-bound state. mTOR is increasingly recognized for its ability to integrate 
growth factor signals such as IGF, FGF, PDGF and insulin via PI3K.  In response to these and 
other growth factors, Akt directly phosphorylates TSC2 inactivating its GAP activity, leading 
to an accumulation of GTP-bound Rheb. This leads to the activation of downstream effectors 
S6 ribosomal protein S6 kinases (S6Ks) and the eukaryotic initiation factor (eIF) 4E binding 
proteins (4EBPs) (Fingar and Blenis, 2004; Ponticelli, 2004) (Fig. 1.16a-c).   Accordingly, it 
is likely that mTOR may play a key role in integrating a number of growth factors that are 
directly relevant to the regulation of fibroblasts in fibrosis. 
Given that autonomous fibroblast proliferation and aberrant collagen synthesis are key 
roles of activated fibroblasts in fibrosis, this study was aimed at elucidating the roles of these 
kinases in the regulation of rat fibroblasts derived from fibrotic rat kidneys.  This study has 
investigated the role of mTOR and PI3K in the regulation of fibroblast function by using the 
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rapamycin derivative RAD and the PI3K inhibitor LY294002 (LY). Rapamycin and its 
derivatives, best known for their immunosuppressive properties (Breslin et al., 2005), have 
been shown to inhibit mTOR by binding to the intracellular binding protein FKBP12 (Meric-
Bernstam and Mills, 2004) which binds to the FKBP12 rapamycin binding (FRB) domain of 
mTOR inhibiting its activity.  LY binds to the ATP binding site of PI3K inhibiting all classes 
of PI3K (with less affinity for class II PI3K) (Fig. 3.1).   
 
3.2 EXPERIMENTAL DESIGN 
This study utilised cells derived from kidneys at 3 days post-UUO.  Cells were treated 
for 48hr with (a) various doses of RAD (10, 100, 200nM), LY (10µM), or the Mek1 inhibitor 
PD98059 (PD; 20µM), (b) treated with combinations of these drugs, or (c) maintained in 
control medium, as indicated. Drugs were added to standard medium (1xDMEM 
supplemented with 10%FCS, 1M N-2-hydroxethypiperazine-N’-2-ethansulfonic acid; 
HEPES, 2mM glutamine and 500Units/ml penicillin/streptomycin), unless specified 
otherwise.  These studies were based on the response of fibroblasts to serum-based growth 
factor/cytokine stimulation.  Using these standard procedures, this chapter examined the 
signalling pathways encompassing PI3K and mTOR including Akt S-473 and S6RP, and then 
carried out a number of functional studies assessing the role of these kinases in cell 
proliferation and collagen synthesis. 
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Mechanism of action of rapamycin derivative RAD and LY
ECF = extracellular fluid, ICF = intracellular fluid.
Fig. 3.1
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3.3 RESULTS 
 
3.3.1 Cell signalling mechanisms in renal fibroblasts 
3.3.1.1 LY inhibits the phosphorylation of Akt S-473 
Akt is a serine/threonine kinase with an N-terminal pleckstrin homology (PH) domain. 
When the formation of PIP3 is catalysed by the p110 catalytic subunit of PI3K, Akt is 
translocated to the plasma membrane to bind PIP3 at its PH domain. Akt can then be 
phosphorylated at S-473 by PDK2 and this precedes and facilitates the phosphorylation of T-
308 by PDK1.  Activation of Akt can lead to the downstream phosphorylation of mTOR of 
which S-2448 and T-2446 have been identified as the likely phosphorylation sites targets for 
Akt (Sekulic et al., 2000).  In order to confirm that Akt is a downstream mediator of PI3K in 
renal fibroblasts, Akt phosphorylation at S-473 was examined.  Western blotting indicated 
that 10µM LY completely inhibited the serum-induced phosphorylation of Akt S-473, as 
compared to total Akt (lane 2 vs. lane 1; Fig. 3.2).  This is consistent with LY mediated 
inhibition of downstream PI3K signalling and is representative of duplicated experiments 
(independent experiments). 
 
3.3.1.2 RAD down-regulates the phosphorylation of Akt S-473 
Western blot analysis also indicated that the phosphorylation of S-473 Akt was down-
regulated in response to 10nM RAD (Fig. 3.2, lane 4 vs. lane 3).  This provides a novel 
finding into the regulation of Akt in renal fibroblasts. 
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Fig. 3.2
Fig. 3.3
48hr treatment
Western blotting was performed on equal volumes of cell protein using a polyclonal antibody 
against phosphorylated-Akt (p-Akt S-473). Akt phosphorylation was completely inhibited by 10µM 
LY in response to serum-based mitogen stimulation for 48hr (lane 2 vs. lane 1). This is an expected 
and established result. More interestingly, Akt S-473 phosphorylation was partially inhibited by 
100nM RAD (lane 4 vs. lane 3). Even loading was confirmed by examining total Akt
phosphorylation levels.
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3.3.1.3 S6RP phosphorylation is inhibited by both RAD and LY but not by the 
MEK1 inhibitor, PD 
To confirm that both RAD and LY inhibit downstream targets of mTOR, the effect of 
these kinase inhibitors on the phosphorylation of S6 ribosomal protein (S6RP) was examined. 
The ratio of p-S6RP to total S6RP was measured using enzyme-linked immunosorbent assay 
(ELISA).  Fig. 3.3 demonstrates that S6RP (S-235/236) is a downstream target of mTOR.  
Relative to the control group, 100nM RAD and 10µM LY reduced phosphorylation of S6RP 
by approximately 80% (p<0.001, n=3).  Fig. 3.3 is representative of a duplicate set of 
experiments.     
Given that the literature indicates that PI3K and mTOR can cross-talk with other 
substrates, the potential for the MAPK pathway to phosphorylate S6RP was also investigated.  
In contrast to LY and RAD, 20µM of the MEK1 inhibitor PD did not affect p-S6RP as a ratio 
compared to total S6RP levels (Fig. 3.4). Again, Fig. 3.4 is representative of a duplicate 
experiment. 
 
3.3.1.4 mTOR can be constitutively activated independent of serum-based factors 
It is believed that the mTOR pathway contains a constitutively active circuitry and 
recently it has been shown that smooth muscle cells exhibit a proliferative phenotype 
independent of growth factors (Mourani et al., 2004).  In light of the ability of mTOR to be 
constitutively activated by amino acids and nutrients, this experiment was carried out to 
determine if, as in smooth muscle cells, mTOR can be constitutively activated in the absence 
of FCS in fibroblasts by using S6RP as a read-out.  
To examine this, fibroblasts were exposed to either serum free medium or medium 
supplemented with 2.5% or 10% FCS. Fig. 3.5 demonstrates that compared to the control, 
cells grown in 2.5% and 10%FCS displayed an increase in S6RP phosphorylation by 176%  
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S6RP phosphorylation was examined as a ratio of p-S6RP:total S6RP. Compared to the serum 
free medium, cells grown in 2.5% and 10% FCS displayed an increase in S6RP phosphorylation
by 176% and 212% respectively (illustrative of a duplicate experiment). This indicates that, 
consistent with its ability to be activated by amino acids and nutrients, mTOR maintains a 
constitutively active circuitry in the absence of growth factors within FCS.
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and 212% respectively (illustrative of a duplicate experiment).  Very little change in 
phosphorylation was evident in response to the varying degrees of FCS.  This confirms that 
mTOR can maintain a constitutively active circuitry independently of growth factors.  
 
3.3.2 LY and RAD down-regulate fibroblast mitogenesis 
Dose response studies were undertaken to establish if mTOR and PI3K are involved in 
regulation of renal fibroblast kinetics. 
 
3.3.2.1 LY and RAD reduce the number of renal fibroblasts  
RAD (10, 100, 200nM) decreased proliferation over 5 days by 64±5, 59±8 and 66±6% 
respectively (Fig. 3.6; all p<0.001 vs. control).  Similarly, LY reduced proliferation by 
68±11% (Fig. 3.7; p<0.001 vs. control).   
 
3.3.2.2 LY and RAD reduce DNA synthesis in renal fibroblasts 
Changes in cell number were reflected by a reduction in DNA synthesis, as measured 
by incorporation of tritiated [
3
H] thymidine.  RAD (10, 100, 200nM) inhibited serum induced 
DNA synthesis by 53±7%, 50±9% and 42±7% respectively (Fig. 3.8; all p<0.001 vs. control).  
10µM LY also decreased thymidine incorporation by 68±2.3% (Fig. 3.9; p<0.001 vs. control).  
This indicates the involvement of both mTOR and PI3K in the regulation of the cell cycle and 
supports rapamycin’s well-known inhibitory effect on cell cycle arrest.   
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Both RAD (Fig. 3.6) and LY (Fig. 3.7) decreased cell number over 5 days. RAD (10, 100 
and 200nM) decreased proliferation by 64±5, 59±8 and 66±6% respectively (*all 
p<0.001 vs. control) while LY (10µM) reduced growth by 68±2.3% (**p < 0.001 vs. 
control). Results are expressed as mean ± S.D.% of a duplicate experiment (n=4) and 
are presented as a percentage of control means. 
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Changes in cell proliferation were paralleled by RAD and LY-mediated reductions in DNA 
synthesis, as measured by tritiated [3H] thymidine incorporation. RAD (10, 100 and 200nM) 
decreased thymidine incorporation by 53±7, 50±9 and 42±7% (Fig. 3.8, *all p < 0.001 vs. 
control). LY (10µM) reduced DNA synthesis by 67.1 ± 2.3% (Fig. 3.9, p < 0.001 vs. 
control). Results are expressed as mean ± S.D.% of a representative duplicate experiment 
(n=4) and are presented as a percentage of control means. 
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3.3.2.3 Combined LY and RAD treatment further decreases fibroblast mitogenesis 
In addition to their individual effects, treatment with both RAD and LY further 
decreased serum-induced fibroblast mitogenesis. Co-inhibition with 10µM LY and 100µM 
RAD decreased cell number by 97±1.6%, significantly more than either drug alone (Fig. 3.10; 
p<0.05 vs. control, p<0.05 vs. 100nM RAD).  Similarly, the 78±4% reduction in DNA 
synthesis with both drugs was more than that seen individually (Fig. 3.11; p<0.001 vs. 
control, p<0.05 vs. 100nM RAD;) suggesting that these pathways may work in cooperation to 
regulate the cell cycle.  
 
3.3.2.4 The ERK1/2 MAPK pathway and PI3K may act cooperatively to regulate 
fibroblast proliferation 
The role of the ERK1/2MAPK cascade in fibroblast proliferation was examined by 
using the Mek-1 inhibitor PD which inhibits the ERK1/2MAPK cascade (Dudley et al., 1995).  
As shown by Fig. 3.12, PD, a known inhibitor of proliferation, inhibited fibroblast 
proliferation by 43.4±6% (p<0.001 vs. control means) whilst individually RAD and LY 
inhibited proliferation by 58.9±8% and 67±2.5% respectively (p<0.001 vs. control). In 
response to co-inhibition with LY and PD, a further decrease in proliferation by 15.9±3% was 
noted as compared to LY (p<0.05 vs. LY, n=4), whilst no further significant decrease resulted 
from co-inhibition with PD and RAD.  It has been noted that PI3K can stimulate the MAPK 
pathway, and these results, representative of a duplicate experiment, suggest that the 
ERK1/2MAPK cascade may act in parallel or cross talk with PI3K in the regulation of 
fibroblast proliferation.  
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Combined treatment of cells with RAD (100nM) and LY (10µM) further decreased serum-induced 
fibroblast proliferation by 97±1.6%, significantly more than either drug alone (Fig. 3.10). 
Similarly, the reduction in DNA synthesis (78±4%) with both drugs was more than that seen 
individually (Fig. 3.11). Results illustrate a duplicate experiment. Data is expressed as 
mean ± S.D.%, with findings presented as a percentage of control means (*p < 0.001 vs. control, 
**p < 0.05 vs. control, #p < 0.05 vs. 100nM RAD & 10µM LY, n=4). 
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Fig. 3.12
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PD inhibited fibroblast proliferation by 43.3±6% (*p<0.001 vs. control) whilst individually,
RAD and LY inhibited proliferation by 58.9±8% and 67±2.5% (**p<0.001 vs. control). Co-
inhibition of PD with LY mediated a further decrease in proliferation by 15.9±3% as 
compared to LY (#p<0.05 vs. LY, n=4).  No significant difference was noted in response to co-
inhibition with RAD and PD. 
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3.3.3 Changes in proliferation are independent of apoptosis or changes to cell viability 
Previous studies of PI3K have implicated it as a major regulator of cell survival. To 
determine if the demonstrated effects of RAD and LY on proliferation were due to changes in 
the incidence of cell apoptosis, apoptosis and cell viability testing was carried out.  LY and 
RAD treated cells were assessed with TUNEL (terminal deoxynucleotidyl transferase 
mediated dUTP nick end labelling assay), nuclear morphology was quantified (propidium 
iodide), and mitochondrial activity (MTT; dimethylthiazol-yl-diphenyl tetrazolium bromide) 
was examined.  
 
3.3.3.1 TUNEL 
The role of apoptosis was specifically examined by comparing results of TUNEL in 
control, LY (10µM) and RAD (200nM) treated cells (Fig. 3.13). This technique identifies the 
presence of DNA fragmentation in apoptotic cells caused by activation of endonuclease 
activity during cell death (Hewitson et al., 2000a). While TUNEL detected almost universal 
labelling of DNase digested cells (Fig. 3.13e), labelling in 200nM RAD (Fig. 3.13b) and 
10µM LY (Fig. 3.13c) treated groups was not qualitatively different from cells grown in 
control medium (Fig. 3.13a). Only the occasional cell labelled positive for TUNEL (Fig. 
3.13d, arrow).  Quantifying these results confirmed that apoptosis was not significantly 
increased in any of the treated groups (Fig. 3.13f). 
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The incidence of apoptosis, as assessed by TUNEL, was not significantly affected by 200nM 
RAD or 10µM LY. Cells were exposed to control medium, RAD or LY supplemented medium. 
Photomicrographs of cells grown in (a) control, (b) RAD and (c) LY were not qualitatively 
different, and only occasional TUNEL positive cells could be found (arrows). (d) At higher 
magnification, these cells show the characteristic condensation of chromatin (arrow) and 
formation of apoptotic bodies (arrowheads). (e) In the positive control, most DNase treated 
cells were labelled with TUNEL. (f) Quantitative assessment showed no significance difference 
between groups in the incidence of TUNEL positive cells. The graph represents pooled 
observations (n=4) from two independent experiments. Results are represented as a 
percentage of total cells counted. 
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3.3.3.2 Propidium Iodide 
Qualitative assessment of cell morphology using propidium iodide staining only 
identified very rare instances of nuclear fragmentation, condensation or cytological changes 
associated with cell apoptosis in all RAD (10, 100, 200nM) (Fig. 3.14b-d) and LY (10µM) 
(Fig. 3.14e) treated groups compared to the control (Fig. 3.14a).  A higher incidence of 
apoptotic bodies was noted in response to 50µM LY (Fig. 3.14f, arrow).  
 
3.3.3.3 MTT Assay 
The experimental doses of 10, 100, 200nM RAD or 10µM LY did not effect cell 
viability, as measured by the ability of cell mitochondria to reduce MTT to a formazan salt 
(Fig. 3.15).  It was therefore concluded that mitochondrial viability was not affected by any of 
these doses over the standards time-course of these experiments. Fig. 3.15 represents an 
average of three independent experiments. 
Preliminary experiments incorporated the use of 50µM LY. Propidium iodide staining 
(3.3.3.2) indicated that a higher incidence of apoptotic bodies were present in response to this 
dose.  The MTT viability test also indicated that mitochondrial activity was compromised in 
cells treated with 50µMLY (0.510±0.158) compared to the control group (0.75±0.197) (Fig. 
3.15, p<0.05 vs. control, n=4).  This dose was therefore excluded from the final results.  
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Fig. 3.14 
Qualitative assessment of cell 
morphology in two separate 
experiments using propidium 
iodide staining only identified 
very occasional instances of 
nuclear fragmentation or
cytological changes 
associated with apoptosis in 
the RAD (10, 100, 200nM; b-
d) and LY (10µM; e) treated 
groups compared to the 
control (a).  A higher 
incidence was however noted 
in the higher dose of LY 
(50µM; f, arrow).
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Fig. 3.15 
Neither drug had any effect on cell viability, as measured by the ability of cell mitochondria to reduce 
MTT. There was no significant difference between dye reduction in LY (10uM), RAD (10, 100, 200nM)
and the control group.  Because 50uM LY was found to effect mitochondrial viability (*p<0.05 vs. 
control) , this dose was not included in the final results.  
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3.3.4 PI3K and mTOR regulate the synthesis of total collagen and α1(I) mRNA  
 
3.3.4.1 Inhibition of PI3K and mTOR decrease total collagen synthesis 
To determine whether PI3K or mTOR were involved in regulating collagen synthesis, 
further implicating their involvement in fibrosis, incorporation of radioactively labelled 
hydroxyproline was analysed.  Incorporation of hydroxyproline by cells treated with RAD 
(100nM) and LY (10µM) was significantly reduced by 78.5±7.8% and 73.3±2% (Fig. 3.16; 
both p<0.001 vs. control, n=4).  These results are representative of duplicate experiments.  
 
3.3.4.2 Procollagen mRNA synthesis is regulated by mTOR  
The hydroxyproline incorporation assay has established that total collagen synthesis is 
decreased in response to both RAD and LY.  To determine whether α1(I) procollagen mRNA 
levels were also regulated by mTOR  Northern blotting analysis was carried out on fibroblasts 
treated with 100nM RAD. Loading was standardised using densitometry software according 
to 18S levels (Fig. 3.17a). Representative of duplicate experiments, Fig. 3.17b illustrates that 
α1(I) procollagen mRNA synthesis is decreased by 29.2%, 53.8%  and 66.5%  in response to 
respective doses of 10, 100, and 200nM RAD (n=4).   
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A reduction in total collagen synthesis via hydroxyproline incorporation can be demonstrated in 
renal fibroblasts treated with RAD and LY. Total collagen synthesis was reduced 79±8% and 
73±2% by 100nM RAD and 10µM LY respectively (*p < 0.001 vs. control). Results are 
presented as a percentage of control means and illustrate a duplicate experiment. 
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α1(I) mRNA
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Fig. 3.17
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These results highlight the potential for mTOR to control transcription in addition to its well 
known role in translation. Northern blotting was carried out to determine the role of mTOR in 
a(I)1 procollagen synthesis. (a) Loading was standardised to 18S levels using densitometry 
software. (b) Treatment of fibroblasts with all doses of RAD mediated decreases in a1(I) 
mRNA levels by 29.2% (10nM), 53.8% (100nM) and 66.5% (200nM). These results are 
representative of a duplicate experiment.
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3.4 DISCUSSION 
Defining the components of a signalling pathway that control fibrosis is integral to 
developing rational treatment strategies. The studies described within have attempted to 
identify novel signalling axes through which fibroblasts are regulated.  Indeed, given that 
pathways governing fibroblast function have not been well documented in the literature, a 
number of novel findings have resulted from this work.  
Initial studies were aimed at elucidating the signalling pathways encompassing mTOR 
and PI3K by examining the phosphorylation of Akt S-473 and S6RP S-235/236 in response to 
RAD and LY. This study supports previous studies by demonstrating that inhibition of PI3K 
with LY completely inhibits the serum-stimulated phosphorylation of S-473 Akt after 48hr. A 
novel finding however, was the ability of RAD to modestly down-regulate Akt S-473 
phosphorylation in renal fibroblasts.  Downstream of mTOR, phosphorylation of the S6RP S-
235/236 was inhibited in response to both mTOR and PI3K inhibition.  Functional studies 
were then carried out to ascertain the role of mTOR and PI3K in activated renal fibroblasts 
derived from UUO. Antagonism of mTOR and PI3K decreased mitogenesis, which also 
occurred in an additive fashion when both inhibitors were used in combination.  Inhibition of 
PI3K and mTOR also lead to decreases in total collagen synthesis with the latter kinase 
playing a regulatory role in the synthesis of α(I)1 procollagen mRNA.  Given the complexity 
of cell signalling pathways and their likelihood to interact, the role of the ERK1/2MAPK 
pathway in mTOR and PI3K-mediated proliferation was investigated.  Whilst the MEK1 
inhibitor (PD) did not affect the phosphorylation status of S6RP, when used in combination 
with the PI3K inhibitor, it led to a further decrease in cell proliferation. Lastly, mTOR is 
increasingly known for its ability to integrate growth factors via PI3K however this study 
highlights that its constitutive activation is not dependent on growth factor signalling. 
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3.4.1 Akt S-473 and S6RP: Respective substrates of PI3K and mTOR  
  To better understand the intracellular signal transduction pathways encompassing 
PI3K and mTOR, the relationship between these kinases and the phosphorylation status of 
respective downstream targets Akt S-473 and S6RP S-235/236 was ascertained.  
  These studies indicated that in the presence of LY, the phosphorylation of the S-473 
Akt was completely inhibited, which supports previous findings (Le Pabic et al., 2005), and 
this confirms that PI3K activation leads to the downstream recruitment of Akt in renal 
fibroblasts.  Akt S-473 is phosphorylated by PDK2 and this is believed to precede and 
facilitate phosphorylation of Akt T-308 by PDK1 (Sarbassov et al., 2005; Yang et al., 2002a) 
leading to full activation of Akt and increasing its activity 4-5 fold compared to PDK1-
mediated T-308 phosphorylation alone.   
  More interestingly, a modest RAD-mediated down regulation of Akt S-473 
phosphorylation was also evident.  At the time, although this finding was unexpected, it is 
however consistent with the very recent in vivo findings in mouse embryonic fibroblasts 
(MEF) (Sarbassov dos et al., 2006).  This group has demonstrated that the rictor-mTOR 
complex (mTORC2) directly phosphorylates Akt S-473 in numerous different human cell 
lines.  The real identity of the kinase responsible for phosphorylation (named 
phosphoinositide dependent kinase 2; PDK2) of Akt S-473 has been controversial for many 
years with PDK1 (Balendran et al., 1999b) ILK (Persad et al., 2001), autophosphorylation 
(Toker and Newton, 2000), PKCβ (Kawakami et al., 2004) and DNA-dependent protein 
kinase (DNA-PK) (Feng et al., 2004) all postulated as possible mediators. However, recently 
Sabatini’s group has shown convincingly that mTORC2 is the bona fide PDK2 (Sarbassov et 
al., 2005).  Furthermore, they have also shown that prolonged exposure to rapamycin can lead 
to inhibition of the assembly of mTORC2 by interfering with the ability of rictor to bind 
mTOR (Sarbassov dos et al., 2006).  This occurs because although mTORC2 is rapamycin 
insensitive (Sarbassov et al., 2005), rapamycin can still bind free mTOR and inhibit the 
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assembly of mTORC2. Consequently, this mechanism prevents mTORC2 from 
phosphorylating Akt S-473.  This has been demonstrated in numerous transformed or primary 
human cell lines (Fig. 3.18a) and is consistent with the findings in this study (Fig. 3.18b) 
which also supports the discovery that the actual identity of PDK2 is the rictor-mTOR 
complex (Sarbassov et al., 2005). 
S6RP is a substrate of the upstream S6K isoforms and is believed to be involved in the 
control of glucose homeostasis, cell size and the negative regulation of protein synthesis 
(Ruvinsky et al., 2005). Numerous studies have established a strong correlation between S6K 
activity and S6RP phosphorylation (Gressner and Wool, 1974; Nemenoff et al., 1988; Proud, 
2002), and based on the premise that phosphorylation of S6K should demonstrate a 
proportional increase in the phosphorylation of its ribosomal protein target, this experiment 
examined S6RP phosphorylation in renal fibroblasts.  Similar to previous findings, this 
experiment showed that S6RP S-235/236 phosphorylation was inhibited by both RAD (Calvo 
et al., 1992; Chen et al., 2005; Chung et al., 1992; Fingar and Blenis, 2004; Gerasimovskaya 
et al., 2005b; Jefferies et al., 1997; Le Pabic et al., 2005; Price et al., 1992), and LY (Adi et 
al., 2001; Cheatham et al., 1994; Monfar et al., 1995; Weng et al., 1995).  The present results 
therefore verify S6RP as a downstream effector of mTOR and PI3K in renal fibroblasts, 
however its exact role in these cells is unknown.  
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Akt S-473 phosphorylation after 24hr rapamycin
treatment
Rapamycin can inhibit the phosphorylation of Akt S-473 by mTORC2 in a number of cell lines (a) 
and in renal fibroblasts (b) in response to prolonged treatment.
BJAB = B cell lymphoma cell line; U937 = human leukemic monocyte lymphoma cell line; Jurkat = human
T-cell leukaemia cell line.
(a) Sarbassov et al (2006).
Rapamycin (hr)
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Fig. 3.18
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Increasing evidence suggests that S6RP can be regulated by mechanisms in addition to mTOR 
and PI3K including the MEK pathway (Herbert et al., 2000). In fact it has been shown that 
S6RP phosphorylation at S-235/236 in S6K1 and S6K2 deficient cells still occurs (Pende et 
al., 2004).  This was found to be due to a MAP-dependent kinase, most likely p90rsk (Pende 
et al., 2004).  Whilst studies using this inhibitor have found that ERK1/2 activation is 
important in the phosphorylation of S6K in HEK293 cells (Herbert et al., 2000), 
haematopoeitic cells (Blalock et al., 2003) and hepatocytes (Okano et al., 2003), S6RP S-
235/236 phosphorylation levels were not significantly changed in response to treatment with 
the MEK1 inhibitor, PD.  Whilst it may therefore be possible that cross-talk of mTOR with 
MEK is a cell-specific mechanism as indicated by Lin et al (Lin et al., 1995) who 
demonstrated that the rapamycin sensitive activation of downstream effectors has been shown 
to be independent of MAPK, it is also likely that the upstream S6K’s may compensate for any 
lack of S6RP phosphorylation by a MAP-dependent kinase.  
 
3.4.2 Constitutive activation of mTOR 
mTOR is an evolutionary conserved kinase whose signalling depends on the 
integration of signals from nutrients and amino acids to mediate its downstream effects. 
Withdrawal of amino acids or glucose within the medium of cultured mammalian cells leads 
to deactivation of S6K and de-phosphorylation of 4E-BP (Hara et al., 1998; Patel et al., 2001).  
To determine whether mTOR maintains a constitutively active circuitry independent of 
growth factors, the phosphorylation of S6RP was examined in the absence of FCS, and 
compared to cells exposed to increasing gradations of FCS.  This work indicated that S6RP 
can be phosphorylated independently of serum-based growth factors in renal fibroblasts, 
presumably by intracellular amino acids and nutrients found within components of the media.  
These results concur with the ability of mTOR to act as a constitutively activated pathway, as 
previously demonstrated in VSMC (Mourani et al., 2004).  Even though LY or mutated 
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PDGF receptors (which are responsive to extracellular growth factors) inhibit the downstream 
phosphorylation of S6K1 (Brunn et al., 1996; Cheatham et al., 1994; Chung et al., 1994), it 
appears that mTOR does not solely depend on growth factor-mediated signalling to be 
constitutively activated.  However, activation of mTOR may be facilitated in the presence of 
growth factors, as indicated by phosphorylation levels in cells maintained in higher 
concentrations of FCS.  Given that renal fibrosis involves a marked up-regulation of growth 
factors and cytokines, many of which are capable of signalling through PI3K and mTOR, it is 
therefore possible to hypothesise that during fibrosis, mTOR activity may be significantly up-
regulated.   
 
3.4.3 Regulation of fibroblast mitogenesis 
Proliferation of fibroblasts is a fundamental response during chronic renal disease 
(Hewitson et al., 1995).  As a result of proliferation, these cells can facilitate fibrosis through 
the secretion of chemotactic substances, differentiation and secretion of abundant ECM 
proteins. Regulation of the cell cycle by mTOR can be best demonstrated by its ability to 
regulate levels of cyclin D, p21
cip
 p27
kip
 polypeptides and hence regulate the G1-S phase of 
the cell cycle.  mTOR inhibition therefore causes G1-phase cell cycle arrest. Both rapamycin 
and its derivatives, and more general PI3K inhibitors, are known to inhibit proliferation in a 
variety of mesenchymal cells including cardiac fibroblasts (Hafizi et al., 1999), glomerular 
mesangial cells (Wang et al., 2001a) and VSMC (Mohacsi et al., 1997; Moon et al., 2000).  
This work therefore expands upon previous studies by showing that both RAD and LY inhibit 
proliferation of renal fibroblasts.  
RAD has also been shown to inhibit the proliferation of fibroblasts from lung 
transplant recipients (Azzola et al., 2004).  Studies such as these have direct clinical 
implications in the treatment of renal transplant recipients and provide a good premise to 
assess the likely in vivo responses of human fibroblasts in response to rapamycin and its 
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derivatives.  Although RAD and LY mediated decreases in S6RP S-235/236 phosphorylation, 
knock-out of its upstream kinases leads to a decrease in cell size not cell number (Montagne 
et al., 1999). It is therefore possible that proliferation is not mediated through this downstream 
effector.  Because phosphorylation of 4EBP1 facilitates translation, it may be possible that 
this substrate is a key mediator of cell proliferation.   
The combined effect of RAD and LY on proliferation has been highlighted by Breslin 
et al (Breslin et al., 2005) who showed that treatment of T cells with both rapamycin and LY 
results in a cooperative inhibition of T cell proliferation.  Similarly, this study has also shown 
that when RAD and LY are used in combination, it mediates a further decrease in fibroblast 
proliferation.  Since LY completely inhibited the phosphorylation of Akt S-473 (Fig. 3.19a), 
the further decrease in proliferation seen with a combination of RAD and LY is consistent 
with other studies showing that mTOR can activated by pathways other than PI3K (Fig. 
3.19b). For instance, studies in Drosophilia show that mTOR can be activated by dPDK1 
independent of dAkt/dPI3K to mediate dS6K activation (Radimerski et al., 2002).  Further 
studies are needed to establish this mechanism in renal fibroblasts. However, it is worthy to 
note that because the other phosphorylation site T-308 (phosphorylated by PDK1) has not 
been examined, complete inactivation of Akt activity cannot be assumed (Fig. 3.19c).  
Furthermore, the results contained herein have shown that co-incubating PD with LY 
resulted in a further reduction in cell proliferation.  The MAPK pathway, well known for the 
regulation of proliferation and differentiation, has also been increasingly acknowledged for its 
ability to signal through mTOR, corroborated by TSC2’s ability to act as a direct substrate of 
ERK and to activate mTOR (Shaw and Cantley, 2006) (Fig. 3.20).  This study indicates that 
the ERK1/2MAPK cascade and PI3K may act cooperatively to regulate fibroblast 
proliferation. Once again, because Akt phosphorylation was completely inhibited by LY, 
PI3K and the ERK1/2MAPK cascade may regulate proliferation independently of Akt. This  
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Potential for mTOR to be activated by alternate pathways in the regulation of fibroblast 
proliferation.
c
a
Fig. 3.19
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Rationale for investigating the potential for cross-talk between ERK/MAPK and PI3K/mTOR. The 
ERK1/2/MAPK pathway targets two substrates within the mTOR pathway (TSC2 and S6RP) 
suggesting that PI3K and mTOR may cross-talk with this kinase cascade. The Mek inhibitor PD 
was therefore used to examine S6RP and its role in proliferation.
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has indeed been shown Bondeva et al (Bondeva et al., 1998), who demonstrated that PI3K 
regulates the MAPK pathway independently of Akt.   
 
3.4.4 Apoptosis 
The assessment of cell viability was particularly important in functional studies 
because LY completely inhibited the phosphorylation of Akt S-473. Shutting down PI3K/Akt 
is associated with an increased incidence of apoptosis in many studies primarily because Akt 
lacks the regulatory capability to phosphorylate (and inactivate) a number of pro-apoptotic 
molecules including Bad and GSK-3 (Downward, 2004) (Fig. 3.21). Given the significance of 
PI3K in cell survival, a number of cell viability tests including tests for apoptosis and 
mitochondrial viability were carried out which indicated that cell survival and viability were 
not affected by treatment with RAD or LY.  This confirms that the results of functional 
studies were not due to apoptosis or changes to cell viability. 
 
3.4.5 Regulation of collagen synthesis 
Aberrant collagen deposition is the histological hallmark of fibrosis and its destructive 
consequences. mTOR plays a key role in the regulation of protein synthesis through 
downstream effectors S6K and eEF2 and eIF4B (Fig. 3.22) (Ruvinsky and Meyuhas, 2006). 
As noted by Martin et al (Martin et al., 2004), given that mTOR plays a key role in the 
regulation of protein synthesis, inhibition of this pathway would lead to a decrease in total 
protein synthesis (Boluyt et al., 2004; Chen et al., 2005), a process that is likely to have 
ramifications in the regulation of collagen synthesis (Martin et al., 2004).  In this study, 
treatment with RAD and LY demonstrated a significant inhibition in total collagen, as 
measured by hydroxyproline incorporation.  These results were not due to a decrease in cell 
number because cells were grown to confluency after treatment.  In agreement, a number of 
studies have also highlighted that an additional benefit of rapamycin treatment is the  
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Akt as a key anti-apoptotic mediator.  Akt can phosphorylate and inactivate a number of 
downstream pro-apoptotic factors including Caspase-9, FKHR, Bad and GSK-3. 
Adapted from www.cellsignal.com
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inhibition of collagen production.  Rapamycin significantly decreases collagen secretion in rat 
mesangial cells in vitro (Kim et al., 2004), and activation of the PI3K-PDK1-Akt axis by 
leads to increased collagen I expression (Runyan et al., 2004).  Furthermore, PI3K has been 
shown to be involved in the regulation of ECM proteins in keloids (Lim et al., 2003) and in 
the liver by regulating MMP-13 expression (Lechuga et al., 2004).  However, other studies 
make the in vivo relevance of my findings are unclear.  Rapamycin has variously been shown 
to inhibit collagen synthesis in UUO (Wu et al., 2006) and hepatic fibrosis (Zhu et al., 1999), 
leave collagen III expression unchanged  (Jain et al., 2001) and even up-regulate collagen 
deposition (Shihab et al., 2004a; Shihab et al., 2004b).    
Interestingly, studies that found that rapamycin increases collagen, also found that 
TGFβ1 levels were increased in renal transplant biopsies (Shihab et al., 2004a; Shihab et al., 
2004b).   Similarly, those studies that found that rapamycin-mediated decreases in collagen 
(Runyan et al., 2004; Wu et al., 2006; Zhu et al., 1999), also found that TGFβ1 levels were 
significantly decreased, as was the activity of the downstream Smads (Runyan et al., 2004). 
Whether there is a relationship between TGFβ1 and collagen in these studies has not been 
determined.  However, it is increasingly acknowledged that components of the PI3K and 
mTOR pathways cross-talk with the TGFβ-Smad signalling axis. 
 
3.4.6 Regulation of collagen transcription 
Whilst mTOR is most well known for its role in translation, increasing evidence 
suggests mTOR plays a role in the control of transcription and rapamycin has been shown to 
inhibit members of the forkhead family of transcription factors including forkhead homologue 
of rhabdomyosarcomma (FKHR; Foxo1) and Foxo4a (Sarbassov dos et al., 2006).  This is 
consistent with the findings described within which suggest that mTOR may regulate 
transcription. This is of novel importance in renal fibroblasts because, dictated by what are 
seemingly cell-dependent or stimulus-dependent effects, studies have shown that the 
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regulation of collagen gene expression varies.  Whilst collagen mRNA inhibition has been 
shown to be mediated by changes at the transcriptional level in (a) amino acid-starved 
fibroblasts (Krupsky et al., 1997),  (b) dermal fibroblasts in response to LY (Shegogue and 
Trojanowska, 2004), and (c) in response to mTOR inhibition using small interfering RNA 
(siRNA) (Shegogue and Trojanowska, 2004), the stability of α1(I) collagen mRNA may 
change without changes to the rate of transcription, as shown in lung fibroblasts due to 
inhibition of PI3K (Ricupero et al., 2001), and in activated hepatic stellate cells 
(myofibroblast-like cells) (Stefanovic et al., 1997).   
 
3.4.7 Summary 
 In summary, this study has provided novel insights into the cell signalling mechanisms 
of mTOR and PI3K with regard to their role in renal fibroblasts.  Whilst mTOR can function 
in a constitutively activated manner, PI3K and Akt function upstream of mTOR. RAD is a 
universal inhibitor of the mTORC1 complex, and this study has shown that with prolonged 
RAD treatment (48hr), it can also inhibit mTORC2, therefore regulating signalling both 
upstream and downstream of mTOR in these cells. S6RP functions as a downstream effector 
of mTOR, however whether this kinase mediates the functional effects noted in response to 
mTOR and PI3K inhibition awaits further delineation.   
Functional studies have provided important insights into the mechanisms of renal 
fibroblast regulation during a number of key pro-fibrotic events and highlight rapamycin’s 
therapeutic potential in addition to its roles in immunosuppression.  mTOR and PI3K play 
roles in mediating fibroblast proliferation and collagen synthesis and co-inhibition of these 
pathways propagates additive decreases to fibroblast mitogenesis.  It is likely that PI3K and 
mTOR cross-talk with a number of other intracellular substrates and this study has 
demonstrated the potential for the ERK1/2MAPK pathway to interact with the PI3K axis 
during fibroblast proliferation.  By identifying the components of signalling pathways that 
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play key roles in the mediation of fibroblast proliferation and ECM synthesis, major features 
of fibrosis, this study hopes to contribute toward the development of potential intervention 
strategies that may be used to ameliorate fibrosis.   
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3.5 SPECIFIC METHOD PROTOCOLS 
 
The end of each experimental chapter contains a version of Table 3.1 for reference to methods 
used in this chapter that are described within Chapter 2. 
Method Section 
UUO  2.2.1 
Protein extraction 2.7.1 
Western blotting  2.7.3 
Cell counting  2.6.1.1 
Northern blotting  2.7.2 
Table 3.1: References for methods described in Chapter 2 used in this chapter.  
 
3.5.1 Western blotting for Akt S-473 
Cellular protein was extracted from fibroblasts treated with either RAD (10nM), LY 
(10µM) or from those cells maintained in control medium.  Western blotting was used to 
determine the ratio of total Akt to phosphorylated Akt with polyclonal antibodies to the 
phosphorylated S-473 residue of Akt according to 2.7.3. This antibody recognizes all 
isoforms of Akt at S-473. Membranes were incubated with either a 1:500 dilution of anti-
phosphorylated Akt or a 1:1000 dilution of anti-Akt O/N, followed by a 1:2000 incubation 
with HRPconjugated anti-rabbit IgG (Table Apx. 3.2).  
 
3.5.2 S6RP phosphorylation (S-235/236) 
 
The effect of serum-starvation, and the PI3K, mTOR and MEK inhibitors on S6RP 
was determined by measuring the ratio of phosphorylated S6RP S-235/236 to total S6RP.  
Cells were grown to confluency in 6-well plates in 10%FCS + DMEM and starved O/N in 
1%FCS + DMEM. RAD (100nM), LY (10µM), PD (20µM) or differing concentrations of 
FCS (0%, 2.5%, 10%) were then administered for 120min and incubated at 37ºC.  The p-
S6RP ELISA was then carried out according to the manufacture’s protocol.   
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3.5.3 Cell kinetics 
3.5.3.1 Cell number assay 
Cellular proliferation was determined by measuring total cell number over a 5-day 
period.  Fibroblasts were trypsinised and seeded into 6cm diameter petri dishes at a density of 
2x10
4
 cells per dish in DMEM+10% FCS and left O/N to adhere at 37°C.  Following cell 
adhesion, control medium or medium containing RAD (10, 100, 200nM), LY (10µM), or 
combinations of these drugs were added and cells were left at 37°C. On day 5, cells were 
trypsinised, resuspended and counted with a haemocytometer.  Non-viable cells were 
excluded by adding trypan blue in a 1:1 ratio to each aliquot.    
 
3.5.3.2 DNA synthesis  
Fibroblast DNA synthesis was estimated by measuring incorporation of tritiated [
3
H] 
labelled thymidine in FCS stimulated cells as described previously (Hewitson et al., 2001). 
Thymidine incorporation was used to determine the effects of various drugs on DNA 
synthesis.  Equal numbers of cells were seeded in DMEM + 10%FCS in 36 mm
2 
multiwell 
plates at 2x10
4
 per well and left O/N at 37
 o
C.  On day 2, cells were then grown in DMEM + 
5% FCS for 24hr to arrest cell cycle progression. Cells were incubated for 24hr in 
DMEM+10%FCS only or medium containing RAD (10, 100, 200nM), LY (10µM), PD 
(20µM), or combinations of these drugs at 37°C.  On day 3, media was removed and 0.25µCi 
(250µCi/250µls) of tritiated thymidine was added with or without test drug to each well and 
left O/N at 37°C.  At the end of the incubation period, medium was removed, cells were 
washed in 2-5ml PBS×2, and 200µl of 5% trichloroacetic acid (TCA) was added to each well. 
Cells were then incubated at 4
o
C for 60min.  TCA supernatant was removed, and cells were 
scraped in the presence of 200µl 0.25M NaOH and transferred to scintillation vials. 
Approximately 10ml of scintillation fluid was added and radioactivity was counted in a 
scintillation counter as counts per minute (cpm).  
 121
3.5.4 Cell viability 
3.5.4.1 TUNEL  
Apoptotic nuclei were detected using TUNEL (Hewitson et al., 2000a).  Cells were 
passaged as described previously and an equal number of cells were seeded onto sterile 
coverslips within petris and grown in DMEM + 10% FCS.  Once cells were subconfluent, 
they were treated with RAD (200nM) or LY (10µM) or maintained in control medium at 
37°C. Cells were then fixed in 4% paraformaldehyde in PBS for 5min and the assay was 
carried out according to the manufacturer’s instructions.  A number of coverslips were also 
included as positive controls by treating them with DNase to digest cells (1000U/ml).  
Apoptotic cells were identified by a combination of nuclear morphology and brown nuclear 
staining, as described previously (Hewitson et al., 2000a).   
 
3.5.4.2 Propidium iodide 
Propidium iodide staining was used to examine nuclear morphology after treatment 
with RAD (10, 100, 200nM) or LY (10, 50µM).  Cells were fixed in cold methanol, washed in 
PBSx2 and incubated with propidium iodide diluted in PBS (1mg/ml).  Cells were then 
washed in PBSx2 and analysed with a fluorescent microscope.  Apoptotic cells were 
identified as containing clusters of small round nuclear bodies.   
 
3.5.4.3 MTT ELISA  
Cell viability was estimated using an MTT assay.  This assay is based on the ability of 
the mitochondria to reduce colourless MTT to a purple formazan salt. Fibroblasts were 
trypsinised as normal and an equal number of cells seeded into 96 well plates with DMEM + 
5% FCS in low HEPES (10mM).  Once cells were confluent, they were incubated for 48hr in 
DMEM + 5%FCS in 10mM HEPES with RAD (10, 100, 200nM), LY (10, 50µM), or 
maintained in control medium.  Following this, media was removed and 5mg/ml MTT was 
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added with DMEM + 5%FCS in 10mM HEPES at a 1:4 ratio.  Plates were placed in foil and 
incubated at 37ºC for 4hr.  Cells were then lysed by the addition of DMSO and Sorensen’s 
glycine buffer was added at a 1:8 ratio. Reaction product was estimated from the optical 
density at 570nm on a Sunrise ELISA plate reader. 
 
3.5.5 Collagen synthesis 
Total collagen synthesis was estimated form hydroxyproline incorporation, as 
described previously (Fullerton and Funder, 1994) to determine the role of mTOR and PI3K 
in total collagen synthesis.  The method was carried out according to the following passages. 
1. Cells were trypsinised and an equal number of cells were then seeded and grown to 
confluency.  Cells were then treated with standard media supplemented with 1ml of 
100mM ascorbic acid and RAD (100nM) or LY (10µM), or maintained in control 
medium with 100mM ascorbic acid.  This treatment regime was repeated every 24hr 
over a 72hr period.  
2. On the fourth day, 3.3ml of incubation medium per well was added containing the 
drug being tested for 4hr at 37ºC.   After 4hr, 33µl of the labelling isotope [2,3-3H 
Pro]-Pro was added to the incubation medium for 18hr at 37ºC.   
3. After the 18hr exposure, plates were placed on ice and the medium fraction was 
collected in a 10ml tube.  The volume collected was used to calculate how much 100% 
TCA, 10% proline and 10% bovine serum albumin (BSA) to add to each sample.   
4. Each sample received appropriate concentrations of 10% TCA, 0.04% proline and 
0.1% BSA and were then placed at 4ºC O/N to precipitate the protein.   
5. The next day medium fractions were centrifuged down for 20min at 13000rpm at 4
o
C. 
On ice, supernatant was removed and the pellet resuspended with 1ml 10%TCA /1mM 
proline. 
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6.  Samples were then centrifuged at 6-7000rpm for 5min at 4
o
C.  On ice, the pellet was 
resuspended in 1ml 5% TCA/1mM proline and centrifuged at 6-7000rpm for 5min at 
4
o
C.  
7. Removal of the supernatant and resuspension of the pellet in 1ml 5%TCA/1mM 
proline was repeated and samples were centrifuged at 6-7000rpm for 5min at 4
o
C 
again. The pellet was then dissolved in 500µl 0.2M NaOH.   
8. From each sample dissolved in 0.2M NaOH, duplicate aliquots of 200µl were made in 
clean tubes.  The NaOH in each sample was neutralised by adding 100µl of 1M 
HEPES buffer and using pH strips, the pH was adjusted with HCl or NaOH to 7.2-7.4.  
9. Samples were then left O/N at 4oC.   
10. The next day, equal numbers of samples were treated with either 40µls of positive 
collagenase mix or 40µl of negative collagenase mix. Samples were then incubated at 
37
o
C for 90min.   
11. Samples were immediately placed on ice and 0.5ml of 20% TCA/0.5% tannic acid was 
added and leave for 60min.  Samples were then centrifuged in tubes at 6-7000rpm at 
4
o
C for 5min.   
12. Then the supernatant was removed and placed in labelled scintillation vials.  Pellets 
were washed with 0.5ml 5% TCA, centrifuged at 6-7000rpm at 4
o
C for 5min and the 
remaining supernatant was combined with the original in scintillation vials.  
13. 10ml of scintillation fluid was then added to each sample, and radioactive counts 
measured as disintegration per minute (dpm) was determined using a beta counter.  
The non-collagenase digested sample (‘-‘) counts were subtracted from the ‘+’ sample 
in order to gain the final collagen count for each sample tested.  
 
 124
3.5.6 Northern blotting for procollagen α1(I) 
To examine levels of procollagen α1(I) mRNA in response to RAD, RNA was 
extracted from cells treated with RAD (10, 100, 200nM) or from those maintained in control 
medium, and Northern blotting was then carried out according to section 2.7.2.  Procollagen 
mRNA was quantified using densitometry software.   
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4.1 INTRODUCTION 
It is now widely acknowledged that interstitial fibroblasts are an important cellular 
mediator of all progressive renal disease, regardless of etiology.  Myofibroblasts in particular 
are key to the pathogenesis of scarring.  However, much less is known about the derivation of 
these cells, and the regulation of their phenotype. 
A growing body of evidence however highlights the interrelationship between tubular 
epithelial cells and interstitial fibroblasts.  Fibroblasts, and by implication myofibroblasts, 
may be derived from a variety of sources including epithelial-mesenchymal transition (EMT).  
This chapter sets out to develop and validate an experimental model of EMT that can be used 
to examine the regulation of this important process.  This is particularly relevant because 
EMT is a highly complex process that is inherently dependent on the surrounding 
microenvironment, numerous cellular programs and a plethora of cytokines including 
TGFβ1(Yang and Liu, 2001) and FGF-2 (Strutz et al., 2002), vasoactive peptides such as 
angiotensin II (Chen et al., 2006), and non-cytokine mediated pathways such as AGEs 
(Oldfield et al., 2001) and tPA (Yang et al., 2002b).  Although pathways involved in EMT 
have been progressively identified, it is important to fully characterise the pathways involved 
in engaging the EMT proteome. 
Initial studies on EMT concentrated on utilising nrk-52e cells, an immortalized line of 
rat tubular epithelial cells, thought to be of proximal tubule origin (Fan et al., 1999).  As 
outlined in section 4.2, difficulties in its application led to the development and validation of a 
new model of EMT (section 4.3), based on the ex vivo culture of explanted renal tissue.  
Consequently, this model hopes to better represent the in vivo environment and over-comes 
some inherent difficulties with in vivo studies of EMT. 
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4.2 AN IN VITRO MODEL OF EMT USING TRANSFORMED EPITHELIAL 
CELLS 
4.2.1 METHODS AND RESULTS 
In pilot studies, 3x10
4 
trypsinised nrk-52e cells were seeded onto uncoated sterile 3cm 
diameter petri dishes, supplemented with DMEM + 10% FCS, and grown to confluence 
(approx 4-5 days).  Cells were fixed in ice-cold methanol and stained with anti-αSMA using 
the techniques described in 2.6.1.  An unexpected and consistent finding was that 
approximately 60% of cells expressed αSMA, even when FCS was reduced to 1% (data not 
shown).  
In an attempt to reduce basal αSMA expression, petri dishes were coated evenly with 
800µl of cold Cellagen solution (bovine skin collagen I).  Petris were then washed with 2-3ml 
of PBS.  After incubating at 37°C for 30min, 3ml DMEM + 10% FCS medium was added to 
each petri to neutralise the pH, and they were incubated at 37°C for at least 15min.  Coating 
with Cellagen consistently reduced expression of αSMA, although cells at the periphery were 
often αSMA-positive (Fig. 4.1a, arrow).  This was presumably in response to lack of cell 
adhesion to collagen, compromising their integrity and stimulating the development of stress 
fibres. 
Cells were then treated with 10ng/ml of TGFβ1, an established inducer of EMT in this 
cell line (Fan et al., 1999).  TGFβ1 was replenished every second day, before cells were fixed 
and stained.  Qualitative analysis of cells treated with TGFβ1 indicated an increase in αSMA 
staining, albeit of a highly focal nature (Fig. 4.1b, arrow). This was estimated to only 
comprise 1-2% of total cells.  Western blotting with antisera to αSMA was also used, however 
changes were minimal when corrected for β-actin, and there were therefore no detectable 
differences in αSMA protein (data not shown).   
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Fig. 4.1
TGFβ1Control
a b
Once expression of αSMA expression was reduced in nrk-52e cells, cells were 
treated with 10ng/ml TGFβ1. Although an increase in αSMA expression could be 
detected (b), no significant changes could be detected by immunohistochemistry as 
compared to the control.  Fig. 4.1a highlights the characteristic and focal expression 
of αSMA at the periphery of cells (arrow).
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4.2.2 DISCUSSION 
Initial experiments with the immortalised nrk-52e cell line indicated a consistent 
expression of αSMA when grown on plastic.  In order to resolve this issue, cells were seeded 
onto a collagen matrix (Cellagen). Phenotyping of the cells confirmed that the basal 
expression of αSMA was reduced.  Ironically, it has been shown that the α1NC1 domain of 
type I collagen induces EMT in vitro by inhibiting the assembly of type IV collagen (Zeisberg 
et al., 2001).  In retrospect, it would therefore be expected that adherance to this type of 
collagen matrix, which is a type I collagen, would facilitate EMT and therefore increase the 
expression of the mesenchymal marker αSMA.  
 The ability of this cell line to undergo EMT was then examined with TGFβ1.  Whilst 
Fan et al (Fan et al., 1999) found that nrk-52e cells stimulated with 10ng/ml showed profound 
changes in morphology and phenotype, chiefly through loss of the epithelial marker E-
cadherin and de novo expression of αSMA, studies described within using 10ng/ml of TGFβ1 
found that only 1-2% of cells underwent EMT.  Consequently, changes in αSMA protein, as 
determined by western blotting, were minimal when compared to β-actin and no real changes 
were detected.  
 Given the issues that were raised using this cell line and the difficultly in establishing 
these cells as a reliable model of EMT in vitro, this model was felt to be of limited practical 
value in examining the regulation of EMT.  It was therefore apparent that a different model of 
EMT was needed to study the mechanisms of this process. 
 130
4.3 AN EX VIVO RENAL EXPLANT CULTURE MODEL OF EMT 
 
The next passages describe the development and validation of a novel ex vivo model of EMT 
based on explanting of the normal rat renal cortex. 
 
4.3.1 DESIGN OF MODEL 
Fortuitously, the observation of typical growth patterns that have been observed 
during explanting of cortical tissue derived from the normal kidneys of rats led to the 
hypothesis that EMT occurs during the explanting process.  On many occasions, it has been 
observed that cells that grow out of tissue fragments of explant tissue seem to 
characteristically change their morphology as they travel further away from the deposited 
tissue.  Given that EMT can occur in response to mechanical injury (Bascands and Schanstra, 
2005), and that explanting also mimics a form of mechanical injury sustained by tubular 
epithelial cells, this underscores the potential for EMT to occur during this process.  A 
number of key features observed during explanting (described below), along with the growing 
understanding of the process of EMT, indeed highlight the presence of EMT during the 
growth of cells from explants.  
This chapter therefore examines the potential for epithelial cells growing out of 
explants to undergo EMT.  This was specifically investigated by phenotyping cells for 
epithelial, endothelial and mesenchymal markers using immunoperoxidase techniques and 
double-labelling immunofluorescence.  This model was then tested using established 
regulators of EMT.  
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4.3.2 EXPERIMENTAL DESIGN 
 
 
4.3.2.1 Explants for the study of EMT 
Cell explant outgrowths from normal rat kidneys were established using explanting 
methods described in 2.3.1.  Studies in this lab have repeatedly shown that the first cells to 
grow out of explants of normal kidney tissue are epithelial in nature.  In each case, explants 
were grown in DMEM + 20% FCS, treated in DMEM + 10% FCS, and fixed in cold 
methanol after various intervals between 3 and 17 days post explanting.  Morphology analysis 
and immunocytochemistry were used to identify, mesenchymal (FSP-1, αSMA+, desmin+), 
epithelial (cytokeratin+) and endothelial (RECA+) cells. 
 
4.3.3 RESULTS 
 
4.3.3.1 Primary cell outgrowth  
 After cortical renal tissue was minced into gelatin coated petri dishes, it took 
approximately 3 days before cell growth could be identified (Fig. 4.2).  Those cells that grow 
out initially displayed a cuboidal phenotype, typical of epithelial cells.  These cells grew out 
in sheets around the tissue presumably through the secretion of growth factors/cytokines and 
matrix interactions.  Typical of epithelial cell growth, they grew out in a uniform manner 
representative of them being tightly bound by cell-cell junctions and adhesions (Lee et al., 
2006).   
 
4.3.3.2 Two sub-populations of cells grow from explants of the renal cortex 
Cells that surrounded explant tissue were characterised with phenotypic markers of 
mesenchymal cells, epithelial cells and endothelial cells.  By day 7, cells were 21±18% 
αSMA+, 26±18% desmin+, and 79±12% were cytokeratin+ positive.  At this stage it was 
evident that two cell predominant cell populations were present: epithlelial cells and 
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myofibroblasts.  Fig. 4.3a-b illustrates that at day 7, explants typically contained clusters of 
E-cadherin and cytokeratin positive cells.  These cells displayed a typical cobblestone 
morphology and were tightly bound to their neighbours.  Fig. 4.4a-b illustrates the presence 
of myofibroblasts, as demonstrated by positive staining for the mesenchymal markers αSMA 
and FSP1.  These cells displayed a spindle-shaped morphology and were dissociated from 
their neighbours.  There were not however any RECA positive cells, confirming endothelial 
cells were not a feature of explanting (Fig. 4.5).  
This process of phenotyping indicated that either epithelial cells or myofibroblasts 
grew out from tissue fragments.  However, when examined further, it was revealed that these 
sub-populations may be related.  Such speculation was based on (a) that there were sub-
populations of cells that partially but consistently stained for αSMA (Fig. 4.6a), and although 
this may have represented different sub-populations of cells over-growing each other 
(fibroblasts over myofibroblasts or epithelial cells over myofibroblasts); (b) there were also 
cells that stained positive for cytokeratin but they clearly did not display an epithelial 
morphology (Fig. 4.6b).  These cells looked larger, had started to dissociate from their 
neighbours and did not display the typical cobblestone morphology of epithelial cells.  This 
strongly suggests that these cells were undergoing some type of transition process. 
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Fig. 4.2
It took approximately 3 days before cell 
growth from explant tissue could be observed.
Endothelial cells do not typically grow out of 
explant tissue as demonstrated by sub-
populations of cells staining negatively for 
RECA.
Cells stain positive for cytokeratin (a) and E-cadherin (b), indicating that 
epithelial cells grow out from explants.
Sub-populations of myofibroblasts are also present, as demonstrated by 
positive staining for FSP-1 (a) and αSMA (b). 
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Fig. 4.6
CytokeratinαSMA
At day 7, cells typically stained for αSMA or cytokeratin, however there were also 
populations of cells present that stained partially for αSMA (a, arrow). 
Furthermore, morphological changes in cytokeratin positive cells could also be 
demonstrated (b).  These cells displayed a morphology not typical to epithelial cells 
including hypertrophy, elongation and dissociation from neighbor cells (arrows).    
a b
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4.3.3.3. Double labelling indicates cell progressive EMT in explants 
To determine if the mesenchymal and epithelial cells shown in Fig. 4.6 were indeed 
undergoing a phenotype change, double labelling immunofluorescence was performed at 
various time points post-explanting.  At day 3, outgrowths from tissue labelled only for 
epithelial cell markers, with no cells expressing αSMA (day 3; Fig. 4.7).  At day 10, 
myofibroblasts were also present, and by double-labelling, it was demonstrated that 
populations of cells co-expressed αSMA and cytokeratin (cytokeratin+/αSMA+) (day 10; 
Fig. 4.7).  This indicated that a process of EMT was occurring and when quantified, it was 
revealed that 50±12% (n=5) of cytokeratin positive cells also co-expressed αSMA at day 10.  
By day 17, cultures were all myofibroblasts and it was apparent that those cells at day 10 that 
co-expressed cytokeratin had lost their staining for cytokeratin (cytokeratin-/αSMA+; day 17; 
Fig. 4.7).  These changes were also accompanied by morphological changes.  Cells lost their 
cobblestone appearance typical of epithelial cells, were dissociated from their neighbours, and 
became hypertrophic and elongated as they progressively changed into spindle-shaped 
myofibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 136
 
 
 
α
S
M
A 
    Day 3   Day 10    Day 17 
 
C
y 
t 
o 
 
 
    
M
e 
r 
g 
e 
d 
Fig. 4.7 
Double-labelling immunofluorescence indicates that EMT occurs during growth of cells from tissue 
explants. Initially,cells can be characterised as cytokeratin positive however by the later stages of 
explanting, these cells acquire αSMA. 50% of these cells co-expressed αSMA and cytokeratin (n=5).  
By the later stages post-explanting, cells lose their epithelial markers and express αSMA only. 
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The Role of  
Phosphatidylinositol 3-Kinase and mTOR in 
the Regulation of 
Myofibroblast Differentiation and EMT 
 
 
Chapter 5 
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5.1 INTRODUCTION 
 
The process of myofibroblast differentiation is of pivotal importance to the 
progression of tubulointerstitial fibrosis as these are the cells that are responsible for the 
secretion of copious amounts of ECM proteins.  We have come to understand that this form of 
differentiation is a highly complex process that depends not only on the differentiation of 
resident fibroblasts but also on the differentiation of a number of heterogenous cell types.  
These include blood-borne fibrocytes (Iwano et al., 2002), bone-marrow derived 
pluripotential cells (Iwano et al., 2002), mesangial cells (Sam et al., 2006), resident and 
perivascular fibroblasts (Hewitson et al., 1995), pericytes (Postlethwaite et al., 2004) and 
tubular epithelial cells (Roxburgh et al., 2006).  
Of those cells in the tubulointerstitial compartment, fibroblasts and epithelial cells are 
known to be the most important sources of myofibroblasts.  It is therefore important to 
characterise the signalling pathways involved in differentiation.  This study therefore set out 
to elucidate the role of phosphatidylinositol 3-kinase (PI3K) and mammalian target of 
rapamycin (mTOR) in (a) the differentiation of fibroblasts and in (b) EMT. 
Although fibroblasts represent a highly heterogenous population of cells, 
differentiation of these cells is based on a common mechanism.   In response to mechanical or 
environmental stressors such as stretch or hypoxia respectively, these cells are thought to be 
able to transdifferentiate into proto-myofibroblasts (Fig. 1.9).  The proto-myofibroblast is an 
intermediate form of a fully differentiated myofibroblast that expresses stress fibres (α and β), 
however only in the presence of TGFβ1 can these cells then differentiate into myofibroblasts 
acquiring the ability to secrete large amounts of the ED-A splice variant of fibronectin and 
express αSMA (Tomasek et al., 2002). Given that TGFβ seems indispensable in mediating 
myofibroblast differentiation, many of the regulatory studies of myofibroblast differentiation 
have, perhaps not surprisingly, focused on the role of the TGFβ-Smad signalling axis.    
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The process of differentiation is likely however to involve more than one signalling 
axis.  Whilst PI3K and mTOR are more well-known for their roles in proliferation and 
growth, a number of studies have identified this axis as a key mediator of cell differentiation. 
Recent work in VSMC’s is of particular interest (Martin et al., 2004).  In this study the 
investigators were able to establish that inhibition of mTOR was sufficient to induce VSMC 
differentiation, thereby implicating mTOR as a negative regulator of VSMC differentiation. 
The phenotypic similarity between vascular smooth muscle cells and fibroblasts suggests 
obvious parallels and underscores the potential for mTOR to be involved in mediating 
fibroblast differentiation.  
Although epithelial cells display a higher level of homogeneity than fibroblasts, these 
cells can respond in a variety of different ways in the presence of an injurious stimulus. As 
outlined in Chapter 4, this seems to be inherently dependent of the state of the cell cycle 
(Bonneton et al., 1999; Yang et al., 2006c).  Tubular epithelial cells can (a) proliferate, (b) 
degenerate and undergo apoptosis, (c) secrete a number of inflammatory cytokines including 
MCP-1 and RANTES, or (d) they can transition into myofibroblasts via EMT.  Furthermore, 
epithelial cells may also de-differentiate in an attempt to regenerate the damaged tubular 
segments or repair the damaged area (Forino et al., 2006; Rastaldi et al., 2002). With the 
likelihood that EMT can act as a source for a substantial number of myofibroblasts and even 
replenish fibroblast pools late in fibrosis (Yang and Liu, 2001), it is important to identify the 
signalling axes through which EMT is mediated.  Whilst members of the Smads (Valcourt et 
al., 2005; Zavadil and Bottinger, 2005), MAPK (Li et al., 2004b; Yu et al., 2002) and Rho 
(Kaartinen et al., 2002; Masszi et al., 2003) signalling pathways have notably gained the most 
attention, it is increasingly accepted that EMT is complex and likely to involve a number of 
signalling pathways. Furthermore, with the ongoing elucidation of signalling pathways in 
fibrosis, it is increasingly recognised that TGFβ, MAPK and PI3K can cross-talk in a number 
of different cells types. With this in mind, and also given that PI3K/Akt play roles in EMT in 
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various other contexts (Bakin et al., 2000; Grille et al., 2003; Irie et al., 2005), an 
investigation into the role of PI3K and mTOR in EMT is warranted.  To carry out this 
investigation, the previously established model of EMT (Chapter 4) was utilised.   
This study therefore set out to investigate the role of PI3K and mTOR in the 
regulation of rat renal fibroblast differentiation and renal EMT, which can both supply the 
myofibroblast population with significant numbers of myofibroblasts.  Once again, using 
rapamycin derivative RAD and LY294002 (LY) acting as a inhibitor of the ATP binding 
domain of PI3K (Fig. 3.1), a number of novel findings have been observed in this study.   
 
5.2 EXPERIMENTAL DESIGN 
This study utilised rat renal fibroblasts derived from 3 days post-UUO as outlined in 
Chapter 3 to examine the differentiation of fibroblasts to myofibroblasts, and the model of 
EMT, established in Chapter 4, to study the transition of tubular epithelial cells into 
myofibroblasts. Unless specified, cells were treated for 48hr in medium alone, or medium 
supplemented with various doses of RAD (10, 100, 200nM), LY (10µM) and TGFβ1 
(10ng/ml).  These studies were based on the response of fibroblasts to serum-based growth 
factor/cytokine stimulation.   In each case, medium consisted of 1xDMEM supplemented with 
10%FCS, 1M HEPES, 2mM glutamine and 500Units/ml penicillin/streptomycin, unless 
specified.  
  
 158
5.3. RESULTS 
 
5.3.1 PI3K and mTOR regulate fibroblast differentiation 
Martin et al (Martin et al., 2004) have recently demonstrated the ability of mTOR to 
regulate VSMC differentiation, as demonstrated by a rapamycin induced increase in αSMA, 
calponin, and SM myosin heavy chain.  Western blotting and cytochemistry were therefore 
used to examine the role of the PI3K and mTOR in renal fibroblast differentiation.  
 
5.3.1.1 Regulation of αSMA protein by PI3K and mTOR in renal fibroblasts 
The functional significance of PI3K and mTOR in differentiation was confirmed by 
using western blotting to demonstrate that all doses of RAD (10, 100, 200nM) and LY 
(10µM) induced αSMA expression, an established protein marker of myofibroblast 
differentiation (Fig. 5.1a).  Results of densitometry from a representative experiment 
indicated that RAD and LY increased αSMA expression relative to β−actin by 1.9, 2.2, 2.4 
and 2.2 fold respectively (ratio αSMA: β-actin; Fig. 5.1b). 
 
5.3.1.2 Cytochemistry for αSMA 
The change in total αSMA protein expression was reflected by an increase in the 
proportion of myofibroblasts, as determined by the number of cells staining for αSMA (Fig. 
5.2a, arrows) which were visibly larger compared to negative staining cells (Fig. 5.2a, arrow 
heads). Treatment with 100, 200nM RAD and 10µM LY increased the percentage of cells 
staining for αSMA, and therefore myofibroblasts, by 34±8 %, 46±12% and 20±8% 
respectively (Fig. 5.2b-c; p<0.05 vs. control, n=3 each group), implicating both PI3K and 
mTOR in the regulation of fibroblast differentiation.  No significant change in αSMA 
immunostaining in response to 10nM RAD was noted however. 
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(a) Treatment with RAD and LY increased total αSMA protein expression. Membranes 
were probed with a monoclonal antibody against ß-actin to correct for loading. (b) 
Compared to control groups, RAD increased αSMA by 1.9-fold (10 nM), 2.2-fold (100nM) 
and 2.4-fold (200nM) whilst LY (10µM) increased αSMA by 2.2-fold. The results illustrate 
a duplicate experiment. 
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proportion of myofibroblasts. After exposure to RAD or LY, cells were evaluated with 
immunocytochemistry to determine the effect on myofibroblast differentiation. (a) In each 
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(arrows) appeared larger than their αSMA negative counterparts (arrowheads). The 
proportion of myofibroblasts was increased by (b) 34±8% (100nM RAD) 46±12% (200nM 
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To confirm that these changes in differentiation were not simply a consequence of 
change in cell confluency, the proportion of myofibroblasts in cells seeded at varying 
densities was specifically examined.  When seeded in control medium at 1x10
4
, 3x10
4
 and 
6x10
4
cells/well, a similar proportion of cells stained for αSMA in each group after 72hr of 
treatment (data not shown). 
 
5.3.2 Changes in αSMA expression may be independent of transcriptional activation 
Steady state mRNA levels can be affected by the level of gene transcription as well as 
changes to mRNA stability (Jinnin et al., 2006).  To determine if the increase in αSMA 
protein, regulated by PI3K and mTOR, was attributed to translational or transcriptional 
regulation, cells were treated with either actinomycin D or cycloheximide preceding treatment 
with 10µM LY.  Based on the premise that LY should increase the proportion of αSMA cells 
(29.6±7.5% vs. control, p<0.001, n=7), cyclohexamide (translational inhibitor) was the only 
agent capable of inhibiting this response (p=not significant (ns) vs. control, n=7).  Conversely, 
pre-treatment with Actinomycin D, a transcriptional inhibitor, did not inhibit αSMA 
expression as shown by Fig. 5.3, which illustrates a 31±14% increase compared to the control 
group (p<0.001 vs. control, n=7).  These preliminary results suggest that PI3K regulates 
αSMA expression via translational activation rather than direct transcriptional activation of 
αSMA.  
 
 162
Control LY
α
S
M
A
p
o
s
it
iv
e
 (
%
)
0
20
40
60
80
100
+ 10µM LY
1
0
µ
M
**
C
y
c
lo
h
e
x
a
m
id
e
A
c
ti
n
o
m
y
c
in
D
Fig. 5.3
To determine if mTOR and PI3K regulate transcription or translation, cells were pre-treated 
with actinomycin D and cyclohexamide for 1hr prior to treatment with 10µM LY. Based on the 
premise that LY should increase the proportion of αSMA cells (29.6±7.5 vs. control, *p<0.001, 
n=7), cyclohexamide was the only agent capable of inhibiting this response (**p=ns vs. control,  
n=7). αSMA was still increased by 31±14% in the presence of actinomycin D (***p<0.001 vs. 
control, n=7). This suggests PI3K may not regulate αSMA at the transcriptional level.  This data 
represents an average of three independent experiments.
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expression did not significantly change in response to all doses of RAD (10, 100, 200nM) and 
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5.3.3 Changes in αSMA expression independent of transcriptional activation can be 
further confirmed by real time PCR  
Consistent with actinomycin D not being able to prevent the LY-mediated increase in 
αSMA, there was no demonstrable effect of LY on αSMA mRNA expression using real time 
PCR (Fig. 5.4).  In both RAD (10, 100, 200nM) and LY (10µM) treated groups, αSMA gene 
expression was not meaningfully changed, as compared to the house-keeper gene, Ribosomal 
protein L32 (average of two experiments).  These changes to αSMA gene expression were 
reasoned to be insignificant due to the sensitivity of this method as compared to western 
blotting where similar fold differences are likely to be more significant.   
 
5.3.4 RAD and LY induce differentiation and decreases in proliferation in the same cell 
sub-populations. 
Because mTOR and PI3K regulate proliferation and differentiation inversely in 
fibroblasts, it is possible that these kinases may be inducing mitogenesis and differentiation in 
different sub-populations of cells. To evaluate this, cells treated with LY or RAD were 
double-labelled with αSMA and proliferating nuclear cell antigen (PCNA).  Consistent with 
studies that have evaluated fibroblast DNA synthesis (Chapter 3), qualitative evaluation 
indicated that treatment with either LY or RAD resulted in a reduction in PCNA positive 
nuclei (Fig. 5.5a-c).   Double labelling for PCNA and αSMA indicated that 22±10% and 
21±4% of fibroblasts expressed both markers in RAD (100nM) and LY (10µM) treated 
groups respectively, compared to 53±13% in the control group (Fig. 5.6, p<0.05 vs. control; 
n=3 each group). Consequently, of the RAD and LY treated groups undergoing proliferation, 
approximately 60% fewer cells (when the control is taken as 100%) are in a differentiated 
state as compared to the control group.  Given that inhibition of PI3K and mTOR facilitates  
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Both RAD and LY affect proliferation and differentiation in the same population of cells. 
Combined immuno-cytochemical staining for myofibroblast differentiation (αSMA; cytoplasmic 
staining) and proliferation (PCNA; nuclear staining) illustrates that the increased 
myofibroblast differentiation was accompanied by a decrease in proliferation (Fig. 5.5 a-c). 
Quantification of these results indicated that the proportion of PCNA positive myofibroblasts 
decreased from 53±13% in the control group to 22±10 and 21±4% in the RAD and LY groups, 
respectively (Fig. 5.6; *p < 0.05 vs. control; n=3 each group). This data represents an average 
of two experiments.
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differentiation and inhibits proliferation, this suggests that the same sub-populations of cells 
are undergoing changes in proliferation and differentiation.   
 
5.3.5 Role of PI3K and mTOR in the regulation of TGFβ1 synthesis  
The recent literature suggests that mTOR and PI3K can regulate TGFβ1 synthesis 
(Runyan et al., 2004; Wu et al., 2006).  Given the importance of TGFβ1 in renal fibrosis, this 
experiment was carried out to determine if mTOR and PI3K play roles in the regulation of 
TGFβ1 in renal fibroblasts.  As indicated in Fig. 5.7, the concentration of TGFβ1 in the 
medium exposed to cells; conditioned medium (1069±76pg/ml) was markedly higher than that 
in the fresh unconditioned medium (not exposed to cells; 470±14pg/ml, p<0.001 vs. medium, 
n=3).  Furthermore, RAD significantly increased TGFβ1 (1740±63pg/ml), more so than that 
in the conditioned medium (p<0.001 vs. conditioned medium, n=3). TGFβ1 levels in LY 
treated cells did not differ from that in conditioned medium (1176±17pg/ml; p=n.s. vs. 
control, p<0.001 vs. medium, n=3).   
 
 
5.3.6 Role of PI3K and mTOR in the regulation of EMT 
 
 The heterogeneous derivation of myofibroblasts includes those that are derived via 
EMT.  Apart from the role of Smads, the MAPK family and Rho, little is known about other 
regulatory pathways that govern EMT, although the potential for PI3K to cross-talk with 
Smads (Runyan et al., 2004) and Ras/MAPK (Pende et al., 2004; Shaw and Cantley, 2006) 
has previously been reported.   
Renal explants (Chapter 4) were treated with either 10, 100, 200nM RAD, 10µM LY 
or maintained in control medium.  At the end of this time period, explants were fixed in cold 
methanol and stained for αSMA.  Addition of the mTOR and PI3K inhibitors decreased 
αSMA expression by 25.3±7% (10nM RAD), 33.5±4.6% (100nM RAD), 38.7±7% (200nM  
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TGFß1 analysis was carried out to determine if RAD and LY affect differentiation through an up-
regulation of TGFß1 in renal fibroblasts. Cells were treated with either: (i) 100nM RAD in 
DMEM + 2.5% FCS, (ii) 10µM LY in DMEM + 2.5%FCS, or (iii) maintained in control medium
(DMEM + 2.5% FCS; conditioned medium). For comparison, TGFß1 concentration in medium
not exposed to cells (Medium) was measured. Results suggest that a RAD-mediated increase in 
TGFß1 synthesis facilitates differentiation, however LY had no effect on TGFβ1 secretion. 
TGFß1 concentrations have been adjusted according to dilutions made throughout the detection 
process. (n=3 each group; *p<0.001 vs. medium;**p<0.001 vs. conditioned medium; #p=n.s. vs. 
conditioned medium; #p<0.001 vs. medium).
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Explants were treated with either RAD or LY for 48hr and stained for the myofibroblast marker 
αSMA. Cell enumeration indicated that all doses of RAD (10, 100, 200nM) and LY (10µM) 
decreased the acquisition of αSMA by by 25.3±7%, 33.5±4.6%, 38.7±7% and 38.9±1.8% 
respectively, indicating the potential for these kinases to regulate EMT in this model (*p<0.001 
vs. control, n=5).  The results illustrate a duplicate experiment. 
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RAD) and 38.9±1.8% (10µM LY) (Fig. 5.8, all p<0.001 vs. control, n=5). This data provides 
novel insights into the mechanisms of EMT regulation. 
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5.4 DISCUSSION 
Whilst the derivation of myofibroblasts is heterogenous, studies have indicated that 
two major sources are derived from the differentiation of local fibroblasts and from tubular 
epithelial cells via EMT.  This study has therefore investigated the role of PI3K and mTOR in 
the regulation of fibroblast differentiation and EMT. Because the presence of αSMA-positive 
cells is often a key indicator of the severity of tubulointerstitial fibrosis, it is important to 
identify the mechanisms that govern this process. This study has shown that PI3K and mTOR 
play roles in regulating both fibroblast differentiation and EMT. Treatment with the respective 
inhibitors led to concurrent increases in αSMA protein, indicative of myofibroblast 
differentiation.  TGFβ1 signalling, increasingly recognised for its ability to cross-talk with 
other pathways including PI3K and mTOR, was markedly up-regulated by the mTOR 
inhibitor RAD. Lastly, by using the ex vivo model of EMT established in Chapter 4, it was 
found that in contrast to their effect on fibroblasts, mTOR and PI3K inhibitors decreased the 
proportion of αSMA-positive epithelial cells, contributing to a down regulation of EMT in 
this model.   
 
5.4.1 Role of PI3K and mTOR in myofibroblast differentiation 
Recent evidence in a variety of cells suggests that PI3K and mTOR may play a role in 
fibroblast differentiation.  PI3K has been shown to be essential for the terminal differentiation 
of skeletal muscle cells (Kaliman et al., 1996), as well as the differentiation of T cells 
(Okkenhaug et al., 2006), lens fibre cells (Weber and Menko, 2006) hepatic stellate cells 
(Reichard and Petersen, 2006) and osteoclasts (Lee et al., 2002).  Furthermore, given the 
similarity between VSMC and myofibroblasts, the recent study on VSMC is perhaps the most 
compelling.  In this work, Martin et al (Martin et al., 2004) found that RAD increased the 
expression of smooth muscle specific proteins including αSMA, calponin, and SM myosin 
heavy chain, suggesting that αSMA expression in VSMC is regulated by mTOR (Martin et 
 169
al., 2004).  Like Martin’s work and others (Yamamoto-Yamaguchi et al., 2001) this study has 
found that rapamycin and its derivatives increase αSMA protein expression in renal 
fibroblasts.  The change in total αSMA protein expression was reflected by an increase in the 
proportion of myofibroblasts staining positive for αSMA.  Of those cells that had reached a 
differentiated state, a contractile morphology was observed with αSMA filaments occupying 
a considerable proportion of the cytoplasm.  
Whilst the studies in VSMC found no effect of LY on differentiation (Martin et al., 
2004), the findings described herein suggest that LY also promotes differentiation, consistent 
with other studies that have implicated PI3K and Akt in PDGF-mediated regulation of αSMA 
in VSMC (Kaplan-Albuquerque et al., 2003).  Furthermore, mTOR and PI3K function in a 
TGFβ1-dependent manner in the differentiation of hepatic stellate cells into a myofibroblast 
phenotype (Le Pabic et al., 2005).  In the context of PI3K/mTOR’s in vivo function in 
fibroblasts, these kinases may therefore negatively regulate αSMA expression.   However, it 
is also worth noting that because cells were treated for an extended period of time (48hr), it 
may be possible that RAD and LY are inhibiting proteosomal degradation of αSMA through 
the inhibition of the ubiquitin-proteasome pathway, responsible for the degradation of 
intracellular proteins. Although this requires further studies, conceivably this would prevent 
the turnover of αSMA, leading to an accumulation of αSMA in the cell without requiring the 
need for new protein synthesis. 
The effects of rapamycin on myofibroblast differentiation have also recently been 
examined in vivo.  Interestingly, rapamycin has been shown to decrease protein expression 
and staining of peri-tubular and peri-glomerular αSMA in a model of UUO (Wu et al., 2006). 
Although the apparent reason for these discrepancies is unknown, it may be an indication of 
the importance of the in vivo environment in the study of fibrotic responses but it may also be 
indicative of the relevance of cell specificity to mTOR and PI3K signalling.  Relevant to this, 
Sarbassov, who examined 33 transformed or cancer cells, found that mTORC2 assembly was 
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rapamycin sensitive in response to prolonged treatment in only one third of these cells 
(Sarbassov dos et al., 2006).  Further studies are required to examine these mechanisms in a 
renal context. 
 
5.4.2 Role of PI3K and mTOR in the regulation of αSMA gene expression 
The results of the studies described herein suggest that the regulation of αSMA 
expression by PI3K and mTOR appears to be through regulation of protein synthesis, 
consistent with the role of mTOR in the positive and negative control of protein synthesis 
(Ruvinsky and Meyuhas, 2006).  In order to examine whether these kinases regulate the gene 
expression of αSMA in renal fibroblasts, cyclohexamide and actinomycin D were used to 
study translational and transcriptional regulation respectively.  These global inhibitors have 
been used by a number of other studies to examine the role of various substrates in gene 
expression (Jinnin et al., 2006; Martin et al., 2004; Price et al., 1989; Ricupero et al., 2001). 
Based on the premise that LY should increase αSMA expression, pre-treatment with these 
inhibitors established that only cyclohexamide prevented cells from undergoing 
differentiation.  This observation is supported by the increase in total αSMA protein observed 
with western blotting, and the failure to detect any meaningful changes in αSMA mRNA 
expression by real time PCR.  
Post-transcriptional regulation plays an important downstream role in many signalling 
pathways in response to growth factors (Dibrov et al., 2006), and is a likely explanation for 
increases in protein synthesis that do not show comparative changes to transcription.  
Although αSMA expression has been shown previously to be controlled at the post-
transcriptional level (Corjay et al., 1990), in support of the present findings, further studies 
will be required to confirm the preliminary data described within.   
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5.4.3 Role of TGFβ1 in PI3K and mTOR-mediated differentiation 
TGFβ1 plays an important role in promoting fibroblast differentiation and an 
increasing appreciation of the complexity of signalling pathways has led to findings that the 
TGFβ signalling axis can cross-talk and integrate its responses with PI3K and mTOR 
(Runyan et al., 2004).  In response to mTOR inhibition, it was found that total TGFβ1 levels 
were markedly increased.  This suggests that the up-regulation of TGFβ1 by RAD treatment 
may mediate the differentiation of fibroblasts in an autocrine fashion, consistent with the 
present studies, which demonstrate a RAD-mediated up-regulation of αSMA expression (Fig. 
5.9). Other pathways are likely to be involved in the regulation of differentiation via PI3K as 
LY had no effect on TGFβ1 synthesis.   
This study suggests that mTOR may play a role in negatively regulating TGFβ1 levels 
in vivo, and is consistent with studies showing a significant up-regulation of rapamycin-
mediated TGFβ1 synthesis in human kidney transplant fine-needle aspiration biopsies 
(Oliveira et al., 2002), and in rapamycin-infused rats with chronic cyclosporine nephrotoxicity 
(Shihab et al., 2004a; Shihab et al., 2004b).  However, other studies contradict these findings 
making the exact role of mTOR in TGFβ1 regulation in vivo ambiguous.  Wu et al (Wu et al., 
2006) has shown that TGFβ1 expression, induced by UUO, was significantly lowered in 
response to rapamycin whilst other studies (Jain et al., 2001) demonstrated a marked 
rapamycin-mediated decrease in TGFβ1 expression in an experimental model of renal 
ischaemia reperfusion injury.  Similar to the regulation of collagen in vivo by PI3K/mTOR, it 
is apparent that the regulation of TGFβ1 levels in vivo by these kinases is also unclear. 
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5.4.4 Role of PI3K and mTOR in EMT 
The process of EMT has been shown to contribute significant numbers of interstitial 
myofibroblasts in vivo (Iwano et al., 2002).  Whilst TGFβ1 is a potent inducer of EMT, the 
intracellular signalling mechanisms governing EMT are far from being fully elucidated. 
TGFβ and the Smad2/3 axis are likely to play roles in most of the sequential events of EMT 
(Flanders, 2004; Roberts et al., 2006; Yang and Liu, 2001), whilst the MAPK cascade is 
thought to mediate αSMA expression and suppress E-cadherin (Li et al., 2004b; Rhyu et al., 
2005; Xie et al., 2004).  Furthermore, Rho has been implicated in the dissociation of epithelial 
cells from their neighbours (Bakin et al., 2000; Ozdamar et al., 2005) and in the formation of 
stress fibres (Bhowmick et al., 2001; Masszi et al., 2003), and ILK has been repeatedly shown 
to regulate E-cadherin expression through the regulation of Snail and β-catenin translocation 
to the nucleus (Li et al., 2003; Tan et al., 2001).  
However, EMT is a highly complex process with the dependence on a number of 
cellular programs (Thiery and Sleeman, 2006) and it is unlikely that the plethora of EMT 
agonists including angiotensin II (Chen et al., 2006), AGEs (Oldfield et al., 2001), CTGF 
(Burns et al., 2006), TGFβ1 (Lan, 2003), IL-1 (Fan et al., 2001), collagen I (Zeisberg et al., 
2001), FGF and EGF (Strutz et al., 2002), and tPA (Yang et al., 2002b) all mediate their 
responses through the currently identified pathways.  The potential for cross-talk between the 
TGFβ axis and PI3K/mTOR in the mediation of EMT has become increasingly acknowledged 
in many cancer-related studies (Bakin et al., 2000; Irie et al., 2005; Larue and Bellacosa, 
2005; Park et al., 2001) and a limited number of renal studies (Wu et al., 2006), suggesting 
that PI3K/mTOR may play roles in renal EMT. 
  By using the previously established model of EMT (Chapter 4), the role of mTOR 
and PI3K in renal EMT was determined.  Using this model, these results indicate that whilst 
RAD has an agonistic effect on the differentiation of renal fibroblasts derived from UUO, 
cells that grow out of renal tissue explants, phenotyped as epithelial, demonstrate a RAD-
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mediated inhibition in their capacity to undergo EMT. These cells down-regulated their 
expression of the myofibroblast marker αSMA in response to both RAD and LY.  This 
provides an insight into the regulatory mechanisms of mTOR in accordance with in vitro 
studies by Wu et al (Wu et al., 2006), who demonstrated a rapamycin-mediated inhibition of 
TGFβ1-induced loss of E-cadherin expression and the de novo expression of αSMA, and 
Aguilera et al (Aguilera et al., 2005), who showed that TGFβ−mediated Snail expression, 
αSMA expression and loss of E-cadherin were prevented by rapamycin.   
  It is worthy to note that rapamycin has been shown to inhibit the proliferation of 
human renal epithelial cells in vitro (Pallet et al., 2005) underscoring the potential for 
rapamycin to actually be inhibiting proliferation rather than preventing expression of αSMA 
in this model.  However, to overcome this problem, cells were only treated with rapamycin 
when a substantial number of epithelial cells were present and cell numbers around a selected 
number of tissue patches were counted to ensure there were not significant changes in cell 
proliferation in each of the treated groups compared to the control (data not shown). 
Furthermore, it has been shown that, as in the case of TGFβ1-mediated EMT, cell cycle arrest 
is necessary in the regulation of PI3K and mTOR-mediated EMT in epithelial cells (Shao et 
al., 2004). This once again suggests that epithelial cells do not undergo proliferation during 
EMT and the effect of RAD on EMT in this model is therefore unlikely to be a result of 
decreased proliferation rather than repression of αSMA. 
  The role of mTOR in EMT is further corroborated by its upstream liaison PI3K in 
this study.  Inhibition of PI3K in epithelial cells that grow out of explants resulted in a 
decrease in αSMA expression. Evidence for a role of PI3K-mediated processes in EMT is 
also emerging in the literature.  Bakin et al (Bakin et al., 2000) has demonstrated that 
TGFβ1−mediated EMT is dependent on PI3K where PI3K dominant-negative mutation or 
pharmacological inhibition (LY) leads to the inhibition of TGFβ1-mediated Smad2 
phosphorylation and repression of the EMT proteome (Fig. 5.10).  It therefore seems likely  
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that PI3K may cross-talk with the TGFβ signalling axis during EMT (Bakin et al., 2000; 
Runyan et al., 2004).  Furthermore, over-expressing mutated forms of Akt were shown to 
induce EMT by the up-regulation of Snail leading to repression of the E-cadherin gene (Batlle 
et al., 2000; Grille et al., 2003).   
 
5.4.5 Summary 
In conclusion, mTOR and PI3K play roles in the regulation of fibroblast 
differentiation and EMT.  Inhibition of these respective pathways promotes the differentiation 
of fibroblasts. This process may result from autocrine TGFβ signalling via mTOR. 
Preliminary evidence also suggests that mTOR and PI3K may mediate changes to mRNA 
stability rather than direct changes to transcription.  In contrast, the acquisition of αSMA 
filaments in epithelial cells during EMT is noticeably suppressed in response to inhibition of 
these kinases.  The effect of rapamycin derivative RAD on tubular epithelial cells during 
EMT, as demonstrated ex vivo, implicates another important role for rapamycin in the context 
of renal fibrosis. 
The differential regulation of αSMA in myofibroblast differentiation and EMT by 
PI3K and mTOR establishes an unusual finding and suggests that these kinases may act in a 
cell-dependent manner in fibroblasts and epithelial cells.  This type of signalling mechanism 
has been established in response to TGFβ1, the key pro-fibrotic mediator in the kidney. 
TGFβ1 is well known for its ability to promote fibroblast proliferation however it can also 
inhibit epithelial cell proliferation. Whilst Smads have been identified as the generic 
signalling pathway in both epithelial cells and fibroblasts, intracellular cross-signalling 
mechanisms govern the response to TGFβ1 in these cells.  Accordingly it has been shown that 
PI3K (Wilkes et al., 2005) and p21-activated kinase-2 (PAK-2) are activated in fibroblasts 
independently of the Smad axis however this inhibition of epithelial cell proliferation is 
mediated by the Smad signalling axis only (Wilkes et al., 2003).  Given that both TGFβ1 and 
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PI3K are likely to be involved in fibroblast differentiation, it is possible that differential cross-
talk mechanisms may dictate the response to cytokine or growth factor signals within different 
cells.   
  These studies provide novel insights into the regulation of cells that contribute to the 
derivation of myofibroblasts.  Furthermore, this highlights the complexity of the cell 
signalling pathways involved in mediating fibroblast differentiation and EMT and provides a 
solid foundation for further elucidation of mTOR and PI3K in mediating pro-fibrotic events. 
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5.5 SPECIFIC METHOD PROTOCOLS 
 
Method Section 
UUO  2.2.1 
RNA and protein extraction 2.7.1  
Western blotting  2.7.3 
Cytochemistry  2.6.1 
Cell enumeration 2.6.1.1 
Real time PCR   2.7.4 
 
Table 5.1: References for methods described in Chapter 2 used in this chapter.  
 
5.5.1 Western blotting for αSMA 
In the case of Western blotting for αSMA protein, protein was extracted from cells 
treated with RAD (10, 100, 200nM) or LY (10µM). Western blotting was used to quantify 
total cellular αSMA where membranes were incubated with a 1:1000 dilution of anti-αSMA 
(Table Apx. 3.3), followed by a 1:2000 incubation with HRP conjugated anti-mouse IgG 
(Table Apx. 3.2).  Membranes probed for αSMA were stripped and re-probed with a 1:2000 
dilution of mouse anti-β−actin O/N to confirm protein loading. Fold differences were 
quantified by densitometry.   
 
5.5.2 Global inhibition of transcription and translation  
 
To determine whether αSMA is regulated by PI3K and mTOR at the translational or 
transcriptional level, cells were pre-treated with actinomycin D (transcriptional inhibitor) or 
cycloheximide (translation inhibitor) and then treated with the PI3K inhibitor, LY (10µM).  
Cells were seeded in 36mm
2 
multiwell plates at a density of 1X10
5
 and grown to sub-
confluence.  2.5ug/ml actinomycin D or 10ng/ml cycloheximide was then added for 1hr. 
Media was removed, and 10µM LY, or no additive (control medium), was then added for 
24hr at 37°C. Cells were washed in PBS and fixed in cold methanol.  Cells were then stained 
for αSMA and enumerated.  
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5.5.3 Real time PCR for αSMA 
Real time PCR and was used to determine the role of PI3K and mTOR in αSMA gene 
expression.  Trizol extraction was carried out on samples treated with RAD (10, 100, 200nM), 
LY (10µM), or from those maintained in control medium. RNA was analysed with 2% 
agarose gels and purified with an RNA clean up kit.  Primers for αSMA (Accession number: 
NM_031004; 1361 bp), in comparison to the house-keeper gene, Ribosomal protein L32 
(Accession number: NM_013226; 564bp) were used.  Twenty µl (0.5µM) of each of the 
forward and reverse primers were added to dH2O.   
αSMA forward primer αSMA reverse primer 
 
5' ACT GGG ACG ACA TGG AAA AG 3' 
 
5' CTA CTC CAG AGT CCA GCA CA 3' 
Table 5.2: αSMA primer sequences  
Previous experiments had established the reliability of this method by testing TGFβ1, 
an inducer of fibroblast differentiation, as a positive control (data not shown). Duplicates of 
each group were analysed and represented according to delta-delta fold differences. 
 
5.5.4 Double labelling of fibroblasts for αSMA and PCNA 
 
To determine if the same sub-populations of cells were responding by proliferation 
and differentiation, peroxidase double-labelling was carried out. An equal number of cells 
were seeded onto sterile coverslips and grown until subconfluent.  Cells were then treated 
with RAD (100nM), LY (10µM), or maintained in control medium and left for 72hr.  Cells 
were then fixed in cold methanol and washed with TBSx2.  Cells were then blocked with 
normal dilute serum for 10min and incubated with PCNA O/N at 4°C (Table Apx. 3.1).  Cells 
were then washed in tris buffered saline (TBS) x2, Alk phos-anti-mouse conjugate added for 
30min, washed in TBSx2 and incubated with Alk-phos anti-alk-phos for 40min (Table Apx. 
3.2).  After washing with TBSx2 Texas fast red was added for 20min in darkness, cells were 
washed in TBSx2, and anti-αSMA (HRP-EPOS) was then added for 30min (Table Apx. 3.1).  
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Cells were then washed in TBSx2, and developed with DAB until a colour change appeared. 
Finally, cells were mounted onto glass slides with aquamount. Approximately 600-800 cells 
were counted for positive staining for αSMA, PCNA or both markers.   
 
5.5.5 Detection of total TGFβ1 
 
 To determine if mTOR and PI3K are involved in the regulation of TGFβ1 secretion, a 
TGFβ1 Quantikine® kit was used.   Fibroblasts were grown to confluency in 6-well plates as 
described previously. In DMEM + 2.5%FCS, cells were then treated with 100nM RAD, 
10µMLY or maintained in control medium (DMEM + 2.5%FCS), named Conditioned 
medium at 37ºC.  Media (including fresh media not exposed to cells; named Medium) was 
then collected, centrifuged at 6000rpm for 10min, placed into sterile nunc tubes and snap 
frozen (into liquid nitrogen).  Samples were activated to detect total TGFβ1 and the ELISA 
was carried out according to the manufacturer’s instructions.  
 
5.5.6 Pharmacological modification of EMT with RAD and LY 
Explants were treated with TGFβ1 (10ng/ml), RAD (10, 100, 200nM), LY (10µM), or 
maintained in control medium (DMEM+ 10% FCS).  After treatment for 48hr, cells were 
fixed in ice-cold methanol, stained for αSMA, and counted on the basis of positive staining.    
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6.1 INTRODUCTION 
Tubulointerstitial fibrosis and its damaging effects on the surrounding renal 
parenchymal tissue may be regulated by a cocktail of locally and systemically derived 
mediators, many of which are cytokines.  Although these soluble factors are key mediators of 
fibrosis, they are not by any means the sole players and we increasingly acknowledge the role 
of non-cytokine mediated pathways in renal fibrosis.  Those that have gained worthy attention 
over recent years include (a) tPA where fibrosis is significantly ameliorated in tPA gene 
knock-out mice (Yang et al., 2002b); (b) PAI-1 where over-expressing PAI-1 transgenic mice 
display severe fibrosis characterized by marked tubular injury and increased myofibroblast 
proliferation (Eddy, 2002; Matsuo et al., 2005); (c) angiotensin II which plays a significant 
role in fibrosis in animal models of UUO (Kellner et al., 2006), 5/6 nephrectomy (Kelly et al., 
2006), anti-Thy1 glomerulonephritis (Yu et al., 2004), and diabetic nephropathy (Anjaneyulu 
and Chopra, 2004), and can also activate TGFβ signalling (Fukami et al., 2004; Kagami et al., 
1994) and lastly; (d) AGEs which can induce cytokine release (Cooper, 2004) and EMT 
independently of TGFβ1 (Oldfield et al., 2001).  
Similarly, although historically known for their role in minimising blood loss, the 
coagulation cascade can be directly activated during injury and inflammation (Grandaliano et 
al., 2001; Sekiya et al., 1994).   Consistent with this, a number of studies have demonstrated 
that serine proteases have cell-mediated effects, in particular, influencing the key fibrogenic 
cells in progressive scarring (Enestrom et al., 1988; Grandaliano et al., 2000b; Hewitson et al., 
2005; Howell et al., 2001; Liu et al., 2004; Monno et al., 2001; Tanaka et al., 2005; Vesey et 
al., 2005).  Firstly, a number of studies on the role of the coagulation cascade in animal 
models of fibrotic lung disease have underscored the potential for the coagulation cascade 
pathway to mediate fibrosis.  Howell et al (Howell et al., 2002) have shown that inhibition of 
thrombin in bleomycin-induced lung fibrosis attenuated ECM deposition and cytokine 
production, whilst Fujimoto et al (Fujimoto et al., 2006) demonstrated that knock-out of 
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thrombin-activatable fibrinolysis inhibitor (TAFI; a strong suppressor of fibrinolysis) 
markedly ameliorated lung fibrosis.   Secondly, members of the coagulation cascade have 
been implicated in a diverse range of glomerular-based diseases including IgA nephropathy 
(Liu et al., 2000), Henoch-Schonlein purpura nephritis, lupus nephritis and hemolytic uremic 
syndrome (Takemura et al., 1987), mesangioproliferative glomerulonephritis (Liu et al., 
2004), human (Cunningham et al., 1999; Grandaliano et al., 2000a) and murine (Cunningham 
et al., 2000) crescentic glomerulonephritis.   
Thirdly and foremost, the presence of coagulation members have also specifically 
been described in various human and experimental models of tubulointerstitial renal diseases 
including ureteric obstruction, allograft rejection and acute ischaemic renal failure (Enestrom 
et al., 1988; Faulk et al., 1989; Grandaliano et al., 2000b; Wang et al., 1997; Wang et al., 
1996; Wendt et al., 1995; Yamamoto and Loskutoff, 1997).  However, unlike their role in the 
formation of glomerular crescents, the significance of such factors in mediating 
tubulointerstitial fibrosis is only beginning to be elucidated.  Perhaps the greatest insight into 
this process can be drawn from studies on the serine protease thrombin.  Thrombin has been 
implicated in facilitating fibroblast mitogenesis (Hewitson et al., 2005), the autocoid up-
regulation of CTGF (Chambers and Laurent, 2002), TGFβ1 (Bachhuber et al., 1997; 
Grandaliano et al., 2001), and PDGF  production (Ohba et al., 1994), and in the up-regulation 
of ECM synthesis (Bachhuber et al., 1997; Chambers et al., 1998; Dabbagh et al., 1998; 
Hewitson et al., 2005; Howell et al., 2001; Shirato et al., 2003; Vesey et al., 2005).  
Moreover, thrombin can stimulate fibroblast differentiation (Bogatkevich et al., 2001), and is 
present with these cells in the inflammatory and early fibrotic stages in a number of 
pathological conditions (Coughlin, 2000).  
Thrombin carries out many of its fibrogenic cell-mediated effects through protease 
activated receptor-1 (PAR-1) (Bogatkevich et al., 2001; Grandaliano et al., 2001; Grandaliano 
et al., 2000b; Hewitson et al., 2005; Howell et al., 2001; Howell et al., 2002).  This GPCR has 
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been identified on endothelial cells of glomerular and interstitial capillaries and arterioles, 
mesangial cells and podocytes, myofibroblasts and tubular epithelial.  Although studies 
(Grandaliano et al., 2001; Grandaliano et al., 2000b) have localised PAR-1 to proximal 
tubular epithelial cells in chronic allograft nephropathy (CAN), the in vivo distribution of 
PAR-1 in a model of UUO has not yet been ascertained.  
Given that the role of serine proteases in glomerular pathology has been well 
documented, this study has therefore examined the temporal and spatial distribution of 
coagulation factors after experimental UUO.  
 
6.2 EXPERIMENTAL DESIGN 
 
To assess the role of the coagulation cascade in tubulointerstitial fibrosis, this study 
has utilised tissue obtained from rats sacrificed at various time points post-UUO.  This study 
is based on the examination of the in vivo temporal and spatial distribution of coagulation 
factors 0, 3, 14 and 21 days post-UUO which relies on immunohistochemistry and in situ 
hybridisation.  Renal fibroblasts propagated from explants of rat renal cortex, 3-days post 
UUO were also used to for in vitro studies, whilst the model of EMT, established in Chapter 
4, was also incorporated to study the role of non-cytokine-mediated pathways in EMT.   
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6.3 RESULTS 
 
6.3.1 Factor V is present in the tubulointerstitium in vivo 
Factor V acts as a membrane-bound co-factor and when present, has the ability to 
accelerate the generation of thrombin by 10
4
 fold (Ono et al., 2001).  Tissue sections derived 
from rat kidneys were stained with an antibody against factor V at 3 days post-UUO.  This 
demonstrated that factor V staining was evident during renal injury as supported by Liu et al 
(Liu et al., 2000), and was predominantly localized to peri-tubular interstitial regions (Fig. 
6.1).    
 
6.3.2 Factor V is expressed by activated fibroblasts 
To determine if cells derived from UUO can actively express factor V in response to 
inflammation, cells derived from 3 days post-UUO were treated with 200U/ml of the 
inflammatory cytokine tumour necrosis factor-α (TNFα) for 24hr  in 1%FCS+DMEM, and 
then stained for factor V.  Obvious staining for factor V was demonstrated in cells grown in 
1% FCS (Fig. 6.2b); this was markedly up-regulated in cells grown in 10% FCS (Fig. 6.2c) 
and when cells were treated with 200U/ml TNF-α (Fig. 6.2d).  Specificity of staining was 
confirmed by replacing anti-factor V with species matched non-immune serum.  No specific 
staining was noted in this group (Fig. 6.2a; rabbit immunoglobulins in 1% FCS). 
Inflammatory-mediated stimulation of factor V synthesis by renal fibroblasts and its ability to 
be modified in vitro by different culture media suggest that fibroblasts may be an alternate 
pathway for generation of this protease.  Results are illustrative of a duplicate experiment. 
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Fig. 6.1
Fig. 6.2
Tissue sections taken from day 3 post-
UUO were incubated with primary 
antisera against the cell specific 
protein factor V. Increased Factor V 
staining can be found in the 
tubulointerstitium during experimental 
fibrogenesis. Factor V was localised
mainly to peri-tubular regions (n=5).
Factor V can be synthesized by fibroblasts derived from obstructed kidneys at 3 days 
post-UUO. Obvious staining for factor V was demonstrated in cells grown in 1% FCS 
(fig 6.2b); this was markedly up-regulated in cells grown in 10% FCS (fig 6.2c) and 
when cells were treated with 200U/ml TNF-α in 1%FCS (fig 6.2d). Specificity of 
staining was confirmed by replacing anti-factor V with species matched non-immune 
serum. No specific staining was noted in this group (fig 6.2a; rabbit immunoglobulins 
in 1% FCS). Photomicrographs are representative of a duplicate experiment, n=3 
slides each group.
a
c
Factor V
Non-immune serum
10% FCS
1% FCS
b
200U/ml TNFα
d
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6.3.3 Fibrin is present in the tubulointerstitium   
In light of thrombin’s rapid turnover rate (Coughlin, 2000) and consequently the 
difficulty in identifying its presence in the interstitium, fibrin/fibrinogen (called fibrin from 
hereon) was used as a surrogate marker for thrombin.  As shown in Fig. 6.3, fibrin has an 
interstitial distribution in a juxtaposition to factor V (Fig. 6.1), and was predominantly 
localized to interstitial peri-tubular regions.  Sections taken from rat kidneys subjected to 
UUO were also stained at 0, 3, 14 and 21 days post-UUO (Fig. 6.4a-d). Cortical and 
medullary distribution of fibrin was enumerated and expressed as a percentage of the 
fractional area (FA).  The distribution of fibrin was chiefly confined to the medullary and 
corticomedullary junction, with relatively small amounts in the cortex.  Fibrin was distributed 
acutely around peri-tubular capillaries, and more diffusely in tubular casts at latter time 
points.  The quantity of staining for fibrin was enumerated and expressed as a percentage of 
the FA over the same time points post-UUO (Fig. 6.5).  Staining for fibrin was increased by 
3-days post-UUO to 11%, further increasing by 14 days post-UUO, at which point it occupied 
16.9% of the FA (p<0.05 vs. Day 0).  By day 21, fibrin occupied 13.4% of the FA (n=3-6). 
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Fig. 6.3
Fig. 6.4
a b
c d
Using an antibody against 
fibrinogen/fibrin, fibrin 
deposits were localized to 
interstitial and peri-tubular 
regions in a juxtaposition to 
factor V. Because of the high 
turn over rate of thrombin, 
these mesh clots are 
representative of the location of 
the serine protease thrombin. 
A temporal examination of fibrin distribution reveals a progressive increase in fibrin. The 
distribution of fibrin was chiefly confined to the medullary and corticomedullary junction, with 
relatively small amounts in the cortex. Fibrin was found acutely around peri-tubular capillaries, 
and more diffusely in tubular casts at latter time points. As renal injury progresses, the renal 
architecture becomes distended and tubular dilation becomes evident and marked by day 21.  
Fibrin
Day 3
Day 14 Day 21
Day 0
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The quantity of staining for fibrin was enumerated and expressed as a percentage of the FA 
over fixed time points post-UUO. Staining for fibrin increased by 11% by 3 days post-
UUO, further increasing by 14 days post-UUO, at which point it occupied 16.9% of the FA. 
At day 21 fibrin occupied 13.4% of the FA (*p<0.05 vs. control, n=3-6). 
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6.3.4 The distribution of fibrin and αSMA is spatially related  
By staining serial sections of rat tissue derived from UUO at day 3 for fibrin and the 
myofibroblast marker αSMA, a spatial relationship can be established between a marker of 
the end point of the coagulation cascade (Fig. 6.6a, arrows), and a marker of tubulointerstitial 
pathology (Fig. 6.6b, arrows). This spatial relationship suggests that a cause and effect 
relationship may exist between serine proteases (thrombin) and fibrosis (myofibroblasts).  
 
6.3.5 PAR-1 expression is confined mainly to renal tubule epithelial cells 
To examine the functional significance of thrombin, immunohistochemistry was used 
to localise the distribution of the thrombin receptor PAR-1 in progressive fibrosis.  PAR-1 
expression was localised to the basolateral surface of renal tubular epithelial cells (Fig. 6.7).  
To determine whether there is a relationship between the localization of fibrin and the 
distribution of PAR-1, comparisons at different time-points were carried out. Staining for 
PAR-1 was maximal during the early time-points, (Fig. 6.8a-b, 0 and 3-days post-UUO), and 
decreased progressively with the progression of fibrosis (Fig. 6.8 c-d, 14 and 21 days post-
UUO). At higher magnification it could be seen that loss of staining was focal, affecting 
occasional cells in tubular cross sections (Fig. 6.9a-b, arrow).  
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Fig. 6.6
The presence of fibrin clots (a, 
arrows), indicative of thrombin, 
can be spatially related to the 
location of αSMA positive 
myofibroblasts (b, arrows) in 
the interstitium. Although it 
cannot be concluded that a 
cause and effect relationship 
does exist, it establishes a 
potential mechanism by which 
thrombin, present in fibrin clots 
may activate myofibroblasts
a
b
αSMA
Fibrin
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Fig. 6.8
PAR-1 was found to be heavily expressed during experimental UUO. Staining for PAR-1 was 
maximal during the early time-points, (a-b, 0 and 3 days post-UUO), and decreased 
progressively with the progression of fibrosis (c-d, 14 and 21 days post-UUO).
Fig. 6.7
PAR-1 was detected at 3 days 
post-UUO by using a monoclonal 
PAR-1 antibody on paraffin 
embedded tissue. PAR-1 receptor 
staining was located to the 
basolateral surface of tubular 
epithelial cells. 
PAR-1
a
dc
b
Day 3Day 0
Day 21Day 14
Fig. 6.9
At higher magnification it could be seen that loss of staining was focal, affecting occasional 
cells in tubular cross sections (a-b, arrow). 
a b
Day 21Day 3
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6.3.6 Expression of PAR-1 mRNA is maintained during progressive fibrosis 
An investigation of PAR-1 receptor kinetics by non-radioactive in situ hybridisation 
illustrated that PAR-1 mRNA synthesis was present at 21 days post-UUO (Fig. 6.10).  This 
suggests that PAR-1 synthesis is maintained in progressive fibrosis.   
 
6.3.7 EMT can be demonstrated in UUO 
In addition to carrying out cell-mediated effects through PAR-1 to induce fibroblast 
differentiation (as shown by spatial positioning of fibrin with αSMA), thrombin may play a 
role in EMT, given the favourable position of PAR-1 on tubular epithelial cells.  Given that 
EMT occurs in fibrosis induced by UUO (Rastaldi et al., 2002), sections were examined to 
localise this phenomenon, as illustrated in Fig. 6.11 (day 3, arrow). The cross-section (within 
the demarcated dotted lines) demonstrates a typical distal convoluted tubule consisting of 
cuboidal epithelial cells surrounded by a basement membrane at its basolateral aspect and a 
luminal aspect devoid of a prominent brush-border.  Whilst αSMA-positive cells can be seen 
surrounding the basement membrane in this region, astute observation indicates that an 
epithelial cell at the superior pole has changed its morphology, become αSMA-positive and 
has started to migrate into the interstitium.  Because of the transient nature of this event, this 
was not a common occurrence.  Given that key mediators fibrin/thrombin and PAR-1 are 
spatially co-localised in UUO, this suggests that they may play an inter-related functional role 
in EMT.   
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Fig. 6.10
In situ hybridization reveals that PAR-1 receptor mRNA in still present at 21 days 
post-UUO.
PAR-1 mRNA
Fig. 6.11
Demonstration of EMT in UUO at 3 days post-UUO. The distal tubular segment 
within the boxed outline and indicated by the arrow not only stains positive for 
αSMA but appears to be migrating into the surrounding interstitium. The 
morphology of this cell has also visibly changed and appears elongated and spindle 
shaped having lost any morphological similarity to tubular epithelial cells.
αSMA
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6.3.8 Activation of PAR-1 on tubular epithelial cells is a trigger for EMT 
To determine if PAR-1 could induce EMT using the ex vivo model of explanting, 
TGFβ1 and thrombin receptor agonist peptide (TRAP; 70µM) were added to explant medium 
(10%FCS+DMEM).  Treatment with 70µM of the synthetic peptide TRAP increased the 
transformation of tubule epithelial cells to myofibroblasts (αSMA +ve cells) by 63%, (Fig. 
6.12; p<0.001 vs. control, n = 3).  This compares to 110% seen with 10ng/ml TGFβ1 
(p<0.001 vs. control, p<0.05 vs. TRAP).  This confirms the potential for thrombin to induce 
EMT through PAR-1.  The results illustrate a duplicate experiment.  
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Using the ex vivo model of EMT, explants were treated with either 10ng/ml TGFβ1 or 70µM 
TRAP. Staining for αSMA demonstrates that the synthetic agonist TRAP increased the 
transformation of tubule epithelia to myofibroblasts (αSMA +ve cells) by 63%, (**p<0.001 
vs. control, n=3). This compares to 110% seen with 10ng/ml TGFß1 (*p<0.001 vs. control, 
*p<0.05 vs. TRAP).
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6.4 DISCUSSION 
 
It has become increasingly apparent that tubulointerstitial fibrosis, and its damaging 
effects on the surrounding renal parenchyma, does not exclusively dependent on cytokine 
mediators.  Coagulation factors can be endogenously activated independently of the 
coagulation cascade during injury and inflammation (Chambers and Laurent, 2002; Sekiya et 
al., 1994), and as a result they have been implicated as having cell-mediated effects in 
addition to their traditional roles in coagulation (Enestrom et al., 1988; Grandaliano et al., 
2000b; Howell et al., 2001).  Consequently, a number of studies have demonstrated that 
members of the coagulation cascade may play a direct or indirect role in a number of pro-
fibrotic processes highlighting their ability to contribute toward the pathogenesis of fibrosis 
(Hewitson et al., 2005; Liu et al., 2004; Monno et al., 2001; Tanaka et al., 2005; Vesey et al., 
2005).  To date, a more comprehensive account of the role of coagulation members localised 
to glomerular lesions has been provided, whilst little is known about the pathological 
significance of serine proteases in the tubulointerstitium.   
This study has therefore examined the interstitial distribution of coagulation factors 
after the induction of UUO and has attempted to identify the significance of coagulation 
factor accumulation during fibrosis.  Accordingly, the work described within has 
demonstrated the presence of coagulation factors in the tubulointerstitium in vivo and their 
temporal and spatial distribution in relation to the cell surface receptor PAR-1 and 
myofibroblasts. This study therefore establishes potential mechanisms whereby spatially 
related coagulation factors can induce cell-mediated effects through PAR-1.  This was further 
supported by the temporal loss of PAR-1 receptor protein, likely to be indicative of receptor 
activation and degradation.  Furthermore, in an attempt to understand the roles of these 
coagulation factors, this study has been able to identify an alternate pathway for factor V 
generation by renal fibroblasts, potentially facilitating the formation of thrombin.  Lastly, 
EMT is an increasingly acknowledged phenomenon in fibrosis, and this study has identified 
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tubular epithelial cells that undergo EMT at the early stages of UUO. Using the ex- vivo 
model of EMT, the potential for thrombin to induce EMT through PAR-1 has been 
demonstrated, providing an insight into the significance of PAR-1 on tubular epithelial cells 
and confirming the likelihood for thrombin to carry out cell mediated effects through this 
GPCR.    
 
6.4.1 Fibrin deposition in experimental tubulointerstitial fibrosis 
Fibrin deposition has been infrequently recognised as a marker of renal 
tubulointerstitial damage and has been described in a number of human and experimental 
renal diseases including UUO, allograft rejection and acute ischaemic renal failure (Enestrom 
et al., 1988; Faulk et al., 1989; Grandaliano et al., 2000b; Wang et al., 1997; Wang et al., 
1996; Wendt et al., 1995; Yamamoto and Loskutoff, 1997).  These studies have documented 
fibrin deposits in the interstitium, peri-tubular capillaries and along the tubular basement 
membrane (Enestrom et al., 1988; Wang et al., 1997; Wendt et al., 1995).  Consistent with 
this, the work described within has shown that interstitial fibrin deposition progressively 
accumulates after the induction of UUO, and it is still present at 21 days post-UUO.  The 
accumulation of fibrin during progressive fibrosis is supported by numerous studies 
(Enestrom et al., 1988; Faulk et al., 1989; Grandaliano et al., 2000b; Smiley et al., 2001; 
Wang et al., 1997; Wang et al., 1996; Wendt et al., 1995; Yamamoto and Loskutoff, 1997) 
and as a result, fibrin deposition has become increasingly recognised as a hallmark of the 
inflammatory response (Smiley et al., 2001).  
 The significance of fibrin deposition can be ascertained from studies which show that 
TAFI knock-out mice display attenuated lung fibrosis suggesting that the anti-fibrinolytic 
activity of TAFI promotes lung fibrosis by hindering the rate at which fibrin is degraded 
(Fujimoto et al., 2006).  Fibrin in its clotted form can promote ischaemia, influx of monocyte-
macrophages and proliferation of epithelial cells in Bowman’s space (Hertig and Rondeau, 
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2004) leading to the release of more cytokines which can facilitate inflammatory and 
fibrogenic processes.   
The accumulation of fibrin is thought to be due to the up-regulation of PAI-1, 
primarily because of its ability to inhibit tPA and uPA which play the role of facilitating 
plasmin formation normally leading to the degradation of fibrin.  The up-regulation of PAI-1, 
principally mediated by TGFβ1, has been noted in a number of animal disease models 
(Ishidoya et al., 2002; Kitching et al., 2003; Matsuo et al., 2005; Wang et al., 1997; Wang et 
al., 1996).  Furthermore, increased levels of PAI-1 have been demonstrated in human CAN 
(Grandaliano et al., 2001) and thrombotic microangiopathy (Eddy, 2002) in concert with 
marked increases in fibrin deposition.  This underscores the potential for PAI-1 to facilitate 
the accumulation of fibrin.  However it has also been noted that activated fibroblasts may also 
invade fibrin deposits, and through the secretion of collagens, make the fibrin deposits more 
resistant to breakdown (Rerolle et al., 2000) underlining another mechanism which may lead 
to the accumulation of fibrin.   
 
6.4.2 Spatial relationship between thrombin and myofibroblasts 
 This study has demonstrated a spatial relationship between fibrin, the end product of 
the coagulation cascade, and the myofibroblast, a key mediator of fibrosis at 3 days post-
UUO.  Because the serine protease thrombin has a rapid turn over rate (Coughlin, 2000), this 
study has utilised fibrin as a surrogate marker for thrombin.  This study therefore supports 
other work showing that thrombin and the myofibroblast marker, αSMA co-exist in the 
inflammatory and early fibrotic stages in various pathological situations (Coughlin, 2000). 
Thrombin may be found in the interstitium as a consequence of increased capillary 
permeability (Plante et al., 1996) and misdirected filtration from the glomerulus to the 
interstitium (Kriz et al., 2001), features of interstitial pathology.   
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By establishing a spatial relationship between markers of fibrosis and thrombin, it can 
be hypothesised that accumulating fibrin clots in the tubulointerstitium act as thrombin 
reservoirs (Grandaliano et al., 2001) in interstitial spaces, thereby allowing thrombin to carry 
out its cell-mediated effects.  Given that thrombin has a short half life, it is thought to act near 
the site where it is produced (Coughlin, 2000) and this therefore underscores the potential for 
thrombin to mediate local fibroblast mitogenesis (Hewitson et al., 2005), differentiation 
(Bogatkevich et al., 2001) or ECM synthesis (Bachhuber et al., 1997; Chambers et al., 1998; 
Dabbagh et al., 1998; Hewitson et al., 2005; Howell et al., 2001; Shirato et al., 2003; Vesey et 
al., 2005) on these αSMA-positive cells. However, because the data is correlative, further 
work needs to be performed to establish definitive functional relationships. 
 
6.4.3 Factor V expression in experimental tubulointerstitial fibrosis in vivo and in vitro 
The presence of the membrane bound co-factor, factor V has also been demonstrated 
in a juxtaposition to fibrin, and the work herein has been shown that like mesangial cells (Ono 
et al., 2001), renal fibroblasts can synthesise factor V in vitro in response to the inflammatory 
mediator TNFα.  The generation of thrombin from prothrombin is potentiated by 104 fold in 
the presence of factor V (Ono et al., 2001).  Accordingly, the presence of membrane-bound 
factor V in the tubulointerstitium, potentially secreted by fibroblasts, provides a mechanistic 
pathway by which the generation of thrombin can occur.  This may then allow thrombin to act 
in an autocrine or paracrine fashion on resident interstitial fibroblasts. 
 
6.4.4 PAR-1 expression in experimental tubulointerstitial fibrosis 
Thrombin may exacerbate fibrosis by inducing mitogenesis and collagen synthesis 
(Hewitson et al., 2005), potentially making it an important fibrogenic mediator.  Cell-
mediated effects of the serine protease thrombin occur via activation of the GPCR, PAR-1. 
When a protease binds to the PAR, it cleaves the amino terminal exo-domain exposing a new 
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amino acid sequence.  This exposed N-terminus then acts as the tethered peptide ligand and 
binds to the heptahelical portion of the receptor to activate transmembrane signalling and G 
protein activation (Coughlin, 2000).  Increasing evidence suggests that thrombin can act 
through this receptor to mediate a number of pro-inflammatory and fibrogenic events 
(Bogatkevich et al., 2001; Dabbagh et al., 1998; Grandaliano et al., 2001; Grandaliano et al., 
2000a; Hewitson et al., 2005), while previous studies have shown that thrombin can induce 
increased expression of PAR-1 in vitro (Ellis et al., 1999).  In human allograft nephropathy, 
the up-regulation of PAR-1 by tubular epithelial cells correlates with interstitial fibrin 
deposition and the severity of tubulointerstitial fibrosis (Grandaliano et al., 2001).  In a 
similar vein to Grandaliano et al [24], this study confirms that PAR-1 is expressed on the 
basolateral surface of tubular epithelial cells, and has established that PAR-1 is spatially 
related to fibrin and factor V deposits.  
The results described within provide a further insight into the significance and kinetics 
of PAR-1 receptor activation during fibrosis.  In contrast to previous findings (Xu, 1995), 
PAR-1 was detected at day 0 (before UUO was elicited).  The reasons for this discrepancy are 
unknown.  Whilst PAR-1 is prominent early during UUO, there is a gradual loss of protein 
staining with increasing fibrosis.  This progressive loss of PAR-1 receptor staining was 
inversely related to the progressive accumulation of fibrin post-UUO.  These fibrin mesh clots 
may house increasing concentrations of thrombin as they accumulate after UUO.  The 
demonstrated loss of PAR-1 receptor staining is consistent with receptor activation and 
internal degradation, as demonstrated previously (Grandaliano et al., 2000a).  Once 
extracellular thrombin activates PAR-1, PAR-1 is then uncoupled from the GPCR and 
internalised for lysosomal degradation [28].  A smaller proportion of these receptors may be 
recycled and returned to the cell membrane (Fig. 6.13) (Xu et al., 1995).  Because this 
facilitates transient signalling, the magnitude of thrombin’s signalling effect is dependent not  
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Kinetics of PAR-1 receptor activation and degradation. After activation of PAR-1, it is 
rapidly phosphorylated and uncoupled from its G-protein. PAR-1 is then internalised into 
endosomes where approximately 75% of these receptors get degraded and a smaller 
proportion are recycled and returned to the cell membrane as naive receptors. Membrane 
expression of PAR-1 is replenished through an intracellular store that shuttles back and forth 
within the cytoplasm.
PAR-1 mRNA in progressive renal disease. 
Grandaliano et al (2001) has shown that 
PAR-1 mRNA increases in CAN. Whilst no 
changes are detected in the control (a), 
marked up-regulation of PAR-1 is 
illustrated in the renal tubules (b-d), 
glomeruli (e) and vessels (f). Similarly, the 
study described within has demonstrated 
that whilst receptor staining for PAR-1 
protein decreased with increasing 
fibrogenesis, PAR-1 mRNA was still evident 
at day 21. 
CAN = chronic allograft nephropathy.
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only on the rate of receptor cleavage and activation, but also on thrombin concentration 
(Bradshaw, 2004b).  Furthermore, activation of PAR-1 by proteolytic cleavage means that one 
single thrombin molecule can activate multiple receptors.  Consequently, in cases where high 
levels of thrombin are transiently present, a high rate of receptor cleavage and internalisation 
would be expected, in accordance with this study.   
In situ hybridisation demonstrated that late in fibrosis (day 21), PAR-1 mRNA 
expression is still present.  This finding is in the same theme as the work by Grandaliano et al 
(Grandaliano et al., 2001), who demonstrated an up-regulation of thrombin receptor mRNA 
levels in relation to increasing fibrin distribution in CAN (Fig. 6.14).  Furthermore, other 
groups support the likelihood that thrombin receptor protein does not always correlate with 
thrombin receptor mRNA level (Xu, 1995). Continued receptor activation, and an 
accumulating extracellular thrombin concentration residing in local fibrin clots is a likely 
explanation for new receptor synthesis late in fibrosis.  Studies in human disease have shown 
that thrombin receptor protein expression is strikingly down-regulated (Grandaliano et al., 
2000a). Similarly, in this study the loss of PAR-1 protein staining was also noted. These 
studies on PAR-1 receptor activation and degradation therefore describe a mechanism by 
which increasing fibrin deposition and thrombin concentrations throughout UUO lead to 
PAR-1 activation and degradation, as represented by a progressive loss of receptor staining 
(Fig. 6.15a-b), and indicate that PAR-1 transcriptional activity occurs late in UUO. 
 
6.4.5 Role of PAR-1 in EMT 
Activation of PAR-1 in renal tubular epithelial cells may lead to pro-fibrogenic effects 
including up-regulation of MCP-1 and DNA synthesis (Grandaliano et al., 2000b).  However, 
given that EMT was demonstrated in this model of UUO, and given the close proximity of 
PAR-1 and fibrin clots, the potential for PAR-1 to mediate EMT was investigated.  This study 
was further warranted by a recent study which demonstrated that thrombin can induce PAR-1- 
 204
 
0           3            14           21
%
 fra
c
tio
n
a
l a
re
a
0
5
10
15
20
25
30
Days post-UUO
Inverse relationship between accumulating fibrin clots and loss of PAR-1 with progressive UUO.
Whilst fibrin accumulates progressively in the interstitial peri-tubular regions during UUO (a; 
*p<0.05 vs. control, n=3-6), PAR-1 staining is lost by the later stages of fibrogenesis (b; arrow). 
Indicative of receptor activation and degradation, this suggests that peri-tubular thrombin, housed 
in accumulating fibrin clots (potentially making it more resistant to degradation), may act through 
PAR-1 to carry out its cell-mediated effects. 
Fig. 6.15
* a
PAR-1
b
%
 F
ib
ri
n
%
 fra
c
tio
n
a
l a
re
a
%
 F
ib
ri
n
 205
mediated endothelial-mesenchymal transition by facilitating the spread and migration of 
endothelial cells (Archiniegas et al., 2004).  To assess the significance of PAR-1 in renal 
EMT, renal explants were treated with TRAP. TRAP contains the amino-acid sequence 
(SFLLRN) of the tethered ligand and effectively mimics thrombin’s actions in vivo.  It is 
commonly used in thrombin-related studies (Cunningham et al., 2000; Dabbagh et al., 1998; 
Grandaliano et al., 1994) because its longer half-life offers improved efficacy.  
Exogenous TRAP facilitated EMT in the ex vivo model of EMT in this study 
highlighting the potential for thrombin to act as a novel mediator of EMT via PAR-1 (Fig. 
6.16), in addition to the multiplicity of agonists already capable of carrying out this 
phenomenon.  Whilst thrombin has been shown to act through PAR-1 to induce ECM 
synthesis (Hewitson et al., 2005; Howell et al., 2001; Shirato et al., 2003), αSMA expression 
(Bogatkevich et al., 2001) and mitogenesis (Hewitson et al., 2005), this study therefore 
highlights another pro-fibrotic role for thrombin, mediated through PAR-1.  However, given 
that factor Xa is capable of activating PAR-1 and PAR-2 (Chambers and Laurent, 2002), the 
possibility that factor Xa is also involved in stimulating PAR-1-mediated EMT cannot be 
excluded.  Furthermore, because thrombin also stimulates TGFβ1 release from proximal 
tubular epithelial cells (Vesey et al., 2005), it should be noted that TGFβ1 may act in an 
autocrine fashion to induce EMT in these cells.  In line with the predominance of TGFβ1 in 
EMT, thrombin may therefore act in a TGFβ-dependent manner to induce EMT.  Further 
studies are required to clarify the mechanism of thrombin’s action.   
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Schematic demonstrating the involvement of PAR-1 in EMT.  This study describes the potential for 
PAR-1 to mediate EMT by demonstrating the ability of TRAP to up-regulate the expression of 
αSMA in the ex vivo model of explanting. 
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6.4.6 Summary 
 In conclusion, these investigations continue to re-define the theory that cytokines are 
the principle mediators of inflammation and highlights the potential for coagulation factors, 
through cell- and receptor-mediated mechanisms, to be involved in non-cytokine mediated 
pathways during the pathogenesis of tubulointerstitial fibrosis.    This study provides insight 
into the distribution of serine proteases during experimental fibrosis entailing a possible 
mechanism whereby thrombin, present in fibrin clots, may be potentially generated through 
factor V expression by fibroblasts, and in turn may act in an autocrine or paracrine manner on 
local interstitial fibroblasts to induce a cascade of fibrotic events.  It also provides an insight 
into the in vivo distribution of PAR-1 in a model of UUO and establishes possible 
mechanisms for the kinetics of PAR-1 receptor activation and degradation.  Furthermore, 
through utilisation of the model of EMT, it has been shown that TRAP can induce PAR-1 
mediated EMT in renal explants and provides a novel insight into the mechanisms of EMT.  
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6.5 SPECIFIC METHOD PROTOCOLS 
 
Method Section 
UUO  2.2.1 
Immunohistochemistry  2.6.2 
Cytochemistry  2.6.1 
Table 6.1: References for methods described in Chapter 2 used in this chapter.   
 
6.5.1 Point counting of fibrin 
 
Point counting was carried out to determine the temporal distribution of fibrin at 0, 3, 
14 and 21 days post-UUO.  Slides were placed under an 11×11 grid and counted according to 
the intersection of the cell with a grid line.  Only regions with a viable and real representation 
of the staining characteristics were counted. 
The percentage of fractional area represented by the item of interest was found by: 
%FA = Staining under grid intersections  × 100 
Total grid intersections 
Results are presented as a percentage of total fractional area. 
 
6.5.2 Factor V expression in activated fibroblasts 
Fibroblasts derived from UUO were characterised for their ability to express factor V 
in response to the inflammatory cytokine TNF-α (200U/ml).  Cells were grown on coverslips 
in DMEM medium supplemented with DMEM + 1% FCS, DMEM + 10% FCS, or treated 
with 200U/ml TNF-α  in DMEM medium supplemented with 1% FCS for 24hr.  Cells were 
then fixed in cold methanol, washed in PBS and stained for factor V.  Non-immune serum 
was added for 10min at room temperature, acted as a negative control.  Groups were 
qualitatively compared. 
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6.5.3 In Situ hybridisation 
In situ hybridisation was carried out to determine PAR-1 mRNA expression during 
progressive UUO according to established protocols (Darby, 2000).  Tissue sections from 
kidneys taken at 21 days post-UUO were fixed in 4% paraformaldehyde, dehydrated, placed 
into a humid chamber and digested with proteinase for 25min at 37°C.  Sections were washed 
in water, dehydrated and air-dried through 95% ethanol.  The Digoxigenin (DIG) PAR-1 
riboprobe was then added and sections were cover-slipped and incubated for 1.5hr at 55°C.  
Slides were then immersed in pre-heated stringent washing buffer and incubated for 25min at 
55°C with shaking, immersed in TBS and placed in a humidity chamber with 2-5 drops anti-
DIG alkaline phosphatase to each section.  After 30min of incubation and washing in TBS 
and water, 2-3 drops of substrate was added to each solution and incubated for 30-60min.  
Substrate was then washed off and slides were immersed in tap water.  Finally, tissue sections 
were counterstained in haematoxylin and mounted in aqueous mountant.  
 
6.5.4 Pharmacological modification of EMT with TRAP 
Explants were treated with DMEM + 10% FCS supplemented with either 10ng/ml 
TGFβ1, 70µM TRAP or maintained in control medium (DMEM+ 10% FCS) for 72hr.  Drugs 
were replenished for another 72hr period, and explants were then fixed in cold methanol.  
Cells were stained for αSMA and quantified on the basis of positive staining for αSMA as a 
percentage of total cell number.     
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7.1 SUMMARY OF EXPERIMENTAL FINDINGS 
Tubulointerstitial fibrosis is dictated by a complex interplay between a cocktail of 
interstitial inflammatory and non-inflammatory mediators, and their effect predominantly on 
renal fibroblasts.  Integral to these processes are the cell signalling pathways that govern the 
responses of these cells.  Although the TGFβ signalling axis has been identified as the chief 
mediator of tubulointerstitial fibrosis, this thesis has identified additional molecular 
mechanisms involved in the regulation of tubulointerstitial fibrosis by examining the 
regulation of the renal interstitial fibroblast, a key mediator in tubulointerstitial fibrosis.  It has 
primarily examined those features of fibroblast function which are most devastating to renal 
function: (a) fibroblast proliferation (b) myofibroblast differentiation, (c) ECM synthesis and 
(d) EMT.  By using fibroblasts and tissue derived from a model of UUO, or tissue exposed to 
mechanical stress (to study EMT), this thesis has ascertained the following findings: 
 
7.1.1 Chapter 3: Role of phosphatidylinositol 3-kinase and mTOR in the regulation of 
renal fibroblast proliferation and collagen synthesis 
This study was aimed at identifying additional novel signalling pathways involved in 
regulating fibroblast proliferation and collagen synthesis by using pharmacological inhibitors 
of PI3K and mTOR.  The signalling circuitry encompassing PI3K and mTOR in renal 
fibroblasts was initially examined by determining Akt S-473 and S6RP S-235/235 
phosphorylation status in response to serum-based mitogen stimulation. This established (a) 
Akt S-473 as a downstream mediator of PI3K and (b) S6RP S-235/235 as a downstream 
target of mTOR.  In response to RAD treatment for the standard experimental treatment 
period (48hr), Akt S-473 phosphorylation was also down-regulated.  Functional studies of 
these pathways have confirmed the involvement of PI3K and mTOR in the regulation of 
fibroblast proliferation, total collagen synthesis and gene expression of α1(I) procollagen 
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mRNA (mTOR).  Results also suggest that the functional studies were independent of 
increases in apoptosis or compromised cell viability.   
 
7.1.2 Chapter 4: Development and validation of an ex vivo model of EMT 
 This chapter has described the development of an ex vivo model of EMT that allows 
for easy tracking of transitioning epithelial cells in an environment that is physiologically 
relevant to its in vivo counterpart, but is displaced from the organism.  By explanting the 
cortex derived from normal kidneys, it has been established that these cells (derived from 
proximal tubules; shown by lectin staining), initially phenotyped as cytokeratin positive, 
progressively acquire a mesenchymal phenotype and gradually lose their epithelial markers. 
These cells became αSMA-positive myofibroblasts and lost morphological characteristics of 
epithelial cells.  Approximately half of the cell population underwent EMT at a given time 
point consistent with studies indicating that a large proportion of renal myofibroblasts may be 
derived from EMT.  Testing this model with the most well known inducer of EMT (TGFβ1) 
and a newly established negative regulator of EMT (lovastatin) has effectively validated this 
model.  
 
7.1.3 Chapter 5: The role of phosphatidylinositol 3-kinase and mTOR in the regulation 
of myofibroblast differentiation and EMT 
 Recent studies have established the role of mTOR in VSCM cell differentiation 
providing a basis to investigate the role in PI3K and mTOR in renal fibroblasts.  In response 
to inhibition of PI3K and mTOR, the expression of αSMA protein was facilitated (when 
exposed to serum-based mitogen stimulation). Preliminary studies described within this 
chapter have indicated that up-regulation of αSMA may not be due to changes in gene 
transcription.  Further investigation into the regulation of differentiation by these pathways by 
examining total TGFβ1 secretion indicated that mTOR, but not PI3K, may regulate TGFβ1 by 
controlling a TGFβ1 autocrine loop.   
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 In addition to the well known TGFβ/Smad signalling axis, MAPK and Rho signalling, 
this study has also established a role for PI3K and mTOR in the regulation of EMT by using 
the ex vivo model of EMT.  Consistent with in vitro studies in mammary epithelial cells 
(Bakin et al., 2000) and in nrk-52e cells (Wu et al., 2006), PI3K and mTOR down-regulate 
EMT by inhibiting the expression of αSMA.  This chapter suggests a possible paradox in the 
ability of PI3K and mTOR to negatively regulate fibroblast differentiation whilst facilitating 
EMT ex vivo. 
 
7.1.4 Chapter 6: Constituents of the coagulation cascade are spatially and functionally 
related to experimental tubulointerstitial fibrosis  
It is apparent that tubulointerstitial fibrosis is highly complex and the interstitial milieu 
involves copious amounts of inflammatory cytokines, vasoactive peptides and an abundance 
of activated cell types.  These factors drive the relentless inflammatory cycle, which can 
propagate a marked decline in renal function over time.  As demonstrated in a number of 
experimental renal models and human renal disease, non-cytokine mediated pathways can 
also mediate fibrosis and in addition to AGEs, tPA and PAI-1, this study has highlighted the 
likely involvement of the coagulation cascade during tubulointerstitial fibrosis.  It has 
primarily localised the interstitial distribution of factor V (and its potential role in fibrosis) 
and fibrin, the latter of which has become a hallmark of the inflammatory response. This 
study has also co-localised fibrin (acting as a surrogate marker for thrombin) to αSMA 
myofibroblasts providing the framework for thrombin to carry out a number of cell-mediated 
effects on these cells.  Furthermore, an evaluation of the specific thrombin receptor PAR-1 at 
time points post-UUO has provided a likely mechanism whereby increasing fibrin clots, likely 
to house substantial concentrations of thrombin may lead to PAR-1 activation and 
degradation.  Lastly, this study has underscored the likelihood of PAR-1 to mediate EMT by 
using the ex vivo model of EMT.   
 
 214
7.2 GENERAL DISCUSSION 
 When taken together, a number of interesting and paradoxical findings emerge from 
the work described within this thesis which deserve further discussion. 
 
7.2.1 The paradox of PI3K and mTOR in the regulation of proliferation, ECM synthesis 
and differentiation  
Whilst inhibition of PI3K and mTOR resulted in inhibition of key events during 
fibrosis including fibroblast proliferation (Fig. 7.1a) ECM synthesis (Fig. 7.1b) and EMT 
(Fig. 7.1c), the differentiation of fibroblasts to myofibroblasts was clearly facilitated, as 
outlined in Chapter 5 (Fig. 7.1d).  Whilst this finding may immediately seem paradoxical 
given that it is thought that inhibition of the cell cycle generally parallels an inhibition of 
differentiation (Wainwright et al., 2001), a number of studies suggest that these processes 
may not be proportionally related.  
Whilst the differentiation and proliferation of both neutrophils (Kanayasu-Toyoda et 
al., 2002) and epithelial cells (Shao et al., 2004) is differentially regulated by PI3K and 
mTOR, more compelling is the parallel role that mTOR plays in regulating functionally 
distinct VSMC phenotypes (Martin et al., 2004; Marx et al., 1995).  VSMC have an inherent 
functional plasticity whereby they can vary between a mature phenotype in which the primary 
function is contraction, to a less differentiated (synthetic) state where the predominant 
functions are protein synthesis and proliferation (Worth et al., 2001).  Similarly to the effect 
of RAD in fibroblasts, rapamycin has also been shown to inhibit proliferation and ECM 
synthesis in VSMC whilst facilitating differentiation in these cells (Martin et al., 2004; Marx 
et al., 1995). 
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Overview of the roles of PI3K and mTOR in renal fibroblasts in vitro.  This study has utilised
fibroblasts derived from UUO which are more activated than their quiescent counterparts. By 
treating these cells with PI3K and mTOR inhibitors significant reductions were noted in fibroblast 
proliferation which is a fundamental response in fibrogenesis (a). Not only does it ultimately lead to 
ECM deposition but it sustains fibrosis through the secretion of more cytokines. Similarly, inhibition 
of PI3K and mTOR led to marked reductions in collagen synthesis which is a principal component 
of the ECM and its aberrant deposition in fibrosis can lead to glomerulosclerosis, tubular atrophy 
and vascular sclerosis (b). Furthermore, by using the ex vivo model of EMT, this study has 
underlined the potential for PI3K and mTOR to mediate EMT through the regulation of αSMA
expression (c). Lastly, inhibition of these kinases facilitates differentiation of renal fibroblasts 
potentially via an autocrine TGFβ1 loop (mTOR only)(d).
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Given the similarities between VSMC and fibroblasts, it is interesting to speculate whether 
the parallels in the differential regulation by PI3K and mTOR in VSMC and fibroblasts (as 
described within this thesis) can be drawn further to underscore the potential for fibroblasts to 
also exhibit a functional plasticity, similar to VSMC.  In tubulointerstitial fibrosis, it could be 
possible that this response may be dictated by the interstitial milieu (ie. mitogen specific), 
which may differentially regulate fibroblast proliferation and differentiation by activating 
different pathways.  This type of response is likely to depend on cross-talk signalling 
mechanisms and is also consistent with findings that (a) only a subset of myofibroblasts 
express αSMA (Strutz and Zeisberg, 2006), (b) myofibroblasts only transiently express 
αSMA during tubulointerstitial fibrosis (Hewitson et al., 1995), and that (c) results described 
within indicated that the changes to proliferation and differentiation occurred within the same 
cells, not within different cell populations (which may suggest sub-populations of cells 
respond differently).  Future studies that are suggested by these outcomes should examine the 
hypothesis that the expression of αSMA in myofibroblasts consistently coincides with the 
secretion of increased ECM proteins (Hinz and Gabbiani, 2003). 
 
7.2.2 The controversy over the effect of rapamycin in vivo  
Whilst an increasing number of studies highlight the potential for rapamycin to 
ameliorate fibrosis in vivo (Bonegio et al., 2005; Jain et al., 2001; Lloberas et al., 2006; 
Stallone et al., 2005; Wu et al., 2006) other studies have also indicated that rapamycin can in 
some cases exacerbate fibrosis by activating the synthesis of TGFβ protein and contributing to 
the deposition of ECM proteins (Shihab et al., 2004a; Shihab et al., 2004b).  Although the 
reasons for these discrepancies are unclear, it is apparent that mTOR signalling is highly 
dependent on the cell context.  Whilst shown in these studies in renal fibroblasts (Fig. 7.2b) 
and by Sarbassov et al (Sarbassov dos et al., 2006) that prolonged RAD/rapamycin treatment 
can inhibit Akt phosphorylation, this effect is highly cell-specific, only being observed in a 
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third of the 33 cell lines tested under identical experimental conditions (Fig. 7.2c). This type 
of differential response has been shown to occur in vivo (Fig. 7.2d) (Sarbassov dos et al., 
2006).  Whether this reflects the ability of rapamycin to have variable effects in vivo is 
currently unknown.  
Moreover, because rapamycin also inhibits the downstream S6K which normally 
forms a negative feedback loop with PI3K and Akt (therefore inhibiting Akt) (Harrington et 
al., 2004; Sarbassov et al., 2005; Shah and Hunter, 2006; Um et al., 2004), prolonged 
rapamycin treatment can actually activate Akt signalling (Sarbassov dos et al., 2006). It is 
therefore evident that rapamycin can (a) inhibit Akt (b) activate Akt or (c) have no effect (as 
demonstrated previously (Sarbassov dos et al., 2006). Although shown to be clinically 
relevant in the treatment of cancer with rapamycin (Eng et al., 1984; Sawyers, 2003; Sun et 
al., 2005), the implication of this circuitry in fibrosis in vivo is unknown, however potentially 
it suggests that in cases where rapamycin activates Akt, cell proliferation would be facilitated 
(given the predominant role of Akt in proliferation). 
It therefore seems evident that whilst rapamycin has the potential to act as an anti-
fibrotic agent in vivo, more experimental models are needed to confirm these findings in 
concert with further elucidation of mTOR signalling, which is developing at a fast pace. 
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7.2.3 The reality of EMT in renal tubulointerstitial fibrosis and the fate of EMT-derived 
cells 
 
7.2.3.1 EMT in renal tubulointerstitial fibrosis 
Although there has been a growing enthusiasm and acceptance of the significance of 
EMT in renal fibrosis, the identification of this process in vivo has to date proved difficult 
(due to the kinetics of EMT and difficultly in tracing these cells).  It has therefore been noted 
that renal EMT is the least well-proven conceptually (Zavadil and Bottinger, 2005) suggesting 
that more in vivo models are needed to substantiate the contribution of this process during 
renal tubulointerstitial fibrosis.  
Moreover, it has been noted that the different types of EMT (renal, cancer and 
embryonic) represent different physiological/pathological contexts and should not be 
interpreted as a universally regulated process (Zavadil and Bottinger, 2005). A glance at the 
literature confirms this and indicates that there are many notable differences between cancer 
and renal-related EMT including the ability of HGF (Li et al., 1994; Muller et al., 2002) and 
PDGF (Jechlinger et al., 2006; Yang et al., 2006a) to induce EMT in cancer, the former of 
which is a major negative regulator of renal EMT (Zeisberg et al., 2003).  This raises concerns 
over the use of nrk-52e cells, which is indeed a transformed immortalised cell line, and the 
most well-known cell line used to study renal EMT in vitro.  When studies use nrk-52e cells, 
it could be questioned whether we are really examining the proteome involved in producing 
populations of myofibroblasts during renal EMT.   
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7.2.3.2 Fate of EMT-derived cells 
Whilst most studies indicate that cells that undergo EMT are bound to become 
myofibroblasts, other studies indicate that EMT serves different purposes.  Whilst this study 
and other studies (Fan et al., 1999; Masszi et al., 2003; Shimizu et al., 2006; Strutz et al., 
2002) have shown that (tubular) epithelial cells can transition into myofibroblasts, other 
studies have highlighted the ability of epithelial cells to undergo de-differentiation 
(Bonventre, 2003; Forino et al., 2006) in order to potentially repair damaged tubular segments 
(Rastaldi et al., 2002).  Furthermore, it has been noted in vivo that EMT can be mistaken for 
encroachment into the renal tubule by αSMA-positive cells during fibrosis (Faulkner et al., 
2005).  Current studies are hindered by the lack of specific markers to detect EMT making it 
difficult to distinguish these events in some cases, however consistent with the complexity of 
the fibrotic process, it is likely that of the above phenomena can occur.  It remains to be 
shown in vivo that cells actually migrate away from the tubule.  Lastly, if one is to accept the 
growing school of thought that EMT is a key pathological process in renal fibrosis, then what 
is the terminal fate of these cells? Whilst Zeisberg et al has shown that EMT can be reversed 
by exogenous BMP-7 in vivo (Zeisberg et al., 2003), whether these cells can also revert to 
their epithelial phenotype after tissue damage is currently unknown. 
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7.3 FUTURE DIRECTIONS 
This study has established a number of novel findings that not only provide a solid 
basis to assess the in vivo role of PI3K and mTOR, but also provide a foundation for the 
further elucidation of the mechanisms involved in various experimental aspects of this work.  
These include the following: 
 
7.3.1 Growing roles for mTOR 
As the identification of mTOR as a central kinase involved in the regulation of 
proliferation, growth and hypertrophy (Chen et al., 2005; Sakaguchi et al., 2006), cancer 
(Hidalgo and Rowinsky, 2000; Manning, 2004; Sabatini, 2006) type II diabetes (Lloberas et 
al., 2006; Um et al., 2004) cell survival and glucose metabolism (Cheatham et al., 1994; 
Ruvinsky et al., 2005), inflammation (Bonegio et al., 2005; Loverre et al., 2004) and fibrosis 
has unravelled over recent years, it is likely that the roles of the downstream substrates and 
furthermore, their upstream regulators will become clearer over the coming years. Although 
the effectors involved in the studies within have not been identified, elucidation of effectors 
would be valuable in defining potential therapeutic intervention strategies. 
Specific to this study, it would also be valuable to further investigate the following: 
(a) The reproducibility of these results with transfection, gene mutation knock-in or small 
interfering RNA (siRNA) of mTOR and PI3K (and the specific isoforms of PI3K). 
The recent development of specific PI3K subunit inhibitors also holds promise to 
elucidate the roles of PI3K subunits (Jackson et al., 2005).  Furthermore, it would be 
useful to determine which Akt isoform is involved in fibrosis in order to identify the 
isoforms involved in metabolism and growth (Cully et al., 2006). The current 
literature suggests that p110α and Akt 1 are the predominant isoforms that control 
proliferation (Easton et al., 2005; Engelman et al., 2006). 
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(b) The in vivo effect of rapamycin on EMT given that growing evidence suggests a role 
for this kinase in EMT in vitro.  Furthermore, given that EMT signalling involves a 
number of pathways, elucidation of the role of PI3K and mTOR in this signalling 
cascade as well as its roles (other than induction of αSMA) in the engagement of the 
EMT proteome would enhance our understanding of this complex event.  Since both 
PI3K (Grille et al., 2003) and mTOR (Aguilera et al., 2005) have been shown to up-
regulate Snail, it would be useful in future studies to examine the roles of these 
kinases in the suppression of E-cadherin.   
(c) Whilst preliminary data indicates αSMA gene expression is not regulated by PI3K and 
mTOR at the transcriptional level, further studies are required to fully elucidate this 
signalling mechanism. 
 (d) The role of mTOR and PI3K in the regulation of proliferation, differentiation and 
ECM synthesis in vivo.  
 
7.3.2 The ex vivo model of EMT  
It would be valuable to further delineate whether the reversal of EMT in this model is 
possible. This would provide further insight into the cellular fate of EMT-derived cells, and 
allow us to understand the extent of epithelial plasticity.  Similarly, an analysis of loss or gain 
of other epithelial and mesenchymal markers would provide further insight into the 
mechanisms of EMT in this model. 
Whilst it is currently difficult to study cellular mechanisms of EMT with the ex vivo 
model of EMT, the potential to improve or improvise using this model can be drawn from the 
advancements made in models used to study cancer-related EMT. Acknowledgement of the 
inherent problems with structural organization and functional differentiation in in vitro 
epithelial cancer studies (Debnath and Brugge, 2005) led to the development of three-
dimensional culture models that involve the generation of physiologically equivalent epithelia 
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structures which are completely embedded in an ECM (Debnath and Brugge, 2005). 
Consequently, models such as these may be promising for the study of renal EMT as they 
overcome micro-environmental isolation and allow for genetic as well as cell biological 
studies with a high throughput (Schmeichel and Bissell, 2003).   
 
7.3.3 Further elucidation of coagulation in fibrosis 
Whilst PAR-1 knock-out studies have been successfully utilized in crescentic 
glomerulonephritis (Cunningham et al., 2000), the effect of PAR-1 knock-out in experimental 
models of fibrosis remains largely unexplored.  It would be particularly interesting to see what 
effect this has on EMT and also on myofibroblast recruitment, given that (a) thrombin can 
facilitate fibroblast differentiation (Bogatkevich et al., 2001) and (b) that PAR-1 has been 
shown in this study to mediate EMT.   Furthermore, because there is some ambiguity over the 
specificity of proteases for PARs (TRAP has been shown to cross-react with PAR-2 whilst 
factor Xa has been shown to activate PAR-1 (Blanc-Brude et al., 2005) and PAR-2 
(Grandaliano et al., 2003) it would be useful to examine the effect of specific inhibitors of 
thrombin.  The examination of whether coagulation factors can independently mediate pro-
fibrotic events would also be useful as it may be possible that these pathways depend on the 
TGFβ signalling axis (Grandaliano et al., 2003; Vesey et al., 2005).  Because of the highly 
correlative nature of this chapter, an obvious future direction would be to explore and 
establish causal relationships. In this sense, it may be useful to include the use of 
pharmacological agonists or antagonists for in vitro studies whilst double labelling would also 
provide a more definitive insight. 
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7.4 CONCLUSION 
Tubulointerstitial fibrosis can be induced through the activation of tubular epithelial 
cells leading to interstitial inflammation and activation and recruitment of interstitial 
fibroblasts.  Beyond this point tubulointerstitial fibrosis may ensue independently of the initial 
stimulus and consequently this can lead to a progressive loss of renal function.  The processes 
involved in these events depend inextricably on cell signalling cascades.  Consistent with the 
complexity of tubulointerstitial fibrosis, studies are beginning to identify the complexity of 
cell signalling events which can act in a cell-specific, stimulus specific or context specific 
manner.  The identification and characterisation of signalling pathways involved particularly 
in propagating a decline in renal function is therefore essential to be able to design effective 
and rational therapeutic interventions to ameliorate fibrosis.  This study has contributed 
towards our understanding of renal fibroblast signalling and myofibroblast derivation and 
highlights the role of non-cytokine mediated pathways in tubulointerstitial fibrosis, providing 
a solid foundation for further studies in these areas. 
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APPENDIX 1 
 
LIST of MATERIALS and SUPPLIERS 
 
Unless indicated, all materials have been obtained from Sigma, St Louis, Mi, USA. 
 
MATERIAL SUPPLIER 
 
Apx. 1.1 Immunohistochemistry  
Avidin-Biotin Complex (Elite) DAKO, CA USA 
Alcohols (70%-100%) BDH, Kilsyth, Vic, Australia 
Antibody diluent  DAKO 
Aquamount Gurr® BDH 
Aqueous mounting medium DAKO  
Digital microscope camera  DP10, Olympus, Tokyo, Japan 
Disodium hydrogen orthophosphate BDH 
Fluorescent microscope  Leika Microsystems, Wetzlar, Germany 
Harris’ haematoxylin BDH 
Histoclear National Diagnostics, Adelaide, Australia 
Hydrogen peroxide BDH 
Methanol BDH 
Neutral Buffered Formalin Histolabs (Fronine) Riverstone, NSW, 
Australia 
Non-immune serum Vector laboratories Burlingame, CA USA 
Normal horse serum Vector laboratories,  
Normal goat serum Vector laboratories 
PaintShop Pro  Jasc Sofware, Minnetonka, MI, USA. 
Paraformaldehyde BDH 
Potassium chloride BDH 
Potassium dihydrogen phosphate BDH 
Sodium chloride BDH 
Sodium thiosulphate BDH 
Glass Slides HD Scientific, Sunshine, Vic, Australia 
Streptavidin Texas red conjugate Molecular Probes, Inc, Eugene, Oregon 
Vectastain kits Vector 
Xylene BDH 
Wax pen DAKO 
Whatman No. 1 filter paper DAKO 
 
  
Apx. 1.2 Cell culture  
Cellagen®  ICN Pharmaceuticals, Costa Mesa, CA, USA 
DMEM CSL, Vic, Australia 
EDTA Boehringer Mannheim, Mannheim, Germany 
Falcon tubes BDH 
Flasks Nunc, Roskilde, Denmark 
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Fetal calf serum  CSL 
Hanks’ salt solution  MP Biomedicals, Costa Mesa, Ca, USA 
HEPES JRH Biosciences Brooklyn Vic Australia 
Gentamycin ICN Pharmaceuticals 
Nunc tubes Nunc 
OptiMEM® Invitrogen, Mount Waverley, VIC  
Australia 
Penicillin/Streptomycin antibiotics  MP Biomedicals 
Petri dishes Nunc 
Scintillation counter  Beckman Coulter, Fullerton, CA, USA  
Scintillation fluid Perkin-Elmer Life and Analytical Sciences, 
Wellesley, MA USA 
TCA  BDH  
[3H] Thymidine  Amersham Pharmacia Biotech, Rydalmere 
NSW, Australia 
 
Apx. 1.3 Extraction of cellular components 
Trizol Invitrogen   
Chloroform BDH 
Guanidine hydrochloride Boehringer Mannheim 
Isopropanol BDH 
Molecular grade alcohols BDH 
SDS BDH 
Sodium citrate BDH 
Sodium hydroxide BDH 
 
Apx. 1.4 Real time PCR 
αSMA forward and reverse primers Sigma Genosys   
Ribosomal protein L32 primers Sigma Genosys 
Dnase Promega, Madison, WI, USA  
DNase buffer  Promega 
MgCl2 Promega 
DNTP Promega 
Random hexamers  Promega 
RNAse out Promega 
RNA clean up kit (RNeasy kit)  Biorad, San Francisco, Ca, USA 
Superscript III enzyme Invitrogen 
SYBR Green RNA kit Invitrogen 
 
Apx. 1.5 Northern blotting 
32
P-nucleotide Amersham Pharmacia Biotech 
Ethidium bromide Invitrogen 
Formamide BDH 
Hybond-N membrane Amersham Pharmacia Biotech 
Formaldehyde BDH 
Glycerol BDH 
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Klenow enzyme Amersham Pharmacia Biotech 
Megaprime DNA labelling system kit  Amersham Biosciences, Piscataway, NJ, USA 
Mixed bed resin Promega 
Sephadex-G50 column Amersham Pharmacia Biotech 
Sodium chloride BDH 
ssDNA Promega 
 
Apx. 1.6 Western blotting 
Acetic Acid BDH 
Biotinylated protein ladder/HRP-conjugated Cell Signaling  
Agarose (Na) Amersham Pharmacia Biotech  
Ammonium persulphate Biorad 
Coomassie blue Biorad 
Film developer Kodak, Rochester, NY, USA 
Densitometry software Kodak  
ECL detection kit  Amersham Biosciences 
Film Fixative Kodak 
Glacial acetic acid BDH 
Hybond nitrocellulose PVDF membrane Amersham Biosciences 
Rainbow standard Biorad 
SDS BDH 
Solution N (Acrylamide) Biorad 
TEMED Biorad 
Tris Base BDH 
Tween 20  Biorad 
X-ray film  Kodak 
 
Apx. 1.7 Hydroxyproline incorporation 
[2,3-3H Pro]-Pro  Amersham Biosciences 
Collagenase  Worthington Biochemical Corporation, NJ, 
USA 
 
Apx. 1.8 In situ hybridisation 
Probe labelling kit and detection system  Roche, Castle Hill, N.S.W., Australia 
 
Apx. 1.9 Apoptosis 
Apx. 1.9.1 TUNEL 
DeadEnd kit Promega 
DNase Promega 
Fluorescent microscope  Leika Microsystems 
 
Apx. 1.9.2 Propidium Iodide 
Propidium iodide Invitrogen 
Triton X-100 BDH 
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Apx. 1.10 Drugs, growth factors and peptides  
Lovastain Merck, Whitehouse Station, NJ, USA 
LY294002  Cell Signaling Technology 
PD98059 Cell Signaling Technology 
RAD  Novartis, Basel, Switzerland 
TGFβ1 Peprotech Inc., Rocky Hill, NJ, USA 
TRAP Auspep, Parkville, Australia  
TNFα  Cytolab, Rehovot, Israel 
 
Apx. 1.11 ELISAs 
 
Apx. 1.11.1  MTT  
DMSO BDH 
 
Apx. 1.11.2 S6RP ELISA (S-235/236)  
S6RP ELISA Cell Signaling Technology 
Sunrise ELISA Plate Reader  Tecan, Salzberg, Austria 
 
Apx. 1.11.3 TGFβ1 ELISA  
TGFβ1 Quantikine® kit R&D Systems, Gymea, N.S.W. 
Australia 
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APPENDIX 2 
 
LIST of REAGENTS, BUFFERS and STOCK SOLUTIONS
*
 
 
 
Apx. 2.1 Immunohistochemistry  
 
PBS (10x) 
Sodium chloride 80g 
Potassium chloride 2g 
Disodium hydrogen orthophosphate 11.5g 
Potassium dihydrogen phosphate 2g 
dH2O 900ml 
The pH was adjusted to 7.2 before final volume was made up to 1L using dH2O.  1x PBS was made up 
at a dilution of 1:10. 
 
Harris’ Haematoxylin 
Haematoxylin 5g 
Ethanol (100%) 50ml 
Ammonium alum 100g 
dH2O 1000ml 
Haematoxylin was dissolved in ethanol. Ammonium alum was dissolved in distilled water. 
The 2 solutions were added together and heated until boiling. The solution was removed from heat and 
1.5g mercuric oxide was added slowly.  The solution was cooled before use.  
 
 
2.1.1 Fixatives 
 
Mercuric Formalin 
37-40% formaldehyde solution 100ml 
Distilled water 900ml 
Sodium chloride 9g 
Ingredients were stirred and mercuric chloride was added until solution was saturated. 
 
Neutral Buffered Formalin 
Formulation according to manufacturer’s specifications 
Formaldehyde 10%w/v 
Disodium phosphate, sodium dihydrogen phosphate were used to buffer the solution to pH 6.95-7.05. 
 
4% Paraformaldehyde 
Paraformaldehyde 4g 
0.1M PBS pH 7.2 100ml 
Paraformaldehyde powder was dissolved in 65°C water and cleared by gradually adding 1M NaOH.  
Solution was cooled before use. 
 
                                                
*
 Unless specified, all agents were stored at room temperature 
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TBS-Tween 
1M Tris-HCl (pH 7.6) 2ml 
1M NaCl 15ml 
dH2O 83ml 
Tween-20 5µl 
Stored at 4ºC 
 
Apx. 2.2 Cell culture  
 
10% BSA 
1g BSA was dissolved in 10ml dH2O.   
Stored at 4°C. 
 
Dialyzed 50% FCS 
One end of dialysis membrane tubing was tied with silk to make a bag enclosed at one end. 
The membrane was filled with 10ml of FCS and top end tied with silk. Membranes containing FCS 
were soaked in 1L of dH2O in a sterile glass beaker O/N at 4°C to allow the FCS to dialyze. The 
following day the tubing was untied and dialyzed FCS poured into a sterile cylinder.  Dialyzed FCS 
was diluted to 50% with dH2O and filter using a 0.2µm acetate membrane with a pre-filter membrane. 
The serum was then aliquoted and stored at -20°C.  
 
DMEM + 20% FCS 
1xDMEM 400ml 
*FCS 80ml 
HEPES 10ml 
Penicillin (5000U/ml) & streptomycin (5000µg/ml) 8ml 
Glutamine 4ml 
Using sterile forceps, a filter unit and a disposable 0.2µM filter, the solution was poured into 
apparatus and filtered through a vacuum pump, and once completed, transferred into a Schott bottle 
and stored at 4oC.  
*DMEM + 10, 5 and 1% FCS contained 40ml, 20ml and 4ml of FCS respectively, all other constituents remained the same.   
 
Hanks buffer solution  
Gentamycin 2.5µl 
HEPES 200µl 
Sodium Bicarbonate (7.5%) 47µl 
Hanks solution (x1)* 100ml  
Using a 60ml syringe and a disposable 0.2µM syringe filter, 60ml of the Hanks solution was 
filtered and the remaining 40ml of Hanks, gentamycin, HEPES and sodium bicarbonate were then 
added as outlined above. The 1xHanks and additives were stored in an autoclaved bottle at 4°C for up 
to 4 days. 
*Hanks solution may exist as a 1x solution or a 10x solution.  If using the 10x solution, Hank’s buffer was diluted 1:10 with 
dH2O before beginning the procedure. 
 
Incubation Medium (Collagen Assay)      
DMEM with additives*        80ml  
50% dialyzed FCS                20ml  
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100mM Ascorbic acid          250ml  
Media was prepared and filtered in a 60ml sterile syringe with a 0.2µM filter.  
*Additives = pen/strep, glutamine and HEPES 
 
Labelling Isotope (Collagen Assay) 
[2,3-
3
H Proline] 250µl 
DMEM 245µl 
0.5M Proline 5µl 
These components were filtered through a 0.2µM filter. 
 
Serum-Free Media (OptiMEM®) 
A sachet of OptiMEM powder was dissolved in 900ml sterile water at room temperature and 
2.4g of sodium bicarbonate was added.  The pH was then adjusted to 7.3 with 1M sodium hydroxide 
or 1M HCl and make up the final volume to 1L with sterile water.  The required volume was filtered 
and penicillin 5000U/ml / streptomycin 5000µg/ml was added.  The solution was then stored at 4°C. 
 
Apx. 2.3 Real time PCR 
 
TE buffer 
10mM Tris 0.1ml 
1mM EDTA 20ml     
Adjust pH to 8 
 
Apx. 2.4 Northern blotting 
 
Agarose-formaldehyde Gel (1%) 
NA agarose 0.5g 
MOPS (x10) 5ml 
Formaldehyde (40%w/v) 8.93g 
dH2O 36.07ml 
The agarose, MOPS and water were heated until the agarose had melted. The solution was cooled to 
approximately 50°C and the formaldehyde was added. 
 
Denhardt’s Solution 
PVP  10g 
BSA  10g 
Ficoll 100    10g 
dH2O 230ml  
The solution was passed through a sterile 0.2µm filter, aliquoted into 10-20ml batches and stored at -
20ºC.  
 
50% Dextran Sulphate 
30g dextran sulphate was added to 60ml dH2O in a sterile bottle, stirred and heated until it dissolved, 
and stored at 4°C.  
 
Formamide (deionised)  
Formamide 50ml 
Mixed bed resin  5g 
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Components were stirred at room temperature until resin was exhausted, filtered through Whatman 
No. 1 filter paper and stored at 4°C. 
 
Hybridisation Buffer  
10x salts 50µl 
Formamide (deionised) 250µl 
Dextran sulphate (50%, heated to 80°C) 100µl 
tRNA 18µl 
Probe in dH2O 82µl 
 
10x MOPS, pH 7.0 
MOPs powder  41.86g 
EDTA (Na2)  3.7g 
Sodium acetate (3M, pH 5.5)  16.66ml 
NaOH pellets 5.0g 
dH2O  932.78ml 
pH was be adjusted to 7.0 and the solution was autoclaved. 
 
Pre-Hybridisation Solution 
Deionised formamide                                               26ml  
20xSSPE, pH 7-7.5 12.5ml 
Denhardt’s solution  2.5ml 
50% Dextran sulphate                                              10ml 
20% SDS                                                              2.5ml  
The solution was stored at 4oC for up to 2 weeks. 
 
RNA Gel Buffer  
MOPS (10x) 25ml 
Formaldehyde (40%w/v) 45ml 
dH2O was added to 250ml 
 
RNA Sample Load Buffer  
Formamide 0.72ml 
MOPS (10x) 0.16ml 
Formaldehyde (40%w/v) 0.26ml 
dH2O 0.18ml 
Glycerol (80%) 0.1ml 
Bromophenol blue 0.08ml 
The solution was aliquoted and stored at -20°C 
 
2 х SDS  
4 х Tris-Cl pH 6.8 25ml 
Glycerol 20ml 
SDS 4g 
BME 2ml 
Bromophenol blue 1mg 
dH20 53ml 
This was then aliquoted and stored at -20ºC. 
 233
 
20x SSC, pH 7.0-7.5  
3M Sodium chloride  350.6g 
Sodium citrate  176.49g 
dH2O 1472.91ml  
pH was adjusted to 7.0-7.5 and the solution was then autoclaved. 
 
2xSSPE, 0.1%SDS 
*20xSSPE 10ml 
SDS 1ml 
Made up to 100ml with dH2O. 
*For 5xSSPE and 10xSSPE respective amounts of 25 and 50ml of SSPE were added. 
 
20×SSPE buffer  
Sodium chloride  87.65g 
Sodium dihydrogen orthophosphate  
(NaH2PO4)  13.8g 
EDTA  3.7g 
dH2O 394.85ml 
pH was adjusted to 7.4 and the solution was autoclaved. 
 
TEN (tris-EDTA-NaCl-) buffer 
Tris  3.03g 
EDTA 0.29g  
NaCl   8.77g 
Components were dissolved in dH2O and the solution adjusted to a pH of 7.6 using HCl. The buffer 
was then made up to a volume of 1L with dH2O. 
 
Tris Buffer (10x) 
Sodium chloride 87.7g 
Tris 60.6g 
dH2O 900ml 
Salts were dissolved in distilled water and pH adjusted to 7.4.  The final volume was then adjusted to 
1L using dH2O. The solution was diluted 1:10 in dH2O before use. Stored at 4ºC 
 
Apx. 2.5 Western blotting 
 
10% Ammonium persulphate 
1g of ammonium persulphate was dissolved in 10ml dH2O and aliquots were stored at -20°C. 
 
Coomassie Blue  
Coomassie Blue R250 2g 
Methanol 500ml 
Glacial acetic acid 100ml 
Made up to 1L with dH2O and filtered before use. 
 
Destain 
Destainer was made up at a ratio of 50% Methanol:10% Acetic Acid. 
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1xPBS-Tween 
10xPBS 100ml 
dH2O 900ml 
Tween-20 1ml 
The solution was stored at 4°C. 
 
Polyacrylamide Gel (7.5%) 
Solution N (acrylamide) 2.5ml 
dH2O 4.85ml 
Solution L pH 8.8 2.6ml 
Ammonium persulphate (10%) 50µl  
TEMED 5.0µl  
 
Polyacrylamide Gel (12.5%) 
Solution N (Acrylamide) 4.67ml 
dH2O 3.33ml 
Solution L pH 8.8 2.5ml 
Ammonium persulphate (10%) 20µl 
TEMED 8.3µl 
 
S20 Load Buffer 
Sucrose 20g 
Solution M pH6.8 10ml 
Urea (4.8M) 41.66ml 
SDS (10%w/v) 1ml 
Bromophenol blue 0.1g 
The solution was aliquoted and stored at -20°C 
 
5% skim milk / PBS-Tween 
Skim milk 10g 
1xPBS-Tween 200ml 
The solution was mixed until dissolved and stored at 4ºC. 
 
Solution L (Lower gel buffer)  
Tris base 18.16g 
SDS 0.4g 
dH2O 100ml 
pH was adjusted to 6.8 with concentrated HCl and stored at 4°C. 
 
Solution M (Upper gel buffer) 
Tris-Cl 6.06g 
SDS powder 0.4g 
dH2O 100ml 
pH was adjusted to 6.8 with concentrated HCl and the solution stored at 4ºC 
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Solution N (Acrylamide) 
Acrylamide 29.2g 
Bisacrylamide 0.8g 
dH2O 100ml 
Stored at 4°C. 
 
Stacking gel (4.5%) 
Solution N (acrylamide) 1.5ml 
dH2O  6.0ml 
Solution M 2.5ml 
Ammonium persulphate (10%) 30µl 
TEMED  15µl 
 
Transfer buffer  
Tris base 3.03g 
Glycine 14.4g 
Methanol 200ml 
dH2O 800ml 
Contents were stirred until dissolved and the pH adjusted to between 8.3-8.6, and stored at 4ºC. 
 
Apx. 2.6 Hydroxyproline incorporation 
 
100mM Ascorbic Acid 
1.761g of ascorbic acid was dissolved in 100ml dH2O and stored at 4°C. 
 
10% BSA 
Dissolve 1g BSA in 10ml dH2O.   
Stored at 4°C. 
 
1M CaCl2  
147.02g CaCl2 in 1L dH2O 
(25mM = 3.675g in 1L dH2O) 
Stored at 4°C 
 
Collagenase  
Made up as 1mg/ml in dH2O (1054 U/mg) 
Stored at -20°C. 
 
Collagenase Negative Solution 
25mM CaCl2 10µl                                                        
62.5mM N-ethylmalemide    20µl                                                      
0.05M Tris 5M CaCl2 pH 7.6    10µl                                                        
A master mix was made up and 40µl was pipetted into each test sample from this mix. 
 
Collagenase Positive Solution 
25mM CaCl2      10µl                                                       
62.5mM N-ethylmalemide    20µl                                                      
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Collagenase (Worthington)    10µl                      
A master mix was made up and 40 µl was pipetted into each test sample from this mix. 
                                   
Apx. 2.7 In situ hybridisation 
 
Salts (10x)  
3M Sodium Chloride  17.35g 
0.1M Disodium hydrogen orthophosphate  
(NaH2PO4)*  1.56g 
0.1M Tris-HCl (pH 7.5)  10ml 
0.05M EDTA (pH8.0)  10ml 
*1.56g Disodium hydrogen orthophosphate was dissolved in 100ml dH2O (pH6.8) and autoclaved. 0.2g each of 
bovine serum albumin, Ficoll and PVP was then added (final concentration was 0.2%). The solution was filtered using a 
0.2µm filter before use.   
 
Apx. 2.8 ELISAs 
 
Apx. 2.8.1 MTT  
 
Sorensen’s glycine buffer  
0.1M Glycine  
0.1M NaCl  
pH 10.5 
Stored at 4ºC 
 
MTT 
0.0015gm MTT was diluted in 3ml PBS. 
 
Apx. 2.8.2 S6RP ELISA (S-235/236) 
 
1mM PMSF 
1ml 20mM PMSF was diluted into 20ml dH2O and mix until dissolved. Stored at 4°C. 
 
 237
APPENDIX 3 
 
PRIMARY AND SECONDARY ANTISERA 
Primary Antigen Supplier CLone Raised  Specificity Dilution 
*Vimentin DAKO V9 Mouse Mesenchymal cells 1:50 
*#αSMA DAKO 1A4 Mouse Smooth muscle cells, 
myofibroblasts, 
mesangial cells 
1:50 
*Anti-αSMA Cy3 
conjugate 
Sigma 1A4 Mouse αSMA isoform (see 
αSMA) 
1:50 
*EPOS Anti-human  
αSMA 
DAKO 1A4 Mouse αSMA isoform (see 
αSMA) 
- 
*Desmin DAKO D33 Mouse Myofibroblasts, 
smooth muscle cells, 
glomerular podocytes 
1:50 
*Collagen III Southern 
Biotech, 
Birmingham, 
Alabama, USA 
- Goat Collagen III 1:300 
*Cytokeratin DAKO LP34 Mouse Epithelial cells 1:10/1:25 
*S100-A4 (FSP1) DAKO - Mouse Various 1:50 
*RECA Serotec, 
Oxford, UK 
HIS 52 Mouse Endothelial cells 1:100 
*E-Cadherin BD 
Biosciences 
Pharmingen, 
San Jose, CA, 
USA 
36 Mouse Epithelial cells 1:100 
#Fibrin / fibrinogen DAKO - Rabbit Fibrinogen, 
fibrinogen fragments 
D, E. 
1:400 
#PAR-1 Santa Cruz 
Biotechnology, 
CA, USA 
- Mouse PAR-1 1:100 
#*Factor V Nordic 
Immunological
s, Netherlands 
- Rabbit Activated and 
degraded Factor V 
1:400 
*PCNA DAKO PC10 Rat Linear epitope in 
PCNA, maximal 
during S phase 
1:50 
 
∗βigH3 Gift of 
Professor 
P.Gibson, 
University of 
Adelaide 
- Rabbit β-inducible gene-H3 1:100 
 
Table Apx. 3.1: Antibodies used for cytochemistry (*) and immunohistochemistry (
#
) 
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Antisera Supplier Raised  Dilution 
Anti-mouse FITC DAKO  Mouse 1:50 
Alk phos-anti mouse IgG Sigma Goat - 
Alk phos anti-alk phos   DAKO Mouse 1:50 
Biotinylated anti-mouse IgG DAKO Mouse - 
Biotinylated anti-rabbit IgG DAKO Rabbit - 
 
Table Apx. 3.2: Secondary antibodies 
 
 
 
 
 
Antibody/conjugate  Supplier Raised  Specificity Dilution 
αSMA DAKO Mouse Smooth muscle, 
myofibroblast and 
mesangial cell protein 
1:1000 
Total Akt Cell 
Signaling 
Technology 
Rabbit Akt 1, Akt 2 and Akt 3 1:1000 
p-Akt (S-473) Cell 
Signaling 
Technology 
Rabbit S-473 residue of Akt 1:500 
β−actin Sigma Mouse β−actin 1:2000 
HRP anti-rabbit IgG DAKO Rabbit Rabbit 
immunoglobulins 
1:2000 
HRP anti-mouse IgG 
 
DAKO Mouse Mouse 
immunoglobulins 
1:2000 
 
Table Apx. 3.3: Western blotting antisera 
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